T
author
1 Methods
1.1 AUC
2 Results
Variable | Details | FALSE | TRUE | Total | Statistics |
GOT>100 | 176 (96.2%) | 7 (3.8%) | 183 | ||
Sex | F | 87 (50.0%) | 5 (71.4%) | 92 (50.8%) | OR=0.40 [0.08, 2.12] (p=0.444) |
M | 87 (50.0%) | 2 (28.6%) | 89 (49.2%) | ||
Age (years) | M (min:max) | 58 (18:87) | 61 (39:84) | 59 (18:87) | MW: p=0.619 |
μ ±SD | 57.22 ±12.9 | 61.14 ±16.7 | 57.59 ±12.8 | ||
Cirrhosis | yes | 79 (44.9%) | 3 (42.9%) | 82 (44.8%) | OR=1.09 [0.24, 5.00] (p>0.999) |
no | 97 (55.1%) | 4 (57.1%) | 101 (55.2%) | ||
Etiology | alcohol | 41 (26.1%) | 1 (20.0%) | 42 (25.9%) | V=0.09 (p=0.694) |
viral | 88 (56.1%) | 4 (80.0%) | 92 (56.8%) | ||
metabolic | 20 (12.7%) | 0 | 20 (12.3%) | ||
cholestatic liver disease | 8 (5.1%) | 0 | 8 (4.9%) | ||
APP_DZ | yes | 40 (23.1%) | 1 (14.3%) | 41 (22.8%) | OR=1.80 [0.21, 15.43] (p>0.999) |
no | 133 (76.9%) | 6 (85.7%) | 139 (77.2%) | ||
APP_HTAE | yes | 54 (31.2%) | 3 (42.9%) | 57 (31.7%) | OR=0.61 [0.13, 2.80] (p=0.681) |
no | 119 (68.8%) | 4 (57.1%) | 123 (68.3%) | ||
APP_CVD | yes | 43 (24.9%) | 2 (28.6%) | 45 (25.0%) | OR=0.83 [0.15, 4.42] (p>0.999) |
no | 130 (75.1%) | 5 (71.4%) | 135 (75.0%) | ||
APP_COPD | yes | 10 (5.8%) | 0 | 10 (5.6%) | OR=0.96 [0.05, 18.04] (p>0.999) |
no | 163 (94.2%) | 7 (100%) | 170 (94.4%) | ||
APP_Renal | yes | 7 (4.3%) | 0 | 7 (4.1%) | OR=0.71 [0.04, 13.71] (p>0.999) |
no | 157 (95.7%) | 7 (100%) | 164 (95.9%) | ||
Alcohol | yes | 43 (33.9%) | 1 (16.7%) | 44 (33.1%) | OR=2.56 [0.29, 22.60] (p=0.663) |
no | 84 (66.1%) | 5 (83.3%) | 89 (66.9%) | ||
Dislipidemia | yes | 9 (15.0%) | 0 | 9 (14.3%) | OR=1.29 [0.06, 27.07] (p>0.999) |
no | 51 (85.0%) | 3 (100%) | 54 (85.7%) | ||
Weight | M (min:max) | 79 (45:120) | 80 (56:102) | 80 (45:123) | T-test: p=0.923 |
μ ±SD | 79.48 ±16.0 | 78.83 ±16.0 | 79.73 ±15.8 | ||
Height | M (min:max) | 168 (150:190) | 162 (160:170) | 168 (150:192) | MW: p=0.160 |
μ ±SD | 168.55 ±8.34 | 163.80 ±3.9 | 168.69 ±8.69 | ||
BMI | M (min:max) | 27.64 (15.57:42.24) | 29.38 (21.34:35.29) | 27.68 (15.57:42.24) | T-test: p=0.609 |
μ ±SD | 27.99 ±5.09 | 29.18 ±5.9 | 28.02 ±4.99 | ||
Fibroscan_Probe | M | 163 (92.6%) | 6 (85.7%) | 169 (92.3%) | OR=2.09 [0.23, 18.69] (p=0.433) |
XL | 13 (7.4%) | 1 (14.3%) | 14 (7.7%) | ||
Fibroscan_Value | M (min:max) | 9.9 (2.5:75) | 9.8 (3.7:75) | 9.7 (2.5:75) | MW: p=0.904 |
μ ±SD | 18.59 ±19.2 | 22.23 ±25.8 | 18.53 ±19.4 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 63 (35.8%) | 3 (42.9%) | 66 (36.1%) | V=0.03 (p=0.922) |
F2 (7-10) | 25 (14.2%) | 1 (14.3%) | 26 (14.2%) | ||
F3-F4 (>10) | 88 (50.0%) | 3 (42.9%) | 91 (49.7%) | ||
Valid Elastography | yes | 155 (88.1%) | 5 (71.4%) | 160 (87.4%) | OR=2.95 [0.54, 16.19] (p=0.215) |
no | 21 (11.9%) | 2 (28.6%) | 23 (12.6%) | ||
Stability index | M (min:max) | 91 (12:99) | 90 (32:92) | 91 (12:99) | MW: p=0.215 |
μ ±SD | 87.28 ±11.8 | 80.29 ±21.9 | 86.94 ±12.8 | ||
CAP_Value | M (min:max) | 261.5 (100:398) | 257 (100:400) | 266 (100:400) | T-test: p=0.840 |
μ ±SD | 262.99 ±60.9 | 258.14 ±92.5 | 263.95 ±61.4 | ||
CAP Steatosis stage | No steatosis | 87 (49.4%) | 4 (57.1%) | 91 (49.7%) | V=0.13 (p=0.353) |
S1 (260-284) | 27 (15.3%) | 0 | 27 (14.8%) | ||
S2 (285-294) | 6 (3.4%) | 1 (14.3%) | 7 (3.8%) | ||
S3 (≥295) | 56 (31.8%) | 2 (28.6%) | 58 (31.7%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 2 (1:3) | 3 (1:4) | MW: p=0.552 |
μ ±SD | 2.30 ±0.974 | 2.00 ±1.15 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.17 (0.66:2.79) | 0.98 (0.6:1.24) | 1.19 (0.6:2.79) | MW: p=0.175 |
μ ±SD | 1.21 ±0.333 | 0.951 ±0.322 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.588 |
μ ±SD | 4.83 ±0.958 | 4.57 ±1.62 | 4.82 ±1.01 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.44 (0.3:0.48) | 0.41 (0.16:0.77) | MW: p=0.782 |
μ ±SD | 0.435 ±0.114 | 0.425 ±0.0631 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.396 |
μ ±SD | 4.95 ±0.796 | 4.57 ±1.62 | 4.95 ±0.88 | ||
Attenuation SOS Mean | M (min:max) | 1526.4 (1478:1598.4) | 1522.6 (1515.6:1546.8) | 1526.6 (1477:1598.4) | MW: p=0.694 |
μ ±SD | 1530.74 ±25.9 | 1525.58 ±11.3 | 1530.58 ±25.2 | ||
Elastography liver median 1 | M (min:max) | 11.25 (3.3:76.7) | 31.5 (4.6:46.7) | 10.4 (3.3:76.7) | MW: p=0.307 |
μ ±SD | 16.60 ±14.2 | 24.30 ±16.7 | 16.52 ±14.1 | ||
Elastography liver IQR 1 | M (min:max) | 1.7 (0.1:23.8) | 2.2 (0.9:24.9) | 1.7 (0.1:24.9) | MW: p=0.258 |
μ ±SD | 2.84 ±3.54 | 7.63 ±9.96 | 2.94 ±3.83 | ||
Elastography IQR/MED | M (min:max) | 14.16 (0:78.95) | 15.52 (0:53.32) | 14.53 (0:78.95) | MW: p=0.534 |
μ ±SD | 16.68 ±12.1 | 21.77 ±18.4 | 16.60 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.3 (1.1:5) | 2.1 (1.5:4) | 2.2 (1.1:5) | MW: p>0.999 |
μ ±SD | 2.40 ±0.848 | 2.40 ±0.86 | 2.39 ±0.833 | ||
Spleen diameter | M (min:max) | 12.09 (6.37:21.8) | 11.66 (9.17:16.97) | 12.02 (6.37:21.8) | MW: p=0.538 |
μ ±SD | 12.51 ±3.07 | 11.77 ±2.59 | 12.60 ±3.12 | ||
Spleen area | M (min:max) | 65.96 (15.73:193.16) | 74.71 (56.04:93.38) | 65.96 (15.73:193.16) | MW: p=0.651 |
μ ±SD | 70.17 ±33.6 | 74.71 ±26.4 | 72.08 ±34.6 | ||
VP Diam cm | M (min:max) | 1.15 (0.52:1.62) | 1.29 (0.98:1.3) | 1.15 (0.52:1.76) | T-test: p=0.849 |
μ ±SD | 1.16 ±0.23 | 1.19 ±0.182 | 1.16 ±0.231 | ||
VP Speed | M (min:max) | 26.45 (14.38:74.5) | 30.3 (20.28:40.32) | 26.49 (14.38:74.5) | MW: p=0.739 |
μ ±SD | 27.85 ±11.6 | 30.30 ±14.2 | 28.39 ±11.5 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.05 (0:0.1) | 0.01 (0:0.1) | MW: p=0.712 |
μ ±SD | 0.0153 ±0.0219 | 0.05 ±0.0707 | 0.0167 ±0.0249 | ||
Hb | M (min:max) | 14 (7.5:19.6) | 12.3 (10.1:15.2) | 13.9 (7.5:19.6) | MW: p=0.059 |
μ ±SD | 13.86 ±1.91 | 12.28 ±1.97 | 13.79 ±1.94 | ||
PTL | M (min:max) | 179 (2.39:536) | 204 (100:427) | 181.5 (2.39:536) | MW: p=0.673 |
μ ±SD | 185.68 ±96.1 | 213.33 ±119.9 | 186.62 ±95.9 | ||
GOT | M (min:max) | 30 (13:97) | 134 (104:570) | 31 (13:570) | MW: p<0.001 |
μ ±SD | 36.26 ±18.3 | 216.86 ±167.6 | 43.16 ±49.5 | ||
GPT | M (min:max) | 24 (7:387) | 183 (41:291) | 24 (7:387) | MW: p<0.001 |
μ ±SD | 31.72 ±33.7 | 154.43 ±111.9 | 36.39 ±45.3 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 1.55 (0.6:6) | 0.9 (0.3:11.1) | MW: p=0.198 |
μ ±SD | 1.40 ±1.47 | 2.50 ±2.26 | 1.46 ±1.52 | ||
BD | M (min:max) | 0.3 (0.09:8.96) | 0.87 (0.27:3.5) | 0.31 (0.09:8.96) | MW: p=0.038 |
μ ±SD | 0.547 ±1.01 | 1.41 ±1.38 | 0.591 ±1.03 | ||
GGT | M (min:max) | 43 (13:1128) | 284 (39:1914) | 46 (13:1914) | MW: p=0.004 |
μ ±SD | 90.06 ±150.5 | 503.57 ±678.6 | 108.40 ±213.7 | ||
FA | M (min:max) | 221.5 (108:899) | 271 (196:1042) | 222 (104:1042) | MW: p=0.077 |
μ ±SD | 256.86 ±128.8 | 400.29 ±301.4 | 261.55 ±141.3 | ||
ALB | M (min:max) | 4.2 (2.6:5.3) | 4.7 (4.7:4.7) | 4.2 (2.6:5.3) | MW: p=0.316 |
μ ±SD | 4.15 ±0.635 | 4.70 ±NA | 4.17 ±0.65 | ||
INR | M (min:max) | 1.14 (0.9:2.7) | 1.21 (1.12:1.36) | 1.14 (0.9:2.7) | MW: p=0.609 |
μ ±SD | 1.24 ±0.309 | 1.22 ±0.117 | 1.24 ±0.299 | ||
COL | M (min:max) | 184 (18:326) | 288 (288:288) | 186 (18:326) | MW: p=0.118 |
μ ±SD | 187.04 ±53.6 | 288.00 ±NA | 189.38 ±54.6 | ||
TG | M (min:max) | 105 (31:380) | 239 (239:239) | 106.5 (31:380) | MW: p=0.111 |
μ ±SD | 118.23 ±60.3 | 239.00 ±NA | 121.04 ±61.8 | ||
Fe | M (min:max) | 99 (24:246) | 99.5 (34:165) | 99 (22:246) | MW: p=0.876 |
μ ±SD | 104.26 ±44.2 | 99.50 ±92.6 | 103.22 ±45.4 | ||
Crea | M (min:max) | 0.77 (0.52:1.52) | 0.79 (0.6:3.43) | 0.77 (0.52:3.43) | MW: p=0.505 |
μ ±SD | 0.802 ±0.182 | 1.22 ±1.09 | 0.822 ±0.276 | ||
Uree | M (min:max) | 31 (10:92) | 38 (23:84) | 31 (10:92) | MW: p=0.078 |
μ ±SD | 34.34 ±14.4 | 46.17 ±21.7 | 35.48 ±15.3 | ||
Na | M (min:max) | 136 (89:142) | 135.5 (126:138) | 136 (89:142) | MW: p=0.339 |
μ ±SD | 135.89 ±5.56 | 133.75 ±5.44 | 135.81 ±5.49 | ||
Glicemie | M (min:max) | 104.25 (75.7:361.7) | 109.7 (92:179) | 104 (75.7:361.7) | MW: p=0.805 |
μ ±SD | 118.67 ±43.4 | 118.57 ±32.5 | 118.35 ±42.2 | ||
CRP | M (min:max) | 0.38 (0.2:15.05) | 1.08 (0.38:22.2) | 0.39 (0.2:22.2) | MW: p=0.035 |
μ ±SD | 0.984 ±2.32 | 5.10 ±9.57 | 1.21 ±3.19 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.33) | 0.09 (0.03:0.22) | 0.06 (0:0.33) | MW: p=0.314 |
μ ±SD | 0.0708 ±0.0545 | 0.107 ±0.0813 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 10 (0:80) | 15 (3.5:38) | 10.88 (0:84) | MW: p=0.349 |
μ ±SD | 12.44 ±10.2 | 16.21 ±11.7 | 12.90 ±11.1 | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
2.1 Valid Elastography
Trebuie vazut daca invaliditatea masuratorii elastografiei, coloana BN, se asociaza cu ceva: greutate, BMI, gradul Fibrozei, gradul steatozei
Variable | Details | yes | no | Total | Statistics |
Valid Elastography | 186 (89.0%) | 23 (11.0%) | 209 | ||
Sex | F | 90 (48.9%) | 12 (52.2%) | 102 (49.3%) | OR=0.88 [0.37, 2.09] (p=0.827) |
M | 94 (51.1%) | 11 (47.8%) | 105 (50.7%) | ||
Age (years) | M (min:max) | 59 (18:87) | 64 (31:79) | 59 (18:87) | MW: p=0.236 |
μ ±SD | 57.20 ±12.8 | 60.70 ±12.6 | 57.59 ±12.8 | ||
Cirrhosis | yes | 81 (43.5%) | 9 (39.1%) | 90 (43.1%) | OR=1.20 [0.49, 2.91] (p=0.824) |
no | 105 (56.5%) | 14 (60.9%) | 119 (56.9%) | ||
Etiology | alcohol | 44 (26.0%) | 4 (21.1%) | 48 (25.5%) | V=0.12 (p=0.412) |
viral | 90 (53.3%) | 12 (63.2%) | 102 (54.3%) | ||
metabolic | 27 (16.0%) | 1 (5.3%) | 28 (14.9%) | ||
cholestatic liver disease | 8 (4.7%) | 2 (10.5%) | 10 (5.3%) | ||
APP_DZ | yes | 41 (22.4%) | 5 (21.7%) | 46 (22.3%) | OR=1.04 [0.36, 2.97] (p>0.999) |
no | 142 (77.6%) | 18 (78.3%) | 160 (77.7%) | ||
APP_HTAE | yes | 62 (33.9%) | 9 (39.1%) | 71 (34.5%) | OR=0.80 [0.33, 1.94] (p=0.646) |
no | 121 (66.1%) | 14 (60.9%) | 135 (65.5%) | ||
APP_CVD | yes | 42 (23.0%) | 7 (30.4%) | 49 (23.8%) | OR=0.68 [0.26, 1.77] (p=0.440) |
no | 141 (77.0%) | 16 (69.6%) | 157 (76.2%) | ||
APP_COPD | yes | 6 (3.3%) | 4 (17.4%) | 10 (4.9%) | OR=0.16 [0.04, 0.62] (p=0.016) |
no | 177 (96.7%) | 19 (82.6%) | 196 (95.1%) | ||
APP_Renal | yes | 6 (3.5%) | 2 (8.7%) | 8 (4.1%) | OR=0.38 [0.07, 1.99] (p=0.238) |
no | 167 (96.5%) | 21 (91.3%) | 188 (95.9%) | ||
Alcohol | yes | 46 (34.1%) | 4 (23.5%) | 50 (32.9%) | OR=1.68 [0.52, 5.44] (p=0.585) |
no | 89 (65.9%) | 13 (76.5%) | 102 (67.1%) | ||
Dislipidemia | yes | 12 (18.2%) | 0 | 12 (16.7%) | OR=2.98 [0.16, 56.48] (p=0.581) |
no | 54 (81.8%) | 6 (100%) | 60 (83.3%) | ||
Weight | M (min:max) | 80 (47:123) | 80 (45:116) | 80 (45:123) | T-test: p=0.427 |
μ ±SD | 80.05 ±15.6 | 76.82 ±17.9 | 79.73 ±15.8 | ||
Height | M (min:max) | 168 (150:192) | 166.5 (150:182) | 168 (150:192) | MW: p=0.436 |
μ ±SD | 168.92 ±8.56 | 166.56 ±9.91 | 168.69 ±8.69 | ||
BMI | M (min:max) | 27.68 (17.26:42.24) | 28.28 (15.57:37.78) | 27.68 (15.57:42.24) | T-test: p=0.819 |
μ ±SD | 28.05 ±4.85 | 27.75 ±6.24 | 28.02 ±4.99 | ||
Fibroscan_Probe | M | 171 (91.9%) | 22 (95.7%) | 193 (92.3%) | OR=0.52 [0.07, 4.12] (p>0.999) |
XL | 15 (8.1%) | 1 (4.3%) | 16 (7.7%) | ||
Fibroscan_Value | M (min:max) | 9.9 (2.5:75) | 7.2 (2.8:75) | 9.7 (2.5:75) | MW: p=0.645 |
μ ±SD | 18.39 ±18.9 | 19.69 ±23.6 | 18.53 ±19.4 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 67 (36.0%) | 11 (47.8%) | 78 (37.3%) | V=0.08 (p=0.529) |
F2 (7-10) | 26 (14.0%) | 3 (13.0%) | 29 (13.9%) | ||
F3-F4 (>10) | 93 (50.0%) | 9 (39.1%) | 102 (48.8%) | ||
Stability index | M (min:max) | 92 (12:99) | 85 (38:94) | 91 (12:99) | MW: p<0.001 |
μ ±SD | 88.00 ±12.0 | 78.43 ±15.9 | 86.94 ±12.8 | ||
CAP_Value | M (min:max) | 268 (100:400) | 253 (113:365) | 266 (100:400) | T-test: p=0.221 |
μ ±SD | 265.78 ±61.2 | 249.13 ±62.7 | 263.95 ±61.4 | ||
CAP Steatosis stage | No steatosis | 86 (46.2%) | 14 (60.9%) | 100 (47.8%) | V=0.12 (p=0.399) |
S1 (260-284) | 32 (17.2%) | 2 (8.7%) | 34 (16.3%) | ||
S2 (285-294) | 9 (4.8%) | 0 | 9 (4.3%) | ||
S3 (≥295) | 59 (31.7%) | 7 (30.4%) | 66 (31.6%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.459 |
μ ±SD | 2.27 ±0.983 | 2.47 ±0.915 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.2 (0.66:2.79) | 0.97 (0.6:1.73) | 1.19 (0.6:2.79) | MW: p=0.061 |
μ ±SD | 1.24 ±0.353 | 1.05 ±0.302 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (1:7) | 5 (1:7) | MW: p=0.189 |
μ ±SD | 4.86 ±0.959 | 4.50 ±1.37 | 4.82 ±1.01 | ||
Attenuation Mean | M (min:max) | 0.42 (0.16:0.77) | 0.36 (0.21:0.63) | 0.41 (0.16:0.77) | MW: p=0.003 |
μ ±SD | 0.444 ±0.117 | 0.373 ±0.101 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.316 |
μ ±SD | 4.92 ±0.891 | 5.14 ±0.774 | 4.95 ±0.88 | ||
Attenuation SOS Mean | M (min:max) | 1526.6 (1477:1598.4) | 1527.8 (1494:1586.4) | 1526.6 (1477:1598.4) | MW: p=0.760 |
μ ±SD | 1530.32 ±25.4 | 1532.66 ±24.7 | 1530.58 ±25.2 | ||
Elastography liver median 1 | M (min:max) | 10.55 (3.3:76.7) | 9.2 (3.5:46.7) | 10.4 (3.3:76.7) | MW: p=0.622 |
μ ±SD | 16.36 ±14.0 | 17.79 ±14.7 | 16.52 ±14.1 | ||
Elastography liver IQR 1 | M (min:max) | 1.4 (0.1:18.6) | 4.2 (1.4:24.9) | 1.7 (0.1:24.9) | MW: p<0.001 |
μ ±SD | 2.34 ±2.65 | 7.70 ±7.18 | 2.94 ±3.83 | ||
Elastography IQR/MED | M (min:max) | 13.07 (0:29.67) | 40.79 (30.12:78.95) | 14.53 (0:78.95) | MW: p<0.001 |
μ ±SD | 13.49 ±7.73 | 41.73 ±10.8 | 16.60 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.25 (1.1:5) | 2.15 (1.5:3.8) | 2.2 (1.1:5) | MW: p=0.725 |
μ ±SD | 2.40 ±0.85 | 2.29 ±0.69 | 2.39 ±0.833 | ||
Spleen diameter | M (min:max) | 12 (6.37:21.8) | 12.26 (7.26:19.73) | 12.02 (6.37:21.8) | MW: p=0.940 |
μ ±SD | 12.59 ±3.06 | 12.64 ±3.62 | 12.60 ±3.12 | ||
Spleen area | M (min:max) | 69.78 (15.73:193.16) | 59.18 (21.3:118.61) | 65.96 (15.73:193.16) | MW: p=0.446 |
μ ±SD | 73.91 ±35.2 | 63.31 ±31.4 | 72.08 ±34.6 | ||
VP Diam cm | M (min:max) | 1.15 (0.52:1.76) | 1.13 (0.76:1.53) | 1.15 (0.52:1.76) | T-test: p=0.773 |
μ ±SD | 1.16 ±0.231 | 1.18 ±0.238 | 1.16 ±0.231 | ||
VP Speed | M (min:max) | 27.91 (14.38:74.5) | 20.28 (18.99:27.79) | 26.49 (14.38:74.5) | MW: p=0.104 |
μ ±SD | 29.26 ±11.9 | 21.58 ±3.53 | 28.39 ±11.5 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.02 (0.01:0.1) | 0.01 (0:0.1) | MW: p=0.080 |
μ ±SD | 0.0143 ±0.0217 | 0.0375 ±0.0427 | 0.0167 ±0.0249 | ||
Hb | M (min:max) | 13.9 (7.5:19.6) | 14 (11.9:17) | 13.9 (7.5:19.6) | MW: p=0.222 |
μ ±SD | 13.70 ±2.0 | 14.36 ±1.47 | 13.79 ±1.94 | ||
PTL | M (min:max) | 181 (2.39:536) | 182 (38:427) | 181.5 (2.39:536) | MW: p=0.786 |
μ ±SD | 185.72 ±95.6 | 192.52 ±99.6 | 186.62 ±95.9 | ||
GOT | M (min:max) | 31 (13:570) | 29 (14:183) | 31 (13:570) | MW: p=0.431 |
μ ±SD | 43.16 ±50.8 | 43.22 ±40.3 | 43.16 ±49.5 | ||
GPT | M (min:max) | 24 (7:291) | 26 (11:387) | 24 (7:387) | MW: p=0.930 |
μ ±SD | 35.61 ±39.3 | 41.83 ±76.0 | 36.39 ±45.3 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 0.9 (0.4:6.6) | 0.9 (0.3:11.1) | MW: p=0.931 |
μ ±SD | 1.43 ±1.47 | 1.72 ±1.82 | 1.46 ±1.52 | ||
BD | M (min:max) | 0.31 (0.09:8.96) | 0.32 (0.12:3.97) | 0.31 (0.09:8.96) | MW: p=0.856 |
μ ±SD | 0.567 ±1.02 | 0.746 ±1.12 | 0.591 ±1.03 | ||
GGT | M (min:max) | 44 (13:1128) | 66 (23:1914) | 46 (13:1914) | MW: p=0.104 |
μ ±SD | 96.03 ±163.7 | 199.53 ±429.0 | 108.40 ±213.7 | ||
FA | M (min:max) | 222 (104:899) | 223 (122:1042) | 222 (104:1042) | MW: p=0.740 |
μ ±SD | 259.40 ±130.8 | 278.39 ±210.4 | 261.55 ±141.3 | ||
ALB | M (min:max) | 4.2 (2.6:5.3) | 4.5 (4.2:5) | 4.2 (2.6:5.3) | MW: p=0.130 |
μ ±SD | 4.13 ±0.672 | 4.50 ±0.276 | 4.17 ±0.65 | ||
INR | M (min:max) | 1.15 (0.9:2.7) | 1.06 (0.9:1.38) | 1.14 (0.9:2.7) | MW: p=0.151 |
μ ±SD | 1.25 ±0.308 | 1.11 ±0.155 | 1.24 ±0.299 | ||
COL | M (min:max) | 183 (18:326) | 206.5 (124:288) | 186 (18:326) | MW: p=0.192 |
μ ±SD | 186.66 ±54.7 | 209.50 ±52.3 | 189.38 ±54.6 | ||
TG | M (min:max) | 100 (31:380) | 151 (58:285) | 106.5 (31:380) | MW: p=0.044 |
μ ±SD | 115.52 ±58.8 | 163.33 ±71.9 | 121.04 ±61.8 | ||
Fe | M (min:max) | 99 (22:246) | 96 (41:165) | 99 (22:246) | MW: p=0.890 |
μ ±SD | 103.65 ±46.2 | 99.44 ±39.8 | 103.22 ±45.4 | ||
Crea | M (min:max) | 0.78 (0.52:3.43) | 0.77 (0.58:1.37) | 0.77 (0.52:3.43) | MW: p=0.774 |
μ ±SD | 0.821 ±0.286 | 0.823 ±0.204 | 0.822 ±0.276 | ||
Uree | M (min:max) | 31 (10:92) | 32 (22:58) | 31 (10:92) | MW: p=0.810 |
μ ±SD | 35.68 ±15.8 | 34.17 ±11.6 | 35.48 ±15.3 | ||
Na | M (min:max) | 137 (125:142) | 135 (89:140) | 136 (89:142) | MW: p=0.318 |
μ ±SD | 136.29 ±3.03 | 132.93 ±12.4 | 135.81 ±5.49 | ||
Glicemie | M (min:max) | 104 (75.7:361.7) | 107.8 (83:282.1) | 104 (75.7:361.7) | MW: p=0.634 |
μ ±SD | 117.82 ±41.8 | 122.63 ±46.8 | 118.35 ±42.2 | ||
CRP | M (min:max) | 0.39 (0.2:15.05) | 0.32 (0.26:22.2) | 0.39 (0.2:22.2) | MW: p=0.531 |
μ ±SD | 0.906 ±2.09 | 3.58 ±7.32 | 1.21 ±3.19 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.33) | 0.05 (0:0.16) | 0.06 (0:0.33) | MW: p=0.601 |
μ ±SD | 0.0707 ±0.0555 | 0.0619 ±0.0414 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 10.62 (0:84) | 17 (2:32.25) | 10.88 (0:84) | MW: p=0.309 |
μ ±SD | 12.76 ±11.3 | 14.08 ±9.0 | 12.90 ±11.1 | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
2.2 Stability index
Subset | N | Mean ±SD | Med (min:max) |
Stability index (Shapiro-Wilk normality test: p<0.001) | |||
(total) | 207 (100.0%) | 86.937 ±12.78 | 91.00 (12.00:99.0) |
Sex (Wilcoxon rank sum test with continuity correction: p=0.068) | |||
F | 102 (49.8%) | 85.755 ±13.07 | 90.00 (28.00:98.0) |
M | 103 (50.2%) | 87.942 ±12.51 | 92.00 (12.00:99.0) |
Age (years) (Spearman's rank correlation rho: R=-0.145, p=0.038) | |||
(total) | 205 (98.1%) | 57.620 ±12.80 | 59.00 (18.00:87.0) |
Cirrhosis (Wilcoxon rank sum test with continuity correction: p=0.466) | |||
yes | 90 (43.5%) | 85.022 ±15.57 | 91.00 (12.00:98.0) |
no | 117 (56.5%) | 88.410 ±9.94 | 91.00 (28.00:99.0) |
Etiology (Kruskal-Wallis rank sum test: p=0.269) | |||
alcohol | 47 (25.3%) | 86.191 ±14.76 | 91.00 (12.00:98.0) |
viral | 101 (54.3%) | 88.436 ±10.77 | 92.00 (32.00:99.0) |
metabolic | 28 (15.1%) | 84.714 ±16.80 | 92.00 (28.00:97.0) |
cholestatic liver disease | 10 (5.4%) | 80.300 ±15.78 | 88.00 (51.00:94.0) |
APP_DZ (Wilcoxon rank sum test with continuity correction: p=0.808) | |||
yes | 45 (22.1%) | 86.556 ±14.20 | 90.00 (12.00:97.0) |
no | 159 (77.9%) | 87.195 ±12.19 | 91.00 (28.00:99.0) |
APP_HTAE (Wilcoxon rank sum test with continuity correction: p=0.283) | |||
yes | 70 (34.3%) | 86.057 ±13.32 | 90.00 (28.00:97.0) |
no | 134 (65.7%) | 87.575 ±12.27 | 92.00 (12.00:99.0) |
APP_CVD (Wilcoxon rank sum test with continuity correction: p=0.345) | |||
yes | 48 (23.5%) | 86.292 ±11.05 | 90.00 (51.00:98.0) |
no | 156 (76.5%) | 87.288 ±13.10 | 91.50 (12.00:99.0) |
APP_COPD (Wilcoxon rank sum test with continuity correction: p=0.334) | |||
yes | 10 (4.9%) | 84.800 ±10.54 | 89.00 (68.00:98.0) |
no | 194 (95.1%) | 87.170 ±12.74 | 91.00 (12.00:99.0) |
APP_Renal (Wilcoxon rank sum test with continuity correction: p=0.313) | |||
yes | 8 (4.1%) | 81.750 ±14.65 | 91.00 (60.00:95.0) |
no | 186 (95.9%) | 87.113 ±12.76 | 91.00 (12.00:99.0) |
Alcohol (Wilcoxon rank sum test with continuity correction: p=0.942) | |||
yes | 49 (32.7%) | 86.367 ±14.49 | 91.00 (12.00:98.0) |
no | 101 (67.3%) | 86.446 ±13.52 | 91.00 (28.00:98.0) |
Dislipidemia (Wilcoxon rank sum test with continuity correction: p=0.476) | |||
yes | 12 (16.7%) | 82.917 ±14.60 | 88.50 (54.00:95.0) |
no | 60 (83.3%) | 85.950 ±15.44 | 91.00 (12.00:98.0) |
Weight (Spearman's rank correlation rho: R=0.017, p=0.823) | |||
(total) | 170 (81.3%) | 79.697 ±15.94 | 80.00 (45.00:123.0) |
Height (Spearman's rank correlation rho: R=0.068, p=0.393) | |||
(total) | 160 (76.6%) | 168.656 ±8.73 | 168.00 (150.00:192.0) |
BMI (Spearman's rank correlation rho: R=0.013, p=0.869) | |||
(total) | 159 (76.1%) | 28.024 ±5.02 | 27.68 (15.57:42.2) |
Fibroscan_Probe (Wilcoxon rank sum test with continuity correction: p=0.105) | |||
M | 191 (92.3%) | 87.309 ±12.47 | 91.00 (12.00:99.0) |
XL | 16 (7.7%) | 82.500 ±15.74 | 86.00 (32.00:96.0) |
Fibroscan_Value (Spearman's rank correlation rho: R=-0.110, p=0.115) | |||
(total) | 206 (98.6%) | 18.660 ±19.42 | 9.80 (2.50:75.0) |
Fibroscan fibrosis stage (Kruskal-Wallis rank sum test: p=0.294) | |||
F0-F1 (<7) | 77 (37.2%) | 90.065 ±6.13 | 92.00 (64.00:99.0) |
F2 (7-10) | 28 (13.5%) | 85.786 ±15.37 | 90.50 (28.00:98.0) |
F3-F4 (>10) | 102 (49.3%) | 84.892 ±15.15 | 90.00 (12.00:98.0) |
Valid Elastography (Wilcoxon rank sum test with continuity correction: p<0.001) | |||
yes | 184 (88.9%) | 88.000 ±11.96 | 92.00 (12.00:99.0) |
no | 23 (11.1%) | 78.435 ±15.91 | 85.00 (38.00:94.0) |
CAP_Value (Spearman's rank correlation rho: R=0.094, p=0.178) | |||
(total) | 207 (99.0%) | 263.758 ±61.70 | 265.00 (100.00:400.0) |
CAP Steatosis stage (Kruskal-Wallis rank sum test: p=0.436) | |||
No steatosis | 100 (48.3%) | 85.570 ±14.95 | 90.00 (12.00:98.0) |
S1 (260-284) | 33 (15.9%) | 89.364 ±7.93 | 91.00 (66.00:99.0) |
S2 (285-294) | 9 (4.3%) | 85.667 ±22.12 | 94.00 (28.00:98.0) |
S3 (≥295) | 65 (31.4%) | 87.985 ±8.92 | 91.00 (51.00:97.0) |
HRI number measurements (Spearman's rank correlation rho: R=-0.299, p<0.001) | |||
(total) | 144 (68.9%) | 2.292 ±0.97 | 3.00 (1.00:4.0) |
HRI Mean (Spearman's rank correlation rho: R=0.147, p=0.080) | |||
(total) | 144 (68.9%) | 1.220 ±0.35 | 1.19 (0.60:2.8) |
Number Attenuation measurements (Spearman's rank correlation rho: R=-0.084, p=0.236) | |||
(total) | 201 (96.2%) | 4.821 ±1.00 | 5.00 (1.00:7.0) |
Attenuation Mean (Spearman's rank correlation rho: R=0.044, p=0.536) | |||
(total) | 199 (95.2%) | 0.436 ±0.12 | 0.41 (0.16:0.8) |
Number Attenuation SOS measurements (Spearman's rank correlation rho: R=-0.125, p=0.076) | |||
(total) | 201 (96.2%) | 4.950 ±0.87 | 5.00 (1.00:7.0) |
Attenuation SOS Mean (Spearman's rank correlation rho: R=0.121, p=0.088) | |||
(total) | 201 (96.2%) | 1 530.459 ±25.27 | 1 526.60 (1 477.00:1 598.4) |
Elastography liver median 1 (Spearman's rank correlation rho: R=-0.077, p=0.269) | |||
(total) | 207 (99.0%) | 16.615 ±14.09 | 10.50 (3.30:76.7) |
Elastography liver IQR 1 (Spearman's rank correlation rho: R=-0.236, p<0.001) | |||
(total) | 203 (97.1%) | 2.951 ±3.84 | 1.70 (0.10:24.9) |
Elastography IQR/MED (Spearman's rank correlation rho: R=-0.256, p<0.001) | |||
(total) | 207 (99.0%) | 16.678 ±12.00 | 14.53 (0.00:78.9) |
Viscosity liver Median 1 (Spearman's rank correlation rho: R=0.009, p=0.904) | |||
(total) | 192 (91.9%) | 2.386 ±0.83 | 2.20 (1.10:5.0) |
Spleen diameter (Spearman's rank correlation rho: R=0.030, p=0.699) | |||
(total) | 173 (82.8%) | 12.568 ±3.11 | 12.01 (6.37:21.8) |
Spleen area (Spearman's rank correlation rho: R=-0.074, p=0.586) | |||
(total) | 56 (26.8%) | 71.894 ±34.53 | 65.96 (15.73:193.2) |
VP Diam cm (Spearman's rank correlation rho: R=-0.055, p=0.605) | |||
(total) | 92 (44.0%) | 1.159 ±0.23 | 1.15 (0.52:1.8) |
VP Speed (Spearman's rank correlation rho: R=-0.079, p=0.617) | |||
(total) | 43 (20.6%) | 27.901 ±11.14 | 26.45 (14.38:74.5) |
VP RI (Spearman's rank correlation rho: R=0.236, p=0.148) | |||
(total) | 39 (18.7%) | 0.017 ±0.02 | 0.01 (0.00:0.1) |
Hb (Spearman's rank correlation rho: R=-0.065, p=0.394) | |||
(total) | 172 (82.3%) | 13.823 ±1.91 | 13.95 (7.50:19.6) |
PTL (Spearman's rank correlation rho: R=-0.023, p=0.767) | |||
(total) | 172 (82.3%) | 186.642 ±95.26 | 181.50 (2.39:536.0) |
GOT (Spearman's rank correlation rho: R=-0.011, p=0.879) | |||
(total) | 181 (86.6%) | 42.967 ±49.75 | 31.00 (13.00:570.0) |
GPT (Spearman's rank correlation rho: R=-0.010, p=0.893) | |||
(total) | 182 (87.1%) | 36.099 ±45.22 | 24.00 (7.00:387.0) |
BT (Spearman's rank correlation rho: R=0.077, p=0.350) | |||
(total) | 150 (71.8%) | 1.459 ±1.52 | 0.90 (0.30:11.1) |
BD (Spearman's rank correlation rho: R=0.080, p=0.351) | |||
(total) | 137 (65.6%) | 0.585 ±1.03 | 0.31 (0.09:9.0) |
GGT (Spearman's rank correlation rho: R=0.005, p=0.950) | |||
(total) | 157 (75.1%) | 109.229 ±214.95 | 46.00 (13.00:1 914.0) |
FA (Spearman's rank correlation rho: R=0.023, p=0.771) | |||
(total) | 157 (75.1%) | 261.420 ±142.05 | 222.00 (104.00:1 042.0) |
ALB (Spearman's rank correlation rho: R=-0.102, p=0.450) | |||
(total) | 57 (27.3%) | 4.172 ±0.65 | 4.20 (2.60:5.3) |
INR (Spearman's rank correlation rho: R=0.019, p=0.846) | |||
(total) | 112 (53.6%) | 1.233 ±0.30 | 1.13 (0.90:2.7) |
COL (Spearman's rank correlation rho: R=-0.035, p=0.749) | |||
(total) | 84 (40.2%) | 189.381 ±54.61 | 186.00 (18.00:326.0) |
TG (Spearman's rank correlation rho: R=0.051, p=0.656) | |||
(total) | 78 (37.3%) | 121.038 ±61.82 | 106.50 (31.00:380.0) |
Fe (Spearman's rank correlation rho: R=-0.078, p=0.470) | |||
(total) | 88 (42.1%) | 103.216 ±45.44 | 99.00 (22.00:246.0) |
Crea (Spearman's rank correlation rho: R=-0.001, p=0.990) | |||
(total) | 156 (74.6%) | 0.821 ±0.28 | 0.77 (0.52:3.4) |
Uree (Spearman's rank correlation rho: R=0.054, p=0.615) | |||
(total) | 89 (42.6%) | 34.989 ±14.92 | 31.00 (10.00:92.0) |
Na (Spearman's rank correlation rho: R=0.094, p=0.343) | |||
(total) | 103 (49.3%) | 135.796 ±5.52 | 136.00 (89.00:142.0) |
Glicemie (Spearman's rank correlation rho: R=-0.024, p=0.774) | |||
(total) | 151 (72.2%) | 118.196 ±42.48 | 104.00 (75.70:361.7) |
CRP (Spearman's rank correlation rho: R=0.114, p=0.296) | |||
(total) | 86 (41.1%) | 1.224 ±3.21 | 0.39 (0.20:22.2) |
Attenuation IQR (Spearman's rank correlation rho: R=-0.189, p=0.008) | |||
(total) | 199 (95.2%) | 0.070 ±0.05 | 0.06 (0.00:0.3) |
Attenuation SOS IQR (Spearman's rank correlation rho: R=-0.106, p=0.132) | |||
(total) | 202 (96.7%) | 12.850 ±11.13 | 10.62 (0.00:84.0) |
2.3 Elastography liver ~ Fibroscan fibrosis stage, SI>95
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 54.2% | 100.0% | 0.0% | 54.2% | |
1 | 54.2% | 100.0% | 0.0% | 54.2% | |
2 | 54.2% | 100.0% | 0.0% | 54.2% | |
3 | 54.2% | 100.0% | 0.0% | 54.2% | |
4 | 54.2% | 100.0% | 0.0% | 54.2% | |
5 | 70.8% | 100.0% | 36.4% | 65.0% | 100.0% |
6 | 79.2% | 100.0% | 54.5% | 72.2% | 100.0% |
7 | 91.7% | 100.0% | 81.8% | 86.7% | 100.0% |
8 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
9 | 87.5% | 76.9% | 100.0% | 100.0% | 78.6% |
10 | 83.3% | 69.2% | 100.0% | 100.0% | 73.3% |
11 | 83.3% | 69.2% | 100.0% | 100.0% | 73.3% |
12 | 79.2% | 61.5% | 100.0% | 100.0% | 68.8% |
13 | 79.2% | 61.5% | 100.0% | 100.0% | 68.8% |
14 | 79.2% | 61.5% | 100.0% | 100.0% | 68.8% |
15 | 75.0% | 53.8% | 100.0% | 100.0% | 64.7% |
16 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
17 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
18 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
19 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
20 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
21 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
22 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
23 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
24 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
25 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
26 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
27 | 70.8% | 46.2% | 100.0% | 100.0% | 61.1% |
28 | 66.7% | 38.5% | 100.0% | 100.0% | 57.9% |
29 | 66.7% | 38.5% | 100.0% | 100.0% | 57.9% |
30 | 66.7% | 38.5% | 100.0% | 100.0% | 57.9% |
31 | 66.7% | 38.5% | 100.0% | 100.0% | 57.9% |
32 | 66.7% | 38.5% | 100.0% | 100.0% | 57.9% |
33 | 62.5% | 30.8% | 100.0% | 100.0% | 55.0% |
34 | 58.3% | 23.1% | 100.0% | 100.0% | 52.4% |
35 | 54.2% | 15.4% | 100.0% | 100.0% | 50.0% |
36 | 54.2% | 15.4% | 100.0% | 100.0% | 50.0% |
37 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
38 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
39 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
40 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
41 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
42 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
43 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
44 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
45 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
46 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
47 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
48 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
49 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
50 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
51 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
52 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
53 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
54 | 50.0% | 7.7% | 100.0% | 100.0% | 47.8% |
55 | 45.8% | 0.0% | 100.0% | 45.8% | |
56 | 45.8% | 0.0% | 100.0% | 45.8% | |
57 | 45.8% | 0.0% | 100.0% | 45.8% | |
58 | 45.8% | 0.0% | 100.0% | 45.8% | |
59 | 45.8% | 0.0% | 100.0% | 45.8% | |
60 | 45.8% | 0.0% | 100.0% | 45.8% | |
61 | 45.8% | 0.0% | 100.0% | 45.8% | |
62 | 45.8% | 0.0% | 100.0% | 45.8% | |
63 | 45.8% | 0.0% | 100.0% | 45.8% | |
64 | 45.8% | 0.0% | 100.0% | 45.8% | |
65 | 45.8% | 0.0% | 100.0% | 45.8% | |
66 | 45.8% | 0.0% | 100.0% | 45.8% | |
67 | 45.8% | 0.0% | 100.0% | 45.8% | |
68 | 45.8% | 0.0% | 100.0% | 45.8% | |
69 | 45.8% | 0.0% | 100.0% | 45.8% | |
70 | 45.8% | 0.0% | 100.0% | 45.8% | |
71 | 45.8% | 0.0% | 100.0% | 45.8% | |
72 | 45.8% | 0.0% | 100.0% | 45.8% | |
73 | 45.8% | 0.0% | 100.0% | 45.8% | |
74 | 45.8% | 0.0% | 100.0% | 45.8% | |
75 | 45.8% | 0.0% | 100.0% | 45.8% | |
76 | 45.8% | 0.0% | 100.0% | 45.8% | |
77 | 45.8% | 0.0% | 100.0% | 45.8% | |
78 | 45.8% | 0.0% | 100.0% | 45.8% | |
79 | 45.8% | 0.0% | 100.0% | 45.8% | |
80 | 45.8% | 0.0% | 100.0% | 45.8% | |
81 | 45.8% | 0.0% | 100.0% | 45.8% | |
82 | 45.8% | 0.0% | 100.0% | 45.8% | |
83 | 45.8% | 0.0% | 100.0% | 45.8% | |
84 | 45.8% | 0.0% | 100.0% | 45.8% | |
85 | 45.8% | 0.0% | 100.0% | 45.8% | |
86 | 45.8% | 0.0% | 100.0% | 45.8% | |
87 | 45.8% | 0.0% | 100.0% | 45.8% | |
88 | 45.8% | 0.0% | 100.0% | 45.8% | |
89 | 45.8% | 0.0% | 100.0% | 45.8% | |
90 | 45.8% | 0.0% | 100.0% | 45.8% | |
91 | 45.8% | 0.0% | 100.0% | 45.8% | |
92 | 45.8% | 0.0% | 100.0% | 45.8% | |
93 | 45.8% | 0.0% | 100.0% | 45.8% | |
94 | 45.8% | 0.0% | 100.0% | 45.8% | |
95 | 45.8% | 0.0% | 100.0% | 45.8% | |
96 | 45.8% | 0.0% | 100.0% | 45.8% | |
97 | 45.8% | 0.0% | 100.0% | 45.8% | |
98 | 45.8% | 0.0% | 100.0% | 45.8% | |
99 | 45.8% | 0.0% | 100.0% | 45.8% | |
100 | 45.8% | 0.0% | 100.0% | 45.8% |
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 37.5% | 100.0% | 0.0% | 37.5% | |
1 | 37.5% | 100.0% | 0.0% | 37.5% | |
2 | 37.5% | 100.0% | 0.0% | 37.5% | |
3 | 37.5% | 100.0% | 0.0% | 37.5% | |
4 | 37.5% | 100.0% | 0.0% | 37.5% | |
5 | 54.2% | 100.0% | 26.7% | 45.0% | 100.0% |
6 | 62.5% | 100.0% | 40.0% | 50.0% | 100.0% |
7 | 75.0% | 100.0% | 60.0% | 60.0% | 100.0% |
8 | 83.3% | 100.0% | 73.3% | 69.2% | 100.0% |
9 | 87.5% | 88.9% | 86.7% | 80.0% | 92.9% |
10 | 91.7% | 88.9% | 93.3% | 88.9% | 93.3% |
11 | 91.7% | 88.9% | 93.3% | 88.9% | 93.3% |
12 | 95.8% | 88.9% | 100.0% | 100.0% | 93.8% |
13 | 95.8% | 88.9% | 100.0% | 100.0% | 93.8% |
14 | 95.8% | 88.9% | 100.0% | 100.0% | 93.8% |
15 | 91.7% | 77.8% | 100.0% | 100.0% | 88.2% |
16 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
17 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
18 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
19 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
20 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
21 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
22 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
23 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
24 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
25 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
26 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
27 | 87.5% | 66.7% | 100.0% | 100.0% | 83.3% |
28 | 83.3% | 55.6% | 100.0% | 100.0% | 78.9% |
29 | 83.3% | 55.6% | 100.0% | 100.0% | 78.9% |
30 | 83.3% | 55.6% | 100.0% | 100.0% | 78.9% |
31 | 83.3% | 55.6% | 100.0% | 100.0% | 78.9% |
32 | 83.3% | 55.6% | 100.0% | 100.0% | 78.9% |
33 | 79.2% | 44.4% | 100.0% | 100.0% | 75.0% |
34 | 75.0% | 33.3% | 100.0% | 100.0% | 71.4% |
35 | 70.8% | 22.2% | 100.0% | 100.0% | 68.2% |
36 | 70.8% | 22.2% | 100.0% | 100.0% | 68.2% |
37 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
38 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
39 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
40 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
41 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
42 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
43 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
44 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
45 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
46 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
47 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
48 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
49 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
50 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
51 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
52 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
53 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
54 | 66.7% | 11.1% | 100.0% | 100.0% | 65.2% |
55 | 62.5% | 0.0% | 100.0% | 62.5% | |
56 | 62.5% | 0.0% | 100.0% | 62.5% | |
57 | 62.5% | 0.0% | 100.0% | 62.5% | |
58 | 62.5% | 0.0% | 100.0% | 62.5% | |
59 | 62.5% | 0.0% | 100.0% | 62.5% | |
60 | 62.5% | 0.0% | 100.0% | 62.5% | |
61 | 62.5% | 0.0% | 100.0% | 62.5% | |
62 | 62.5% | 0.0% | 100.0% | 62.5% | |
63 | 62.5% | 0.0% | 100.0% | 62.5% | |
64 | 62.5% | 0.0% | 100.0% | 62.5% | |
65 | 62.5% | 0.0% | 100.0% | 62.5% | |
66 | 62.5% | 0.0% | 100.0% | 62.5% | |
67 | 62.5% | 0.0% | 100.0% | 62.5% | |
68 | 62.5% | 0.0% | 100.0% | 62.5% | |
69 | 62.5% | 0.0% | 100.0% | 62.5% | |
70 | 62.5% | 0.0% | 100.0% | 62.5% | |
71 | 62.5% | 0.0% | 100.0% | 62.5% | |
72 | 62.5% | 0.0% | 100.0% | 62.5% | |
73 | 62.5% | 0.0% | 100.0% | 62.5% | |
74 | 62.5% | 0.0% | 100.0% | 62.5% | |
75 | 62.5% | 0.0% | 100.0% | 62.5% | |
76 | 62.5% | 0.0% | 100.0% | 62.5% | |
77 | 62.5% | 0.0% | 100.0% | 62.5% | |
78 | 62.5% | 0.0% | 100.0% | 62.5% | |
79 | 62.5% | 0.0% | 100.0% | 62.5% | |
80 | 62.5% | 0.0% | 100.0% | 62.5% | |
81 | 62.5% | 0.0% | 100.0% | 62.5% | |
82 | 62.5% | 0.0% | 100.0% | 62.5% | |
83 | 62.5% | 0.0% | 100.0% | 62.5% | |
84 | 62.5% | 0.0% | 100.0% | 62.5% | |
85 | 62.5% | 0.0% | 100.0% | 62.5% | |
86 | 62.5% | 0.0% | 100.0% | 62.5% | |
87 | 62.5% | 0.0% | 100.0% | 62.5% | |
88 | 62.5% | 0.0% | 100.0% | 62.5% | |
89 | 62.5% | 0.0% | 100.0% | 62.5% | |
90 | 62.5% | 0.0% | 100.0% | 62.5% | |
91 | 62.5% | 0.0% | 100.0% | 62.5% | |
92 | 62.5% | 0.0% | 100.0% | 62.5% | |
93 | 62.5% | 0.0% | 100.0% | 62.5% | |
94 | 62.5% | 0.0% | 100.0% | 62.5% | |
95 | 62.5% | 0.0% | 100.0% | 62.5% | |
96 | 62.5% | 0.0% | 100.0% | 62.5% | |
97 | 62.5% | 0.0% | 100.0% | 62.5% | |
98 | 62.5% | 0.0% | 100.0% | 62.5% | |
99 | 62.5% | 0.0% | 100.0% | 62.5% | |
100 | 62.5% | 0.0% | 100.0% | 62.5% |
2.4 Elastography liver ~ Fibroscan fibrosis stage, SI>90
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 59.3% | 100.0% | 0.0% | 59.3% | |
1 | 59.3% | 100.0% | 0.0% | 59.3% | |
2 | 59.3% | 100.0% | 0.0% | 59.3% | |
3 | 59.3% | 100.0% | 0.0% | 59.3% | |
4 | 61.1% | 100.0% | 4.5% | 60.4% | 100.0% |
5 | 73.1% | 100.0% | 34.1% | 68.8% | 100.0% |
6 | 82.4% | 100.0% | 56.8% | 77.1% | 100.0% |
7 | 89.8% | 96.9% | 79.5% | 87.3% | 94.6% |
8 | 90.7% | 92.2% | 88.6% | 92.2% | 88.6% |
9 | 85.2% | 81.2% | 90.9% | 92.9% | 76.9% |
10 | 85.2% | 78.1% | 95.5% | 96.2% | 75.0% |
11 | 84.3% | 76.6% | 95.5% | 96.1% | 73.7% |
12 | 81.5% | 70.3% | 97.7% | 97.8% | 69.4% |
13 | 79.6% | 67.2% | 97.7% | 97.7% | 67.2% |
14 | 79.6% | 67.2% | 97.7% | 97.7% | 67.2% |
15 | 77.8% | 64.1% | 97.7% | 97.6% | 65.2% |
16 | 73.1% | 56.2% | 97.7% | 97.3% | 60.6% |
17 | 71.3% | 53.1% | 97.7% | 97.1% | 58.9% |
18 | 70.4% | 51.6% | 97.7% | 97.1% | 58.1% |
19 | 68.5% | 48.4% | 97.7% | 96.9% | 56.6% |
20 | 66.7% | 45.3% | 97.7% | 96.7% | 55.1% |
21 | 65.7% | 43.8% | 97.7% | 96.6% | 54.4% |
22 | 63.9% | 40.6% | 97.7% | 96.3% | 53.1% |
23 | 63.9% | 40.6% | 97.7% | 96.3% | 53.1% |
24 | 62.0% | 37.5% | 97.7% | 96.0% | 51.8% |
25 | 62.0% | 37.5% | 97.7% | 96.0% | 51.8% |
26 | 61.1% | 35.9% | 97.7% | 95.8% | 51.2% |
27 | 60.2% | 34.4% | 97.7% | 95.7% | 50.6% |
28 | 57.4% | 29.7% | 97.7% | 95.0% | 48.9% |
29 | 57.4% | 28.1% | 100.0% | 100.0% | 48.9% |
30 | 57.4% | 28.1% | 100.0% | 100.0% | 48.9% |
31 | 57.4% | 28.1% | 100.0% | 100.0% | 48.9% |
32 | 56.5% | 26.6% | 100.0% | 100.0% | 48.4% |
33 | 55.6% | 25.0% | 100.0% | 100.0% | 47.8% |
34 | 54.6% | 23.4% | 100.0% | 100.0% | 47.3% |
35 | 51.9% | 18.8% | 100.0% | 100.0% | 45.8% |
36 | 51.9% | 18.8% | 100.0% | 100.0% | 45.8% |
37 | 50.0% | 15.6% | 100.0% | 100.0% | 44.9% |
38 | 50.0% | 15.6% | 100.0% | 100.0% | 44.9% |
39 | 48.1% | 12.5% | 100.0% | 100.0% | 44.0% |
40 | 48.1% | 12.5% | 100.0% | 100.0% | 44.0% |
41 | 47.2% | 10.9% | 100.0% | 100.0% | 43.6% |
42 | 46.3% | 9.4% | 100.0% | 100.0% | 43.1% |
43 | 46.3% | 9.4% | 100.0% | 100.0% | 43.1% |
44 | 45.4% | 7.8% | 100.0% | 100.0% | 42.7% |
45 | 45.4% | 7.8% | 100.0% | 100.0% | 42.7% |
46 | 44.4% | 6.2% | 100.0% | 100.0% | 42.3% |
47 | 43.5% | 4.7% | 100.0% | 100.0% | 41.9% |
48 | 43.5% | 4.7% | 100.0% | 100.0% | 41.9% |
49 | 43.5% | 4.7% | 100.0% | 100.0% | 41.9% |
50 | 43.5% | 4.7% | 100.0% | 100.0% | 41.9% |
51 | 43.5% | 4.7% | 100.0% | 100.0% | 41.9% |
52 | 42.6% | 3.1% | 100.0% | 100.0% | 41.5% |
53 | 42.6% | 3.1% | 100.0% | 100.0% | 41.5% |
54 | 42.6% | 3.1% | 100.0% | 100.0% | 41.5% |
55 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
56 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
57 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
58 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
59 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
60 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
61 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
62 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
63 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
64 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
65 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
66 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
67 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
68 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
69 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
70 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
71 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
72 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
73 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
74 | 41.7% | 1.6% | 100.0% | 100.0% | 41.1% |
75 | 40.7% | 0.0% | 100.0% | 40.7% | |
76 | 40.7% | 0.0% | 100.0% | 40.7% | |
77 | 40.7% | 0.0% | 100.0% | 40.7% | |
78 | 40.7% | 0.0% | 100.0% | 40.7% | |
79 | 40.7% | 0.0% | 100.0% | 40.7% | |
80 | 40.7% | 0.0% | 100.0% | 40.7% | |
81 | 40.7% | 0.0% | 100.0% | 40.7% | |
82 | 40.7% | 0.0% | 100.0% | 40.7% | |
83 | 40.7% | 0.0% | 100.0% | 40.7% | |
84 | 40.7% | 0.0% | 100.0% | 40.7% | |
85 | 40.7% | 0.0% | 100.0% | 40.7% | |
86 | 40.7% | 0.0% | 100.0% | 40.7% | |
87 | 40.7% | 0.0% | 100.0% | 40.7% | |
88 | 40.7% | 0.0% | 100.0% | 40.7% | |
89 | 40.7% | 0.0% | 100.0% | 40.7% | |
90 | 40.7% | 0.0% | 100.0% | 40.7% | |
91 | 40.7% | 0.0% | 100.0% | 40.7% | |
92 | 40.7% | 0.0% | 100.0% | 40.7% | |
93 | 40.7% | 0.0% | 100.0% | 40.7% | |
94 | 40.7% | 0.0% | 100.0% | 40.7% | |
95 | 40.7% | 0.0% | 100.0% | 40.7% | |
96 | 40.7% | 0.0% | 100.0% | 40.7% | |
97 | 40.7% | 0.0% | 100.0% | 40.7% | |
98 | 40.7% | 0.0% | 100.0% | 40.7% | |
99 | 40.7% | 0.0% | 100.0% | 40.7% | |
100 | 40.7% | 0.0% | 100.0% | 40.7% |
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 46.3% | 100.0% | 0.0% | 46.3% | |
1 | 46.3% | 100.0% | 0.0% | 46.3% | |
2 | 46.3% | 100.0% | 0.0% | 46.3% | |
3 | 46.3% | 100.0% | 0.0% | 46.3% | |
4 | 48.1% | 100.0% | 3.4% | 47.2% | 100.0% |
5 | 60.2% | 100.0% | 25.9% | 53.8% | 100.0% |
6 | 69.4% | 100.0% | 43.1% | 60.2% | 100.0% |
7 | 78.7% | 98.0% | 62.1% | 69.0% | 97.3% |
8 | 85.2% | 98.0% | 74.1% | 76.6% | 97.7% |
9 | 87.0% | 92.0% | 82.8% | 82.1% | 92.3% |
10 | 90.7% | 92.0% | 89.7% | 88.5% | 92.9% |
11 | 91.7% | 92.0% | 91.4% | 90.2% | 93.0% |
12 | 90.7% | 86.0% | 94.8% | 93.5% | 88.7% |
13 | 90.7% | 84.0% | 96.6% | 95.5% | 87.5% |
14 | 90.7% | 84.0% | 96.6% | 95.5% | 87.5% |
15 | 88.9% | 80.0% | 96.6% | 95.2% | 84.8% |
16 | 86.1% | 72.0% | 98.3% | 97.3% | 80.3% |
17 | 84.3% | 68.0% | 98.3% | 97.1% | 78.1% |
18 | 83.3% | 66.0% | 98.3% | 97.1% | 77.0% |
19 | 81.5% | 62.0% | 98.3% | 96.9% | 75.0% |
20 | 79.6% | 58.0% | 98.3% | 96.7% | 73.1% |
21 | 78.7% | 56.0% | 98.3% | 96.6% | 72.2% |
22 | 76.9% | 52.0% | 98.3% | 96.3% | 70.4% |
23 | 76.9% | 52.0% | 98.3% | 96.3% | 70.4% |
24 | 75.0% | 48.0% | 98.3% | 96.0% | 68.7% |
25 | 75.0% | 48.0% | 98.3% | 96.0% | 68.7% |
26 | 74.1% | 46.0% | 98.3% | 95.8% | 67.9% |
27 | 73.1% | 44.0% | 98.3% | 95.7% | 67.1% |
28 | 70.4% | 38.0% | 98.3% | 95.0% | 64.8% |
29 | 70.4% | 36.0% | 100.0% | 100.0% | 64.4% |
30 | 70.4% | 36.0% | 100.0% | 100.0% | 64.4% |
31 | 70.4% | 36.0% | 100.0% | 100.0% | 64.4% |
32 | 69.4% | 34.0% | 100.0% | 100.0% | 63.7% |
33 | 68.5% | 32.0% | 100.0% | 100.0% | 63.0% |
34 | 67.6% | 30.0% | 100.0% | 100.0% | 62.4% |
35 | 64.8% | 24.0% | 100.0% | 100.0% | 60.4% |
36 | 64.8% | 24.0% | 100.0% | 100.0% | 60.4% |
37 | 63.0% | 20.0% | 100.0% | 100.0% | 59.2% |
38 | 63.0% | 20.0% | 100.0% | 100.0% | 59.2% |
39 | 61.1% | 16.0% | 100.0% | 100.0% | 58.0% |
40 | 61.1% | 16.0% | 100.0% | 100.0% | 58.0% |
41 | 60.2% | 14.0% | 100.0% | 100.0% | 57.4% |
42 | 59.3% | 12.0% | 100.0% | 100.0% | 56.9% |
43 | 59.3% | 12.0% | 100.0% | 100.0% | 56.9% |
44 | 58.3% | 10.0% | 100.0% | 100.0% | 56.3% |
45 | 58.3% | 10.0% | 100.0% | 100.0% | 56.3% |
46 | 57.4% | 8.0% | 100.0% | 100.0% | 55.8% |
47 | 56.5% | 6.0% | 100.0% | 100.0% | 55.2% |
48 | 56.5% | 6.0% | 100.0% | 100.0% | 55.2% |
49 | 56.5% | 6.0% | 100.0% | 100.0% | 55.2% |
50 | 56.5% | 6.0% | 100.0% | 100.0% | 55.2% |
51 | 56.5% | 6.0% | 100.0% | 100.0% | 55.2% |
52 | 55.6% | 4.0% | 100.0% | 100.0% | 54.7% |
53 | 55.6% | 4.0% | 100.0% | 100.0% | 54.7% |
54 | 55.6% | 4.0% | 100.0% | 100.0% | 54.7% |
55 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
56 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
57 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
58 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
59 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
60 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
61 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
62 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
63 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
64 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
65 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
66 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
67 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
68 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
69 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
70 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
71 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
72 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
73 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
74 | 54.6% | 2.0% | 100.0% | 100.0% | 54.2% |
75 | 53.7% | 0.0% | 100.0% | 53.7% | |
76 | 53.7% | 0.0% | 100.0% | 53.7% | |
77 | 53.7% | 0.0% | 100.0% | 53.7% | |
78 | 53.7% | 0.0% | 100.0% | 53.7% | |
79 | 53.7% | 0.0% | 100.0% | 53.7% | |
80 | 53.7% | 0.0% | 100.0% | 53.7% | |
81 | 53.7% | 0.0% | 100.0% | 53.7% | |
82 | 53.7% | 0.0% | 100.0% | 53.7% | |
83 | 53.7% | 0.0% | 100.0% | 53.7% | |
84 | 53.7% | 0.0% | 100.0% | 53.7% | |
85 | 53.7% | 0.0% | 100.0% | 53.7% | |
86 | 53.7% | 0.0% | 100.0% | 53.7% | |
87 | 53.7% | 0.0% | 100.0% | 53.7% | |
88 | 53.7% | 0.0% | 100.0% | 53.7% | |
89 | 53.7% | 0.0% | 100.0% | 53.7% | |
90 | 53.7% | 0.0% | 100.0% | 53.7% | |
91 | 53.7% | 0.0% | 100.0% | 53.7% | |
92 | 53.7% | 0.0% | 100.0% | 53.7% | |
93 | 53.7% | 0.0% | 100.0% | 53.7% | |
94 | 53.7% | 0.0% | 100.0% | 53.7% | |
95 | 53.7% | 0.0% | 100.0% | 53.7% | |
96 | 53.7% | 0.0% | 100.0% | 53.7% | |
97 | 53.7% | 0.0% | 100.0% | 53.7% | |
98 | 53.7% | 0.0% | 100.0% | 53.7% | |
99 | 53.7% | 0.0% | 100.0% | 53.7% | |
100 | 53.7% | 0.0% | 100.0% | 53.7% |
2.5 Elastography liver ~ Fibroscan fibrosis stage, SI>85
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 61.0% | 100.0% | 0.0% | 61.0% | |
1 | 61.0% | 100.0% | 0.0% | 61.0% | |
2 | 61.0% | 100.0% | 0.0% | 61.0% | |
3 | 61.0% | 100.0% | 0.0% | 61.0% | |
4 | 64.3% | 100.0% | 8.3% | 63.1% | 100.0% |
5 | 75.3% | 100.0% | 36.7% | 71.2% | 100.0% |
6 | 81.8% | 98.9% | 55.0% | 77.5% | 97.1% |
7 | 87.7% | 95.7% | 75.0% | 85.7% | 91.8% |
8 | 89.6% | 91.5% | 86.7% | 91.5% | 86.7% |
9 | 87.0% | 84.0% | 91.7% | 94.0% | 78.6% |
10 | 85.1% | 78.7% | 95.0% | 96.1% | 74.0% |
11 | 83.8% | 76.6% | 95.0% | 96.0% | 72.2% |
12 | 80.5% | 70.2% | 96.7% | 97.1% | 67.4% |
13 | 78.6% | 67.0% | 96.7% | 96.9% | 65.2% |
14 | 77.9% | 66.0% | 96.7% | 96.9% | 64.4% |
15 | 76.0% | 62.8% | 96.7% | 96.7% | 62.4% |
16 | 72.7% | 57.4% | 96.7% | 96.4% | 59.2% |
17 | 70.8% | 54.3% | 96.7% | 96.2% | 57.4% |
18 | 68.2% | 50.0% | 96.7% | 95.9% | 55.2% |
19 | 66.9% | 47.9% | 96.7% | 95.7% | 54.2% |
20 | 65.6% | 45.7% | 96.7% | 95.6% | 53.2% |
21 | 64.3% | 43.6% | 96.7% | 95.3% | 52.3% |
22 | 63.0% | 41.5% | 96.7% | 95.1% | 51.3% |
23 | 62.3% | 40.4% | 96.7% | 95.0% | 50.9% |
24 | 61.0% | 38.3% | 96.7% | 94.7% | 50.0% |
25 | 60.4% | 37.2% | 96.7% | 94.6% | 49.6% |
26 | 59.7% | 36.2% | 96.7% | 94.4% | 49.2% |
27 | 59.1% | 35.1% | 96.7% | 94.3% | 48.7% |
28 | 57.1% | 31.9% | 96.7% | 93.8% | 47.5% |
29 | 57.1% | 30.9% | 98.3% | 96.7% | 47.6% |
30 | 57.1% | 30.9% | 98.3% | 96.7% | 47.6% |
31 | 57.1% | 30.9% | 98.3% | 96.7% | 47.6% |
32 | 56.5% | 29.8% | 98.3% | 96.6% | 47.2% |
33 | 54.5% | 26.6% | 98.3% | 96.2% | 46.1% |
34 | 53.2% | 24.5% | 98.3% | 95.8% | 45.4% |
35 | 51.3% | 21.3% | 98.3% | 95.2% | 44.4% |
36 | 51.3% | 21.3% | 98.3% | 95.2% | 44.4% |
37 | 48.7% | 17.0% | 98.3% | 94.1% | 43.1% |
38 | 48.7% | 16.0% | 100.0% | 100.0% | 43.2% |
39 | 45.5% | 10.6% | 100.0% | 100.0% | 41.7% |
40 | 45.5% | 10.6% | 100.0% | 100.0% | 41.7% |
41 | 44.8% | 9.6% | 100.0% | 100.0% | 41.4% |
42 | 44.2% | 8.5% | 100.0% | 100.0% | 41.1% |
43 | 44.2% | 8.5% | 100.0% | 100.0% | 41.1% |
44 | 43.5% | 7.4% | 100.0% | 100.0% | 40.8% |
45 | 43.5% | 7.4% | 100.0% | 100.0% | 40.8% |
46 | 42.2% | 5.3% | 100.0% | 100.0% | 40.3% |
47 | 41.6% | 4.3% | 100.0% | 100.0% | 40.0% |
48 | 41.6% | 4.3% | 100.0% | 100.0% | 40.0% |
49 | 41.6% | 4.3% | 100.0% | 100.0% | 40.0% |
50 | 41.6% | 4.3% | 100.0% | 100.0% | 40.0% |
51 | 41.6% | 4.3% | 100.0% | 100.0% | 40.0% |
52 | 40.9% | 3.2% | 100.0% | 100.0% | 39.7% |
53 | 40.9% | 3.2% | 100.0% | 100.0% | 39.7% |
54 | 40.9% | 3.2% | 100.0% | 100.0% | 39.7% |
55 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
56 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
57 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
58 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
59 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
60 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
61 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
62 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
63 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
64 | 40.3% | 2.1% | 100.0% | 100.0% | 39.5% |
65 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
66 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
67 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
68 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
69 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
70 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
71 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
72 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
73 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
74 | 39.6% | 1.1% | 100.0% | 100.0% | 39.2% |
75 | 39.0% | 0.0% | 100.0% | 39.0% | |
76 | 39.0% | 0.0% | 100.0% | 39.0% | |
77 | 39.0% | 0.0% | 100.0% | 39.0% | |
78 | 39.0% | 0.0% | 100.0% | 39.0% | |
79 | 39.0% | 0.0% | 100.0% | 39.0% | |
80 | 39.0% | 0.0% | 100.0% | 39.0% | |
81 | 39.0% | 0.0% | 100.0% | 39.0% | |
82 | 39.0% | 0.0% | 100.0% | 39.0% | |
83 | 39.0% | 0.0% | 100.0% | 39.0% | |
84 | 39.0% | 0.0% | 100.0% | 39.0% | |
85 | 39.0% | 0.0% | 100.0% | 39.0% | |
86 | 39.0% | 0.0% | 100.0% | 39.0% | |
87 | 39.0% | 0.0% | 100.0% | 39.0% | |
88 | 39.0% | 0.0% | 100.0% | 39.0% | |
89 | 39.0% | 0.0% | 100.0% | 39.0% | |
90 | 39.0% | 0.0% | 100.0% | 39.0% | |
91 | 39.0% | 0.0% | 100.0% | 39.0% | |
92 | 39.0% | 0.0% | 100.0% | 39.0% | |
93 | 39.0% | 0.0% | 100.0% | 39.0% | |
94 | 39.0% | 0.0% | 100.0% | 39.0% | |
95 | 39.0% | 0.0% | 100.0% | 39.0% | |
96 | 39.0% | 0.0% | 100.0% | 39.0% | |
97 | 39.0% | 0.0% | 100.0% | 39.0% | |
98 | 39.0% | 0.0% | 100.0% | 39.0% | |
99 | 39.0% | 0.0% | 100.0% | 39.0% | |
100 | 39.0% | 0.0% | 100.0% | 39.0% |
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 46.8% | 100.0% | 0.0% | 46.8% | |
1 | 46.8% | 100.0% | 0.0% | 46.8% | |
2 | 46.8% | 100.0% | 0.0% | 46.8% | |
3 | 46.8% | 100.0% | 0.0% | 46.8% | |
4 | 50.0% | 100.0% | 6.1% | 48.3% | 100.0% |
5 | 61.0% | 100.0% | 26.8% | 54.5% | 100.0% |
6 | 68.8% | 100.0% | 41.5% | 60.0% | 100.0% |
7 | 77.3% | 98.6% | 58.5% | 67.6% | 98.0% |
8 | 84.4% | 98.6% | 72.0% | 75.5% | 98.3% |
9 | 87.0% | 94.4% | 80.5% | 81.0% | 94.3% |
10 | 91.6% | 94.4% | 89.0% | 88.3% | 94.8% |
11 | 92.9% | 94.4% | 91.5% | 90.7% | 94.9% |
12 | 92.2% | 88.9% | 95.1% | 94.1% | 90.7% |
13 | 91.6% | 86.1% | 96.3% | 95.4% | 88.8% |
14 | 90.9% | 84.7% | 96.3% | 95.3% | 87.8% |
15 | 89.0% | 80.6% | 96.3% | 95.1% | 84.9% |
16 | 87.0% | 75.0% | 97.6% | 96.4% | 81.6% |
17 | 85.1% | 70.8% | 97.6% | 96.2% | 79.2% |
18 | 82.5% | 65.3% | 97.6% | 95.9% | 76.2% |
19 | 81.2% | 62.5% | 97.6% | 95.7% | 74.8% |
20 | 79.9% | 59.7% | 97.6% | 95.6% | 73.4% |
21 | 78.6% | 56.9% | 97.6% | 95.3% | 72.1% |
22 | 77.3% | 54.2% | 97.6% | 95.1% | 70.8% |
23 | 76.6% | 52.8% | 97.6% | 95.0% | 70.2% |
24 | 75.3% | 50.0% | 97.6% | 94.7% | 69.0% |
25 | 74.7% | 48.6% | 97.6% | 94.6% | 68.4% |
26 | 74.0% | 47.2% | 97.6% | 94.4% | 67.8% |
27 | 73.4% | 45.8% | 97.6% | 94.3% | 67.2% |
28 | 71.4% | 41.7% | 97.6% | 93.8% | 65.6% |
29 | 71.4% | 40.3% | 98.8% | 96.7% | 65.3% |
30 | 71.4% | 40.3% | 98.8% | 96.7% | 65.3% |
31 | 71.4% | 40.3% | 98.8% | 96.7% | 65.3% |
32 | 70.8% | 38.9% | 98.8% | 96.6% | 64.8% |
33 | 68.8% | 34.7% | 98.8% | 96.2% | 63.3% |
34 | 67.5% | 31.9% | 98.8% | 95.8% | 62.3% |
35 | 65.6% | 27.8% | 98.8% | 95.2% | 60.9% |
36 | 65.6% | 27.8% | 98.8% | 95.2% | 60.9% |
37 | 63.0% | 22.2% | 98.8% | 94.1% | 59.1% |
38 | 63.0% | 20.8% | 100.0% | 100.0% | 59.0% |
39 | 59.7% | 13.9% | 100.0% | 100.0% | 56.9% |
40 | 59.7% | 13.9% | 100.0% | 100.0% | 56.9% |
41 | 59.1% | 12.5% | 100.0% | 100.0% | 56.6% |
42 | 58.4% | 11.1% | 100.0% | 100.0% | 56.2% |
43 | 58.4% | 11.1% | 100.0% | 100.0% | 56.2% |
44 | 57.8% | 9.7% | 100.0% | 100.0% | 55.8% |
45 | 57.8% | 9.7% | 100.0% | 100.0% | 55.8% |
46 | 56.5% | 6.9% | 100.0% | 100.0% | 55.0% |
47 | 55.8% | 5.6% | 100.0% | 100.0% | 54.7% |
48 | 55.8% | 5.6% | 100.0% | 100.0% | 54.7% |
49 | 55.8% | 5.6% | 100.0% | 100.0% | 54.7% |
50 | 55.8% | 5.6% | 100.0% | 100.0% | 54.7% |
51 | 55.8% | 5.6% | 100.0% | 100.0% | 54.7% |
52 | 55.2% | 4.2% | 100.0% | 100.0% | 54.3% |
53 | 55.2% | 4.2% | 100.0% | 100.0% | 54.3% |
54 | 55.2% | 4.2% | 100.0% | 100.0% | 54.3% |
55 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
56 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
57 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
58 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
59 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
60 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
61 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
62 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
63 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
64 | 54.5% | 2.8% | 100.0% | 100.0% | 53.9% |
65 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
66 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
67 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
68 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
69 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
70 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
71 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
72 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
73 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
74 | 53.9% | 1.4% | 100.0% | 100.0% | 53.6% |
75 | 53.2% | 0.0% | 100.0% | 53.2% | |
76 | 53.2% | 0.0% | 100.0% | 53.2% | |
77 | 53.2% | 0.0% | 100.0% | 53.2% | |
78 | 53.2% | 0.0% | 100.0% | 53.2% | |
79 | 53.2% | 0.0% | 100.0% | 53.2% | |
80 | 53.2% | 0.0% | 100.0% | 53.2% | |
81 | 53.2% | 0.0% | 100.0% | 53.2% | |
82 | 53.2% | 0.0% | 100.0% | 53.2% | |
83 | 53.2% | 0.0% | 100.0% | 53.2% | |
84 | 53.2% | 0.0% | 100.0% | 53.2% | |
85 | 53.2% | 0.0% | 100.0% | 53.2% | |
86 | 53.2% | 0.0% | 100.0% | 53.2% | |
87 | 53.2% | 0.0% | 100.0% | 53.2% | |
88 | 53.2% | 0.0% | 100.0% | 53.2% | |
89 | 53.2% | 0.0% | 100.0% | 53.2% | |
90 | 53.2% | 0.0% | 100.0% | 53.2% | |
91 | 53.2% | 0.0% | 100.0% | 53.2% | |
92 | 53.2% | 0.0% | 100.0% | 53.2% | |
93 | 53.2% | 0.0% | 100.0% | 53.2% | |
94 | 53.2% | 0.0% | 100.0% | 53.2% | |
95 | 53.2% | 0.0% | 100.0% | 53.2% | |
96 | 53.2% | 0.0% | 100.0% | 53.2% | |
97 | 53.2% | 0.0% | 100.0% | 53.2% | |
98 | 53.2% | 0.0% | 100.0% | 53.2% | |
99 | 53.2% | 0.0% | 100.0% | 53.2% | |
100 | 53.2% | 0.0% | 100.0% | 53.2% |
2.6 Elastography liver ~ Fibroscan fibrosis stage, SI>80
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 57.8% | 100.0% | 0.0% | 57.8% | |
1 | 57.8% | 100.0% | 0.0% | 57.8% | |
2 | 57.8% | 100.0% | 0.0% | 57.8% | |
3 | 57.8% | 100.0% | 0.0% | 57.8% | |
4 | 61.3% | 100.0% | 8.2% | 59.9% | 100.0% |
5 | 72.3% | 100.0% | 34.2% | 67.6% | 100.0% |
6 | 80.9% | 99.0% | 56.2% | 75.6% | 97.6% |
7 | 87.9% | 96.0% | 76.7% | 85.0% | 93.3% |
8 | 90.2% | 92.0% | 87.7% | 91.1% | 88.9% |
9 | 88.4% | 85.0% | 93.2% | 94.4% | 81.9% |
10 | 86.7% | 80.0% | 95.9% | 96.4% | 77.8% |
11 | 85.0% | 77.0% | 95.9% | 96.2% | 75.3% |
12 | 82.1% | 71.0% | 97.3% | 97.3% | 71.0% |
13 | 79.8% | 67.0% | 97.3% | 97.1% | 68.3% |
14 | 78.6% | 65.0% | 97.3% | 97.0% | 67.0% |
15 | 76.9% | 62.0% | 97.3% | 96.9% | 65.1% |
16 | 74.0% | 57.0% | 97.3% | 96.6% | 62.3% |
17 | 72.3% | 54.0% | 97.3% | 96.4% | 60.7% |
18 | 69.9% | 50.0% | 97.3% | 96.2% | 58.7% |
19 | 68.8% | 48.0% | 97.3% | 96.0% | 57.7% |
20 | 67.6% | 46.0% | 97.3% | 95.8% | 56.8% |
21 | 66.5% | 44.0% | 97.3% | 95.7% | 55.9% |
22 | 65.3% | 42.0% | 97.3% | 95.5% | 55.0% |
23 | 64.7% | 41.0% | 97.3% | 95.3% | 54.6% |
24 | 63.6% | 39.0% | 97.3% | 95.1% | 53.8% |
25 | 63.0% | 38.0% | 97.3% | 95.0% | 53.4% |
26 | 62.4% | 37.0% | 97.3% | 94.9% | 53.0% |
27 | 61.8% | 36.0% | 97.3% | 94.7% | 52.6% |
28 | 60.1% | 33.0% | 97.3% | 94.3% | 51.4% |
29 | 60.1% | 32.0% | 98.6% | 97.0% | 51.4% |
30 | 60.1% | 32.0% | 98.6% | 97.0% | 51.4% |
31 | 60.1% | 32.0% | 98.6% | 97.0% | 51.4% |
32 | 59.5% | 31.0% | 98.6% | 96.9% | 51.1% |
33 | 57.8% | 28.0% | 98.6% | 96.6% | 50.0% |
34 | 56.1% | 25.0% | 98.6% | 96.2% | 49.0% |
35 | 54.3% | 22.0% | 98.6% | 95.7% | 48.0% |
36 | 54.3% | 22.0% | 98.6% | 95.7% | 48.0% |
37 | 51.4% | 17.0% | 98.6% | 94.4% | 46.5% |
38 | 51.4% | 16.0% | 100.0% | 100.0% | 46.5% |
39 | 48.6% | 11.0% | 100.0% | 100.0% | 45.1% |
40 | 48.6% | 11.0% | 100.0% | 100.0% | 45.1% |
41 | 48.0% | 10.0% | 100.0% | 100.0% | 44.8% |
42 | 47.4% | 9.0% | 100.0% | 100.0% | 44.5% |
43 | 47.4% | 9.0% | 100.0% | 100.0% | 44.5% |
44 | 46.8% | 8.0% | 100.0% | 100.0% | 44.2% |
45 | 46.8% | 8.0% | 100.0% | 100.0% | 44.2% |
46 | 45.7% | 6.0% | 100.0% | 100.0% | 43.7% |
47 | 45.1% | 5.0% | 100.0% | 100.0% | 43.5% |
48 | 45.1% | 5.0% | 100.0% | 100.0% | 43.5% |
49 | 45.1% | 5.0% | 100.0% | 100.0% | 43.5% |
50 | 45.1% | 5.0% | 100.0% | 100.0% | 43.5% |
51 | 45.1% | 5.0% | 100.0% | 100.0% | 43.5% |
52 | 44.5% | 4.0% | 100.0% | 100.0% | 43.2% |
53 | 44.5% | 4.0% | 100.0% | 100.0% | 43.2% |
54 | 44.5% | 4.0% | 100.0% | 100.0% | 43.2% |
55 | 43.9% | 3.0% | 100.0% | 100.0% | 42.9% |
56 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
57 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
58 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
59 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
60 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
61 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
62 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
63 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
64 | 43.4% | 2.0% | 100.0% | 100.0% | 42.7% |
65 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
66 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
67 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
68 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
69 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
70 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
71 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
72 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
73 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
74 | 42.8% | 1.0% | 100.0% | 100.0% | 42.4% |
75 | 42.2% | 0.0% | 100.0% | 42.2% | |
76 | 42.2% | 0.0% | 100.0% | 42.2% | |
77 | 42.2% | 0.0% | 100.0% | 42.2% | |
78 | 42.2% | 0.0% | 100.0% | 42.2% | |
79 | 42.2% | 0.0% | 100.0% | 42.2% | |
80 | 42.2% | 0.0% | 100.0% | 42.2% | |
81 | 42.2% | 0.0% | 100.0% | 42.2% | |
82 | 42.2% | 0.0% | 100.0% | 42.2% | |
83 | 42.2% | 0.0% | 100.0% | 42.2% | |
84 | 42.2% | 0.0% | 100.0% | 42.2% | |
85 | 42.2% | 0.0% | 100.0% | 42.2% | |
86 | 42.2% | 0.0% | 100.0% | 42.2% | |
87 | 42.2% | 0.0% | 100.0% | 42.2% | |
88 | 42.2% | 0.0% | 100.0% | 42.2% | |
89 | 42.2% | 0.0% | 100.0% | 42.2% | |
90 | 42.2% | 0.0% | 100.0% | 42.2% | |
91 | 42.2% | 0.0% | 100.0% | 42.2% | |
92 | 42.2% | 0.0% | 100.0% | 42.2% | |
93 | 42.2% | 0.0% | 100.0% | 42.2% | |
94 | 42.2% | 0.0% | 100.0% | 42.2% | |
95 | 42.2% | 0.0% | 100.0% | 42.2% | |
96 | 42.2% | 0.0% | 100.0% | 42.2% | |
97 | 42.2% | 0.0% | 100.0% | 42.2% | |
98 | 42.2% | 0.0% | 100.0% | 42.2% | |
99 | 42.2% | 0.0% | 100.0% | 42.2% | |
100 | 42.2% | 0.0% | 100.0% | 42.2% |
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 45.1% | 100.0% | 0.0% | 45.1% | |
1 | 45.1% | 100.0% | 0.0% | 45.1% | |
2 | 45.1% | 100.0% | 0.0% | 45.1% | |
3 | 45.1% | 100.0% | 0.0% | 45.1% | |
4 | 48.6% | 100.0% | 6.3% | 46.7% | 100.0% |
5 | 59.5% | 100.0% | 26.3% | 52.7% | 100.0% |
6 | 69.4% | 100.0% | 44.2% | 59.5% | 100.0% |
7 | 78.6% | 98.7% | 62.1% | 68.1% | 98.3% |
8 | 85.5% | 98.7% | 74.7% | 76.2% | 98.6% |
9 | 88.4% | 94.9% | 83.2% | 82.2% | 95.2% |
10 | 92.5% | 94.9% | 90.5% | 89.2% | 95.6% |
11 | 93.1% | 93.6% | 92.6% | 91.2% | 94.6% |
12 | 92.5% | 88.5% | 95.8% | 94.5% | 91.0% |
13 | 91.3% | 84.6% | 96.8% | 95.7% | 88.5% |
14 | 90.2% | 82.1% | 96.8% | 95.5% | 86.8% |
15 | 88.4% | 78.2% | 96.8% | 95.3% | 84.4% |
16 | 86.7% | 73.1% | 97.9% | 96.6% | 81.6% |
17 | 85.0% | 69.2% | 97.9% | 96.4% | 79.5% |
18 | 82.7% | 64.1% | 97.9% | 96.2% | 76.9% |
19 | 81.5% | 61.5% | 97.9% | 96.0% | 75.6% |
20 | 80.3% | 59.0% | 97.9% | 95.8% | 74.4% |
21 | 79.2% | 56.4% | 97.9% | 95.7% | 73.2% |
22 | 78.0% | 53.8% | 97.9% | 95.5% | 72.1% |
23 | 77.5% | 52.6% | 97.9% | 95.3% | 71.5% |
24 | 76.3% | 50.0% | 97.9% | 95.1% | 70.5% |
25 | 75.7% | 48.7% | 97.9% | 95.0% | 69.9% |
26 | 75.1% | 47.4% | 97.9% | 94.9% | 69.4% |
27 | 74.6% | 46.2% | 97.9% | 94.7% | 68.9% |
28 | 72.8% | 42.3% | 97.9% | 94.3% | 67.4% |
29 | 72.8% | 41.0% | 98.9% | 97.0% | 67.1% |
30 | 72.8% | 41.0% | 98.9% | 97.0% | 67.1% |
31 | 72.8% | 41.0% | 98.9% | 97.0% | 67.1% |
32 | 72.3% | 39.7% | 98.9% | 96.9% | 66.7% |
33 | 70.5% | 35.9% | 98.9% | 96.6% | 65.3% |
34 | 68.8% | 32.1% | 98.9% | 96.2% | 63.9% |
35 | 67.1% | 28.2% | 98.9% | 95.7% | 62.7% |
36 | 67.1% | 28.2% | 98.9% | 95.7% | 62.7% |
37 | 64.2% | 21.8% | 98.9% | 94.4% | 60.6% |
38 | 64.2% | 20.5% | 100.0% | 100.0% | 60.5% |
39 | 61.3% | 14.1% | 100.0% | 100.0% | 58.6% |
40 | 61.3% | 14.1% | 100.0% | 100.0% | 58.6% |
41 | 60.7% | 12.8% | 100.0% | 100.0% | 58.3% |
42 | 60.1% | 11.5% | 100.0% | 100.0% | 57.9% |
43 | 60.1% | 11.5% | 100.0% | 100.0% | 57.9% |
44 | 59.5% | 10.3% | 100.0% | 100.0% | 57.6% |
45 | 59.5% | 10.3% | 100.0% | 100.0% | 57.6% |
46 | 58.4% | 7.7% | 100.0% | 100.0% | 56.9% |
47 | 57.8% | 6.4% | 100.0% | 100.0% | 56.5% |
48 | 57.8% | 6.4% | 100.0% | 100.0% | 56.5% |
49 | 57.8% | 6.4% | 100.0% | 100.0% | 56.5% |
50 | 57.8% | 6.4% | 100.0% | 100.0% | 56.5% |
51 | 57.8% | 6.4% | 100.0% | 100.0% | 56.5% |
52 | 57.2% | 5.1% | 100.0% | 100.0% | 56.2% |
53 | 57.2% | 5.1% | 100.0% | 100.0% | 56.2% |
54 | 57.2% | 5.1% | 100.0% | 100.0% | 56.2% |
55 | 56.6% | 3.8% | 100.0% | 100.0% | 55.9% |
56 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
57 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
58 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
59 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
60 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
61 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
62 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
63 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
64 | 56.1% | 2.6% | 100.0% | 100.0% | 55.6% |
65 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
66 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
67 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
68 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
69 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
70 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
71 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
72 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
73 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
74 | 55.5% | 1.3% | 100.0% | 100.0% | 55.2% |
75 | 54.9% | 0.0% | 100.0% | 54.9% | |
76 | 54.9% | 0.0% | 100.0% | 54.9% | |
77 | 54.9% | 0.0% | 100.0% | 54.9% | |
78 | 54.9% | 0.0% | 100.0% | 54.9% | |
79 | 54.9% | 0.0% | 100.0% | 54.9% | |
80 | 54.9% | 0.0% | 100.0% | 54.9% | |
81 | 54.9% | 0.0% | 100.0% | 54.9% | |
82 | 54.9% | 0.0% | 100.0% | 54.9% | |
83 | 54.9% | 0.0% | 100.0% | 54.9% | |
84 | 54.9% | 0.0% | 100.0% | 54.9% | |
85 | 54.9% | 0.0% | 100.0% | 54.9% | |
86 | 54.9% | 0.0% | 100.0% | 54.9% | |
87 | 54.9% | 0.0% | 100.0% | 54.9% | |
88 | 54.9% | 0.0% | 100.0% | 54.9% | |
89 | 54.9% | 0.0% | 100.0% | 54.9% | |
90 | 54.9% | 0.0% | 100.0% | 54.9% | |
91 | 54.9% | 0.0% | 100.0% | 54.9% | |
92 | 54.9% | 0.0% | 100.0% | 54.9% | |
93 | 54.9% | 0.0% | 100.0% | 54.9% | |
94 | 54.9% | 0.0% | 100.0% | 54.9% | |
95 | 54.9% | 0.0% | 100.0% | 54.9% | |
96 | 54.9% | 0.0% | 100.0% | 54.9% | |
97 | 54.9% | 0.0% | 100.0% | 54.9% | |
98 | 54.9% | 0.0% | 100.0% | 54.9% | |
99 | 54.9% | 0.0% | 100.0% | 54.9% | |
100 | 54.9% | 0.0% | 100.0% | 54.9% |
2.7 Elastography liver ~ Fibroscan fibrosis stage, SI>75
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 59.6% | 100.0% | 0.0% | 59.6% | |
1 | 59.6% | 100.0% | 0.0% | 59.6% | |
2 | 59.6% | 100.0% | 0.0% | 59.6% | |
3 | 59.6% | 100.0% | 0.0% | 59.6% | |
4 | 62.8% | 100.0% | 8.1% | 61.6% | 100.0% |
5 | 73.2% | 100.0% | 33.8% | 69.0% | 100.0% |
6 | 82.0% | 99.1% | 56.8% | 77.1% | 97.7% |
7 | 88.0% | 95.4% | 77.0% | 86.0% | 91.9% |
8 | 89.6% | 90.8% | 87.8% | 91.7% | 86.7% |
9 | 88.0% | 84.4% | 93.2% | 94.8% | 80.2% |
10 | 86.3% | 79.8% | 95.9% | 96.7% | 76.3% |
11 | 83.6% | 75.2% | 95.9% | 96.5% | 72.4% |
12 | 80.9% | 69.7% | 97.3% | 97.4% | 68.6% |
13 | 78.1% | 65.1% | 97.3% | 97.3% | 65.5% |
14 | 77.0% | 63.3% | 97.3% | 97.2% | 64.3% |
15 | 75.4% | 60.6% | 97.3% | 97.1% | 62.6% |
16 | 72.7% | 56.0% | 97.3% | 96.8% | 60.0% |
17 | 71.0% | 53.2% | 97.3% | 96.7% | 58.5% |
18 | 68.9% | 49.5% | 97.3% | 96.4% | 56.7% |
19 | 67.8% | 47.7% | 97.3% | 96.3% | 55.8% |
20 | 66.7% | 45.9% | 97.3% | 96.2% | 55.0% |
21 | 65.6% | 44.0% | 97.3% | 96.0% | 54.1% |
22 | 63.9% | 41.3% | 97.3% | 95.7% | 52.9% |
23 | 62.8% | 39.4% | 97.3% | 95.6% | 52.2% |
24 | 61.7% | 37.6% | 97.3% | 95.3% | 51.4% |
25 | 60.7% | 35.8% | 97.3% | 95.1% | 50.7% |
26 | 59.6% | 33.9% | 97.3% | 94.9% | 50.0% |
27 | 59.0% | 33.0% | 97.3% | 94.7% | 49.7% |
28 | 57.4% | 30.3% | 97.3% | 94.3% | 48.6% |
29 | 57.4% | 29.4% | 98.6% | 97.0% | 48.7% |
30 | 57.4% | 29.4% | 98.6% | 97.0% | 48.7% |
31 | 57.4% | 29.4% | 98.6% | 97.0% | 48.7% |
32 | 56.8% | 28.4% | 98.6% | 96.9% | 48.3% |
33 | 55.2% | 25.7% | 98.6% | 96.6% | 47.4% |
34 | 53.6% | 22.9% | 98.6% | 96.2% | 46.5% |
35 | 51.9% | 20.2% | 98.6% | 95.7% | 45.6% |
36 | 51.9% | 20.2% | 98.6% | 95.7% | 45.6% |
37 | 49.2% | 15.6% | 98.6% | 94.4% | 44.2% |
38 | 49.2% | 14.7% | 100.0% | 100.0% | 44.3% |
39 | 46.4% | 10.1% | 100.0% | 100.0% | 43.0% |
40 | 46.4% | 10.1% | 100.0% | 100.0% | 43.0% |
41 | 45.9% | 9.2% | 100.0% | 100.0% | 42.8% |
42 | 45.4% | 8.3% | 100.0% | 100.0% | 42.5% |
43 | 45.4% | 8.3% | 100.0% | 100.0% | 42.5% |
44 | 44.8% | 7.3% | 100.0% | 100.0% | 42.3% |
45 | 44.8% | 7.3% | 100.0% | 100.0% | 42.3% |
46 | 43.7% | 5.5% | 100.0% | 100.0% | 41.8% |
47 | 43.2% | 4.6% | 100.0% | 100.0% | 41.6% |
48 | 43.2% | 4.6% | 100.0% | 100.0% | 41.6% |
49 | 43.2% | 4.6% | 100.0% | 100.0% | 41.6% |
50 | 43.2% | 4.6% | 100.0% | 100.0% | 41.6% |
51 | 43.2% | 4.6% | 100.0% | 100.0% | 41.6% |
52 | 42.6% | 3.7% | 100.0% | 100.0% | 41.3% |
53 | 42.6% | 3.7% | 100.0% | 100.0% | 41.3% |
54 | 42.6% | 3.7% | 100.0% | 100.0% | 41.3% |
55 | 42.1% | 2.8% | 100.0% | 100.0% | 41.1% |
56 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
57 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
58 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
59 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
60 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
61 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
62 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
63 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
64 | 41.5% | 1.8% | 100.0% | 100.0% | 40.9% |
65 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
66 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
67 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
68 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
69 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
70 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
71 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
72 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
73 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
74 | 41.0% | 0.9% | 100.0% | 100.0% | 40.7% |
75 | 40.4% | 0.0% | 100.0% | 40.4% | |
76 | 40.4% | 0.0% | 100.0% | 40.4% | |
77 | 40.4% | 0.0% | 100.0% | 40.4% | |
78 | 40.4% | 0.0% | 100.0% | 40.4% | |
79 | 40.4% | 0.0% | 100.0% | 40.4% | |
80 | 40.4% | 0.0% | 100.0% | 40.4% | |
81 | 40.4% | 0.0% | 100.0% | 40.4% | |
82 | 40.4% | 0.0% | 100.0% | 40.4% | |
83 | 40.4% | 0.0% | 100.0% | 40.4% | |
84 | 40.4% | 0.0% | 100.0% | 40.4% | |
85 | 40.4% | 0.0% | 100.0% | 40.4% | |
86 | 40.4% | 0.0% | 100.0% | 40.4% | |
87 | 40.4% | 0.0% | 100.0% | 40.4% | |
88 | 40.4% | 0.0% | 100.0% | 40.4% | |
89 | 40.4% | 0.0% | 100.0% | 40.4% | |
90 | 40.4% | 0.0% | 100.0% | 40.4% | |
91 | 40.4% | 0.0% | 100.0% | 40.4% | |
92 | 40.4% | 0.0% | 100.0% | 40.4% | |
93 | 40.4% | 0.0% | 100.0% | 40.4% | |
94 | 40.4% | 0.0% | 100.0% | 40.4% | |
95 | 40.4% | 0.0% | 100.0% | 40.4% | |
96 | 40.4% | 0.0% | 100.0% | 40.4% | |
97 | 40.4% | 0.0% | 100.0% | 40.4% | |
98 | 40.4% | 0.0% | 100.0% | 40.4% | |
99 | 40.4% | 0.0% | 100.0% | 40.4% | |
100 | 40.4% | 0.0% | 100.0% | 40.4% |
Cutoff | Acc | Se | Sp | PPV | NPV |
0 | 46.4% | 100.0% | 0.0% | 46.4% | |
1 | 46.4% | 100.0% | 0.0% | 46.4% | |
2 | 46.4% | 100.0% | 0.0% | 46.4% | |
3 | 46.4% | 100.0% | 0.0% | 46.4% | |
4 | 49.7% | 100.0% | 6.1% | 48.0% | 100.0% |
5 | 60.1% | 100.0% | 25.5% | 53.8% | 100.0% |
6 | 69.9% | 100.0% | 43.9% | 60.7% | 100.0% |
7 | 79.2% | 98.8% | 62.2% | 69.4% | 98.4% |
8 | 86.3% | 98.8% | 75.5% | 77.8% | 98.7% |
9 | 89.1% | 95.3% | 83.7% | 83.5% | 95.3% |
10 | 92.9% | 95.3% | 90.8% | 90.0% | 95.7% |
11 | 92.3% | 91.8% | 92.9% | 91.8% | 92.9% |
12 | 91.8% | 87.1% | 95.9% | 94.9% | 89.5% |
13 | 90.2% | 82.4% | 96.9% | 95.9% | 86.4% |
14 | 89.1% | 80.0% | 96.9% | 95.8% | 84.8% |
15 | 87.4% | 76.5% | 96.9% | 95.6% | 82.6% |
16 | 85.8% | 71.8% | 98.0% | 96.8% | 80.0% |
17 | 84.2% | 68.2% | 98.0% | 96.7% | 78.0% |
18 | 82.0% | 63.5% | 98.0% | 96.4% | 75.6% |
19 | 80.9% | 61.2% | 98.0% | 96.3% | 74.4% |
20 | 79.8% | 58.8% | 98.0% | 96.2% | 73.3% |
21 | 78.7% | 56.5% | 98.0% | 96.0% | 72.2% |
22 | 77.0% | 52.9% | 98.0% | 95.7% | 70.6% |
23 | 76.0% | 50.6% | 98.0% | 95.6% | 69.6% |
24 | 74.9% | 48.2% | 98.0% | 95.3% | 68.6% |
25 | 73.8% | 45.9% | 98.0% | 95.1% | 67.6% |
26 | 72.7% | 43.5% | 98.0% | 94.9% | 66.7% |
27 | 72.1% | 42.4% | 98.0% | 94.7% | 66.2% |
28 | 70.5% | 38.8% | 98.0% | 94.3% | 64.9% |
29 | 70.5% | 37.6% | 99.0% | 97.0% | 64.7% |
30 | 70.5% | 37.6% | 99.0% | 97.0% | 64.7% |
31 | 70.5% | 37.6% | 99.0% | 97.0% | 64.7% |
32 | 69.9% | 36.5% | 99.0% | 96.9% | 64.2% |
33 | 68.3% | 32.9% | 99.0% | 96.6% | 63.0% |
34 | 66.7% | 29.4% | 99.0% | 96.2% | 61.8% |
35 | 65.0% | 25.9% | 99.0% | 95.7% | 60.6% |
36 | 65.0% | 25.9% | 99.0% | 95.7% | 60.6% |
37 | 62.3% | 20.0% | 99.0% | 94.4% | 58.8% |
38 | 62.3% | 18.8% | 100.0% | 100.0% | 58.7% |
39 | 59.6% | 12.9% | 100.0% | 100.0% | 57.0% |
40 | 59.6% | 12.9% | 100.0% | 100.0% | 57.0% |
41 | 59.0% | 11.8% | 100.0% | 100.0% | 56.6% |
42 | 58.5% | 10.6% | 100.0% | 100.0% | 56.3% |
43 | 58.5% | 10.6% | 100.0% | 100.0% | 56.3% |
44 | 57.9% | 9.4% | 100.0% | 100.0% | 56.0% |
45 | 57.9% | 9.4% | 100.0% | 100.0% | 56.0% |
46 | 56.8% | 7.1% | 100.0% | 100.0% | 55.4% |
47 | 56.3% | 5.9% | 100.0% | 100.0% | 55.1% |
48 | 56.3% | 5.9% | 100.0% | 100.0% | 55.1% |
49 | 56.3% | 5.9% | 100.0% | 100.0% | 55.1% |
50 | 56.3% | 5.9% | 100.0% | 100.0% | 55.1% |
51 | 56.3% | 5.9% | 100.0% | 100.0% | 55.1% |
52 | 55.7% | 4.7% | 100.0% | 100.0% | 54.7% |
53 | 55.7% | 4.7% | 100.0% | 100.0% | 54.7% |
54 | 55.7% | 4.7% | 100.0% | 100.0% | 54.7% |
55 | 55.2% | 3.5% | 100.0% | 100.0% | 54.4% |
56 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
57 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
58 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
59 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
60 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
61 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
62 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
63 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
64 | 54.6% | 2.4% | 100.0% | 100.0% | 54.1% |
65 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
66 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
67 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
68 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
69 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
70 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
71 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
72 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
73 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
74 | 54.1% | 1.2% | 100.0% | 100.0% | 53.8% |
75 | 53.6% | 0.0% | 100.0% | 53.6% | |
76 | 53.6% | 0.0% | 100.0% | 53.6% | |
77 | 53.6% | 0.0% | 100.0% | 53.6% | |
78 | 53.6% | 0.0% | 100.0% | 53.6% | |
79 | 53.6% | 0.0% | 100.0% | 53.6% | |
80 | 53.6% | 0.0% | 100.0% | 53.6% | |
81 | 53.6% | 0.0% | 100.0% | 53.6% | |
82 | 53.6% | 0.0% | 100.0% | 53.6% | |
83 | 53.6% | 0.0% | 100.0% | 53.6% | |
84 | 53.6% | 0.0% | 100.0% | 53.6% | |
85 | 53.6% | 0.0% | 100.0% | 53.6% | |
86 | 53.6% | 0.0% | 100.0% | 53.6% | |
87 | 53.6% | 0.0% | 100.0% | 53.6% | |
88 | 53.6% | 0.0% | 100.0% | 53.6% | |
89 | 53.6% | 0.0% | 100.0% | 53.6% | |
90 | 53.6% | 0.0% | 100.0% | 53.6% | |
91 | 53.6% | 0.0% | 100.0% | 53.6% | |
92 | 53.6% | 0.0% | 100.0% | 53.6% | |
93 | 53.6% | 0.0% | 100.0% | 53.6% | |
94 | 53.6% | 0.0% | 100.0% | 53.6% | |
95 | 53.6% | 0.0% | 100.0% | 53.6% | |
96 | 53.6% | 0.0% | 100.0% | 53.6% | |
97 | 53.6% | 0.0% | 100.0% | 53.6% | |
98 | 53.6% | 0.0% | 100.0% | 53.6% | |
99 | 53.6% | 0.0% | 100.0% | 53.6% | |
100 | 53.6% | 0.0% | 100.0% | 53.6% |
2.8 Agreement: Elastography liver ~ Fibroscan fibrosis stage
Variable | Details | yes | no | Total | Statistics |
Agreement | 188 (90.0%) | 21 (10.0%) | 209 | ||
Sex | F | 92 (49.5%) | 10 (47.6%) | 102 (49.3%) | OR=1.08 [0.44, 2.66] (p>0.999) |
M | 94 (50.5%) | 11 (52.4%) | 105 (50.7%) | ||
Age (years) | M (min:max) | 59 (18:87) | 59 (42:78) | 59 (18:87) | MW: p=0.696 |
μ ±SD | 57.43 ±13.0 | 59.00 ±10.4 | 57.59 ±12.8 | ||
Cirrhosis | 90 (47.9%) | 0 | 90 (43.1%) | OR=39.51 [2.36, 661.71] (p<0.001) | |
Etiology | alcohol | 45 (26.6%) | 3 (15.8%) | 48 (25.5%) | V=0.18 (p=0.118) |
viral | 92 (54.4%) | 10 (52.6%) | 102 (54.3%) | ||
metabolic | 22 (13.0%) | 6 (31.6%) | 28 (14.9%) | ||
cholestatic liver disease | 10 (5.9%) | 0 | 10 (5.3%) | ||
APP_DZ | 40 (21.6%) | 6 (28.6%) | 46 (22.3%) | OR=0.69 [0.25, 1.89] (p=0.580) | |
APP_HTAE | 61 (33.0%) | 10 (47.6%) | 71 (34.5%) | OR=0.54 [0.22, 1.34] (p=0.226) | |
APP_CVD | 40 (21.6%) | 9 (42.9%) | 49 (23.8%) | OR=0.37 [0.14, 0.93] (p=0.054) | |
APP_COPD | 9 (4.9%) | 1 (4.8%) | 10 (4.9%) | OR=1.02 [0.12, 8.50] (p>0.999) | |
APP_Renal | 8 (4.6%) | 0 | 8 (4.1%) | OR=2.18 [0.12, 39.16] (p>0.999) | |
Alcohol | 47 (33.6%) | 3 (25.0%) | 50 (32.9%) | OR=1.52 [0.39, 5.87] (p=0.752) | |
Dislipidemia | 10 (16.1%) | 2 (20.0%) | 12 (16.7%) | OR=0.77 [0.14, 4.17] (p=0.669) | |
Weight | M (min:max) | 80 (45:123) | 80 (47:102) | 80 (45:123) | T-test: p=0.648 |
μ ±SD | 79.91 ±16.0 | 78.06 ±15.1 | 79.73 ±15.8 | ||
Height | M (min:max) | 168 (150:192) | 165 (158:182) | 168 (150:192) | MW: p=0.229 |
μ ±SD | 168.93 ±8.85 | 166.33 ±6.74 | 168.69 ±8.69 | ||
BMI | M (min:max) | 27.53 (15.57:42.24) | 28.37 (17.26:40.86) | 27.68 (15.57:42.24) | T-test: p=0.832 |
μ ±SD | 28.00 ±4.81 | 28.29 ±6.67 | 28.02 ±4.99 | ||
Fibroscan_Probe | M | 174 (92.6%) | 19 (90.5%) | 193 (92.3%) | OR=1.31 [0.28, 6.20] (p=0.667) |
XL | 14 (7.4%) | 2 (9.5%) | 16 (7.7%) | ||
Fibroscan_Value | M (min:max) | 11.1 (2.5:75) | 7.3 (4.5:11.6) | 9.7 (2.5:75) | MW: p=0.034 |
μ ±SD | 19.81 ±20.0 | 7.16 ±1.85 | 18.53 ±19.4 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 68 (36.2%) | 10 (47.6%) | 78 (37.3%) | OR=0.62 [0.25, 1.54] (p=0.345) |
F2-F4 (>7) | 120 (63.8%) | 11 (52.4%) | 131 (62.7%) | ||
Valid Elastography | 168 (89.4%) | 18 (85.7%) | 186 (89.0%) | OR=1.40 [0.38, 5.17] (p=0.710) | |
Stability index | M (min:max) | 91 (12:99) | 90.5 (72:95) | 91 (12:99) | MW: p=0.466 |
μ ±SD | 86.75 ±13.3 | 88.65 ±5.84 | 86.94 ±12.8 | ||
CAP_Value | M (min:max) | 259.5 (100:400) | 295 (130:400) | 266 (100:400) | T-test: p=0.214 |
μ ±SD | 262.18 ±61.3 | 279.76 ±62.2 | 263.95 ±61.4 | ||
CAP Steatosis stage | No steatosis | 94 (50.0%) | 6 (28.6%) | 100 (47.8%) | V=0.17 (p=0.106) |
S1 (260-284) | 30 (16.0%) | 4 (19.0%) | 34 (16.3%) | ||
S2 (285-294) | 9 (4.8%) | 0 | 9 (4.3%) | ||
S3 (≥295) | 55 (29.3%) | 11 (52.4%) | 66 (31.6%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:4) | 3 (1:4) | MW: p=0.379 |
μ ±SD | 2.26 ±0.972 | 2.47 ±1.01 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.19 (0.66:2.79) | 1.2 (0.6:1.77) | 1.19 (0.6:2.79) | MW: p=0.572 |
μ ±SD | 1.23 ±0.355 | 1.15 ±0.321 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.470 |
μ ±SD | 4.81 ±1.01 | 4.90 ±1.09 | 4.82 ±1.01 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.46 (0.25:0.71) | 0.41 (0.16:0.77) | MW: p=0.076 |
μ ±SD | 0.431 ±0.116 | 0.48 ±0.124 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.322 |
μ ±SD | 4.93 ±0.88 | 5.10 ±0.889 | 4.95 ±0.88 | ||
Attenuation SOS Mean | M (min:max) | 1526.9 (1478:1598.4) | 1525.6 (1477:1583.67) | 1526.6 (1477:1598.4) | MW: p=0.450 |
μ ±SD | 1530.91 ±24.8 | 1527.69 ±29.7 | 1530.58 ±25.2 | ||
Elastography liver median 1 | M (min:max) | 11.8 (3.3:76.7) | 7.6 (5.3:37.7) | 10.4 (3.3:76.7) | MW: p=0.123 |
μ ±SD | 17.22 ±14.4 | 10.19 ±7.92 | 16.52 ±14.1 | ||
Elastography liver IQR 1 | M (min:max) | 1.7 (0.1:24.9) | 1.3 (0.2:14.6) | 1.7 (0.1:24.9) | MW: p=0.213 |
μ ±SD | 3.04 ±3.9 | 2.04 ±3.08 | 2.94 ±3.83 | ||
Elastography IQR/MED | M (min:max) | 14.55 (0:78.95) | 14.08 (0:43.9) | 14.53 (0:78.95) | MW: p=0.888 |
μ ±SD | 16.59 ±12.1 | 16.65 ±11.7 | 16.60 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.3 (1.1:5) | 2 (1.6:3) | 2.2 (1.1:5) | MW: p=0.271 |
μ ±SD | 2.41 ±0.86 | 2.12 ±0.433 | 2.39 ±0.833 | ||
Spleen diameter | M (min:max) | 11.94 (7.26:21.8) | 13.19 (6.37:17.55) | 12.02 (6.37:21.8) | MW: p=0.465 |
μ ±SD | 12.57 ±3.13 | 12.84 ±3.18 | 12.60 ±3.12 | ||
Spleen area | M (min:max) | 72.84 (15.98:193.16) | 51.14 (15.73:67.79) | 65.96 (15.73:193.16) | MW: p=0.057 |
μ ±SD | 74.94 ±35.0 | 47.36 ±17.7 | 72.08 ±34.6 | ||
VP Diam cm | M (min:max) | 1.12 (0.52:1.62) | 1.3 (0.98:1.76) | 1.15 (0.52:1.76) | T-test: p=0.017 |
μ ±SD | 1.14 ±0.223 | 1.31 ±0.237 | 1.16 ±0.231 | ||
VP Speed | M (min:max) | 24.24 (14.38:74.5) | 26.54 (18:49.44) | 26.49 (14.38:74.5) | MW: p=0.561 |
μ ±SD | 28.11 ±11.9 | 29.46 ±10.1 | 28.39 ±11.5 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.545 |
μ ±SD | 0.0156 ±0.0227 | 0.0214 ±0.0348 | 0.0167 ±0.0249 | ||
Hb | M (min:max) | 13.9 (7.5:19.6) | 13.9 (8.7:16.3) | 13.9 (7.5:19.6) | MW: p=0.885 |
μ ±SD | 13.80 ±1.95 | 13.71 ±1.92 | 13.79 ±1.94 | ||
PTL | M (min:max) | 176 (2.39:536) | 219 (69:338) | 181.5 (2.39:536) | MW: p=0.118 |
μ ±SD | 183.57 ±97.4 | 214.76 ±76.3 | 186.62 ±95.9 | ||
GOT | M (min:max) | 32 (14:570) | 24 (13:183) | 31 (13:570) | MW: p=0.059 |
μ ±SD | 43.63 ±50.4 | 38.65 ±41.0 | 43.16 ±49.5 | ||
GPT | M (min:max) | 25 (7:387) | 20.5 (12:105) | 24 (7:387) | MW: p=0.067 |
μ ±SD | 37.55 ±47.0 | 25.72 ±21.2 | 36.39 ±45.3 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 1.05 (0.5:6) | 0.9 (0.3:11.1) | MW: p=0.525 |
μ ±SD | 1.44 ±1.52 | 1.66 ±1.54 | 1.46 ±1.52 | ||
BD | M (min:max) | 0.32 (0.09:8.96) | 0.29 (0.14:3.5) | 0.31 (0.09:8.96) | MW: p=0.592 |
μ ±SD | 0.575 ±1.04 | 0.729 ±0.924 | 0.591 ±1.03 | ||
GGT | M (min:max) | 48 (13:1128) | 42.5 (20:1914) | 46 (13:1914) | MW: p=0.982 |
μ ±SD | 101.29 ±165.3 | 171.94 ±466.5 | 108.40 ±213.7 | ||
FA | M (min:max) | 225 (104:899) | 207.5 (140:1042) | 222 (104:1042) | MW: p=0.579 |
μ ±SD | 259.94 ±131.0 | 276.00 ±217.9 | 261.55 ±141.3 | ||
ALB | M (min:max) | 4.2 (2.6:5.3) | 4.7 (2.9:5.2) | 4.2 (2.6:5.3) | MW: p=0.273 |
μ ±SD | 4.14 ±0.621 | 4.43 ±0.882 | 4.17 ±0.65 | ||
INR | M (min:max) | 1.15 (0.9:2.7) | 1.05 (0.96:1.38) | 1.14 (0.9:2.7) | MW: p=0.182 |
μ ±SD | 1.25 ±0.308 | 1.13 ±0.161 | 1.24 ±0.299 | ||
COL | M (min:max) | 184 (18:326) | 194 (153:288) | 186 (18:326) | MW: p=0.172 |
μ ±SD | 186.87 ±55.2 | 210.33 ±46.4 | 189.38 ±54.6 | ||
TG | M (min:max) | 106 (31:285) | 111 (58:380) | 106.5 (31:380) | MW: p=0.368 |
μ ±SD | 116.35 ±53.2 | 157.00 ±105.1 | 121.04 ±61.8 | ||
Fe | M (min:max) | 99 (22:246) | 116 (65:165) | 99 (22:246) | MW: p=0.671 |
μ ±SD | 102.80 ±46.2 | 108.00 ±37.6 | 103.22 ±45.4 | ||
Crea | M (min:max) | 0.77 (0.52:3.43) | 0.78 (0.58:1.01) | 0.77 (0.52:3.43) | MW: p=0.576 |
μ ±SD | 0.827 ±0.287 | 0.77 ±0.139 | 0.822 ±0.276 | ||
Uree | M (min:max) | 34 (10:92) | 28 (19:42) | 31 (10:92) | MW: p=0.088 |
μ ±SD | 36.19 ±15.7 | 28.12 ±6.69 | 35.48 ±15.3 | ||
Na | M (min:max) | 136 (89:142) | 137 (132:140) | 136 (89:142) | MW: p=0.907 |
μ ±SD | 135.76 ±5.66 | 136.38 ±2.83 | 135.81 ±5.49 | ||
Glicemie | M (min:max) | 104.25 (75.7:361.7) | 104 (86:167.5) | 104 (75.7:361.7) | MW: p=0.550 |
μ ±SD | 119.49 ±44.1 | 109.27 ±21.4 | 118.35 ±42.2 | ||
CRP | M (min:max) | 0.39 (0.22:22.2) | 0.3 (0.2:0.41) | 0.39 (0.2:22.2) | MW: p=0.168 |
μ ±SD | 1.27 ±3.28 | 0.312 ±0.0881 | 1.21 ±3.19 | ||
Attenuation IQR | M (min:max) | 0.05 (0:0.33) | 0.06 (0:0.16) | 0.06 (0:0.33) | MW: p=0.548 |
μ ±SD | 0.0696 ±0.0551 | 0.0711 ±0.0454 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 10.5 (0:84) | 12 (4:37) | 10.88 (0:84) | MW: p=0.404 |
μ ±SD | 12.84 ±11.4 | 13.39 ±7.99 | 12.90 ±11.1 | ||
Elastography cuts | <7 | 68 (36.2%) | 11 (52.4%) | 79 (37.8%) | OR=0.52 [0.21, 1.28] (p=0.160) |
≥8 | 120 (63.8%) | 10 (47.6%) | 130 (62.2%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Elastography cuts | |||
Fibroscan fibrosis stage | <7 | ≥8 | (total) |
F0-F1 (<7) | 68 (87.2% / 86.1%) | 10 (12.8% / 7.7%) | 78 (37.3%) |
F2-F4 (>7) | 11 (8.4% / 13.9%) | 120 (91.6% / 92.3%) | 131 (62.7%) |
(total) | 79 (37.8%) | 130 (62.2%) | 209 (100%) |
OR=74.18 [29.96, 183.66], phi=0.79 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 194 (92.8%) | 15 (7.2%) | 209 | ||
Sex | F | 94 (49.0%) | 8 (53.3%) | 102 (49.3%) | OR=0.84 [0.29, 2.41] (p=0.794) |
M | 98 (51.0%) | 7 (46.7%) | 105 (50.7%) | ||
Age (years) | M (min:max) | 59 (18:87) | 59 (39:77) | 59 (18:87) | MW: p=0.751 |
μ ±SD | 57.47 ±12.9 | 59.07 ±11.2 | 57.59 ±12.8 | ||
Cirrhosis | 87 (44.8%) | 3 (20.0%) | 90 (43.1%) | OR=3.25 [0.89, 11.89] (p=0.102) | |
Etiology | alcohol | 47 (26.6%) | 1 (9.1%) | 48 (25.5%) | V=0.13 (p=0.355) |
viral | 95 (53.7%) | 7 (63.6%) | 102 (54.3%) | ||
metabolic | 25 (14.1%) | 3 (27.3%) | 28 (14.9%) | ||
cholestatic liver disease | 10 (5.6%) | 0 | 10 (5.3%) | ||
APP_DZ | 45 (23.6%) | 1 (6.7%) | 46 (22.3%) | OR=4.32 [0.55, 33.72] (p=0.199) | |
APP_HTAE | 66 (34.6%) | 5 (33.3%) | 71 (34.5%) | OR=1.06 [0.35, 3.22] (p>0.999) | |
APP_CVD | 44 (23.0%) | 5 (33.3%) | 49 (23.8%) | OR=0.60 [0.19, 1.84] (p=0.357) | |
APP_COPD | 9 (4.7%) | 1 (6.7%) | 10 (4.9%) | OR=0.69 [0.08, 5.86] (p=0.539) | |
APP_Renal | 8 (4.4%) | 0 | 8 (4.1%) | OR=1.41 [0.08, 25.73] (p>0.999) | |
Alcohol | 49 (34.3%) | 1 (11.1%) | 50 (32.9%) | OR=4.17 [0.51, 34.31] (p=0.273) | |
Dislipidemia | 11 (16.9%) | 1 (14.3%) | 12 (16.7%) | OR=1.22 [0.13, 11.19] (p>0.999) | |
Weight | M (min:max) | 80 (45:123) | 72 (47:104) | 80 (45:123) | T-test: p=0.120 |
μ ±SD | 80.27 ±15.7 | 73.15 ±17.4 | 79.73 ±15.8 | ||
Height | M (min:max) | 168 (150:192) | 165 (150:180) | 168 (150:192) | MW: p=0.431 |
μ ±SD | 168.86 ±8.76 | 166.36 ±7.76 | 168.69 ±8.69 | ||
BMI | M (min:max) | 27.85 (15.57:42.24) | 26.45 (17.26:37.78) | 27.68 (15.57:42.24) | T-test: p=0.539 |
μ ±SD | 28.09 ±4.87 | 27.13 ±6.57 | 28.02 ±4.99 | ||
Fibroscan_Probe | M | 179 (92.3%) | 14 (93.3%) | 193 (92.3%) | OR=0.85 [0.10, 6.93] (p>0.999) |
XL | 15 (7.7%) | 1 (6.7%) | 16 (7.7%) | ||
Fibroscan_Value | M (min:max) | 9.8 (2.5:75) | 9.3 (4.8:20.3) | 9.7 (2.5:75) | MW: p=0.684 |
μ ±SD | 19.20 ±19.9 | 9.96 ±4.12 | 18.53 ±19.4 | ||
Fibroscan fibrosis stage | F0-F2 (<10) | 97 (50.0%) | 10 (66.7%) | 107 (51.2%) | OR=0.50 [0.16, 1.52] (p=0.286) |
F3-F4 (>10) | 97 (50.0%) | 5 (33.3%) | 102 (48.8%) | ||
Valid Elastography | 173 (89.2%) | 13 (86.7%) | 186 (89.0%) | OR=1.27 [0.27, 6.01] (p=0.673) | |
Stability index | M (min:max) | 91 (12:99) | 92 (28:97) | 91 (12:99) | MW: p=0.349 |
μ ±SD | 87.06 ±12.1 | 85.33 ±20.1 | 86.94 ±12.8 | ||
CAP_Value | M (min:max) | 266 (100:400) | 252 (100:344) | 266 (100:400) | T-test: p=0.595 |
μ ±SD | 264.58 ±61.3 | 255.80 ±64.5 | 263.95 ±61.4 | ||
CAP Steatosis stage | No steatosis | 92 (47.4%) | 8 (53.3%) | 100 (47.8%) | V=0.13 (p=0.347) |
S1 (260-284) | 34 (17.5%) | 0 | 34 (16.3%) | ||
S2 (285-294) | 8 (4.1%) | 1 (6.7%) | 9 (4.3%) | ||
S3 (≥295) | 60 (30.9%) | 6 (40.0%) | 66 (31.6%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.774 |
μ ±SD | 2.29 ±0.975 | 2.20 ±1.03 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.19 (0.68:2.79) | 1.21 (0.6:1.66) | 1.19 (0.6:2.79) | MW: p=0.892 |
μ ±SD | 1.22 ±0.353 | 1.19 ±0.351 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.074 |
μ ±SD | 4.79 ±1.0 | 5.20 ±1.15 | 4.82 ±1.01 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.43 (0.25:0.62) | 0.41 (0.16:0.77) | MW: p=0.895 |
μ ±SD | 0.436 ±0.118 | 0.435 ±0.112 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.061 |
μ ±SD | 4.91 ±0.867 | 5.33 ±0.976 | 4.95 ±0.88 | ||
Attenuation SOS Mean | M (min:max) | 1526.5 (1477:1598.4) | 1532.86 (1499:1586.6) | 1526.6 (1477:1598.4) | MW: p=0.442 |
μ ±SD | 1529.99 ±24.7 | 1537.88 ±30.9 | 1530.58 ±25.2 | ||
Elastography liver median 1 | M (min:max) | 9.85 (3.3:76.7) | 11.4 (6.5:37.7) | 10.4 (3.3:76.7) | MW: p=0.513 |
μ ±SD | 16.71 ±14.4 | 13.97 ±8.44 | 16.52 ±14.1 | ||
Elastography liver IQR 1 | M (min:max) | 1.7 (0.1:24.9) | 1.95 (0.4:14.6) | 1.7 (0.1:24.9) | MW: p=0.916 |
μ ±SD | 2.96 ±3.86 | 2.74 ±3.59 | 2.94 ±3.83 | ||
Elastography IQR/MED | M (min:max) | 14.16 (0:78.95) | 14.57 (0:44.23) | 14.53 (0:78.95) | MW: p=0.945 |
μ ±SD | 16.60 ±12.0 | 16.49 ±12.6 | 16.60 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.2 (1.1:5) | 2.4 (1.9:3) | 2.2 (1.1:5) | MW: p=0.401 |
μ ±SD | 2.39 ±0.863 | 2.38 ±0.334 | 2.39 ±0.833 | ||
Spleen diameter | M (min:max) | 12 (6.37:21.8) | 12.52 (8.41:16.67) | 12.02 (6.37:21.8) | MW: p=0.621 |
μ ±SD | 12.58 ±3.17 | 12.81 ±2.65 | 12.60 ±3.12 | ||
Spleen area | M (min:max) | 65.96 (15.73:193.16) | 72.32 (54.25:99.41) | 65.96 (15.73:193.16) | MW: p=0.613 |
μ ±SD | 71.90 ±35.4 | 74.58 ±22.9 | 72.08 ±34.6 | ||
VP Diam cm | M (min:max) | 1.12 (0.52:1.76) | 1.26 (0.87:1.55) | 1.15 (0.52:1.76) | T-test: p=0.302 |
μ ±SD | 1.15 ±0.237 | 1.23 ±0.176 | 1.16 ±0.231 | ||
VP Speed | M (min:max) | 24.24 (14.38:49.44) | 40.32 (20.28:74.5) | 26.49 (14.38:74.5) | MW: p=0.046 |
μ ±SD | 26.65 ±8.89 | 41.96 ±20.1 | 28.39 ±11.5 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.788 |
μ ±SD | 0.0153 ±0.0219 | 0.026 ±0.0422 | 0.0167 ±0.0249 | ||
Hb | M (min:max) | 14 (7.5:19.6) | 12.6 (11.4:15) | 13.9 (7.5:19.6) | MW: p=0.109 |
μ ±SD | 13.83 ±1.98 | 13.13 ±1.31 | 13.79 ±1.94 | ||
PTL | M (min:max) | 182 (2.39:536) | 167 (65:366) | 181.5 (2.39:536) | MW: p=0.524 |
μ ±SD | 187.65 ±96.3 | 171.27 ±91.4 | 186.62 ±95.9 | ||
GOT | M (min:max) | 31 (13:570) | 31.5 (20:183) | 31 (13:570) | MW: p=0.493 |
μ ±SD | 42.13 ±49.4 | 57.92 ±51.0 | 43.16 ±49.5 | ||
GPT | M (min:max) | 24.5 (7:291) | 22 (12:387) | 24 (7:387) | MW: p=0.628 |
μ ±SD | 35.05 ±38.1 | 55.58 ±105.2 | 36.39 ±45.3 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 2.2 (0.5:6.6) | 0.9 (0.3:11.1) | MW: p=0.045 |
μ ±SD | 1.36 ±1.4 | 2.90 ±2.37 | 1.46 ±1.52 | ||
BD | M (min:max) | 0.31 (0.09:8.96) | 0.9 (0.19:3.97) | 0.31 (0.09:8.96) | MW: p=0.068 |
μ ±SD | 0.527 ±0.968 | 1.41 ±1.43 | 0.591 ±1.03 | ||
GGT | M (min:max) | 47 (13:1128) | 32 (17:1914) | 46 (13:1914) | MW: p=0.914 |
μ ±SD | 97.57 ±160.9 | 288.78 ±617.3 | 108.40 ±213.7 | ||
FA | M (min:max) | 221.5 (104:899) | 327 (139:1042) | 222 (104:1042) | MW: p=0.393 |
μ ±SD | 254.85 ±125.6 | 373.22 ±292.5 | 261.55 ±141.3 | ||
ALB | M (min:max) | 4.2 (2.6:5.3) | 3.85 (3.3:4.4) | 4.2 (2.6:5.3) | MW: p=0.460 |
μ ±SD | 4.18 ±0.65 | 3.85 ±0.778 | 4.17 ±0.65 | ||
INR | M (min:max) | 1.13 (0.9:2.7) | 1.19 (0.96:1.82) | 1.14 (0.9:2.7) | MW: p=0.944 |
μ ±SD | 1.24 ±0.299 | 1.25 ±0.313 | 1.24 ±0.299 | ||
COL | M (min:max) | 185 (18:326) | 227 (153:288) | 186 (18:326) | MW: p=0.277 |
μ ±SD | 187.84 ±54.7 | 213.80 ±52.8 | 189.38 ±54.6 | ||
TG | M (min:max) | 106 (31:380) | 164 (58:239) | 106.5 (31:380) | MW: p=0.450 |
μ ±SD | 119.15 ±60.2 | 148.60 ±85.9 | 121.04 ±61.8 | ||
Fe | M (min:max) | 99 (22:246) | 126 (65:165) | 99 (22:246) | MW: p=0.672 |
μ ±SD | 102.73 ±45.7 | 111.20 ±44.2 | 103.22 ±45.4 | ||
Crea | M (min:max) | 0.77 (0.52:3.43) | 0.82 (0.64:1.01) | 0.77 (0.52:3.43) | MW: p=0.305 |
μ ±SD | 0.821 ±0.284 | 0.831 ±0.123 | 0.822 ±0.276 | ||
Uree | M (min:max) | 31 (10:92) | 31 (20:43) | 31 (10:92) | MW: p=0.560 |
μ ±SD | 35.92 ±15.8 | 31.00 ±7.95 | 35.48 ±15.3 | ||
Na | M (min:max) | 136 (89:142) | 137.5 (135:140) | 136 (89:142) | MW: p=0.191 |
μ ±SD | 135.69 ±5.62 | 137.67 ±2.07 | 135.81 ±5.49 | ||
Glicemie | M (min:max) | 104 (75.7:361.7) | 106.4 (87:169.3) | 104 (75.7:361.7) | MW: p=0.550 |
μ ±SD | 118.98 ±43.2 | 109.35 ±24.6 | 118.35 ±42.2 | ||
CRP | M (min:max) | 0.38 (0.2:22.2) | 0.55 (0.26:1.3) | 0.39 (0.2:22.2) | MW: p=0.507 |
μ ±SD | 1.25 ±3.3 | 0.672 ±0.438 | 1.21 ±3.19 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.33) | 0.06 (0:0.12) | 0.06 (0:0.33) | MW: p=0.636 |
μ ±SD | 0.0709 ±0.0555 | 0.0557 ±0.0299 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 11 (0:84) | 10.5 (2:28) | 10.88 (0:84) | MW: p=0.928 |
μ ±SD | 12.99 ±11.3 | 11.78 ±7.42 | 12.90 ±11.1 | ||
Elastography cuts | F0-F2 (<10) | 97 (50.0%) | 5 (33.3%) | 102 (48.8%) | OR=2.00 [0.66, 6.07] (p=0.286) |
F3-F4 (>10) | 97 (50.0%) | 10 (66.7%) | 107 (51.2%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Elastography cuts | |||
Fibroscan fibrosis stage | F0-F2 (<10) | F3-F4 (>10) | (total) |
F0-F2 (<10) | 97 (90.7% / 95.1%) | 10 (9.3% / 9.3%) | 107 (51.2%) |
F3-F4 (>10) | 5 (4.9% / 4.9%) | 97 (95.1% / 90.7%) | 102 (48.8%) |
(total) | 102 (48.8%) | 107 (51.2%) | 209 (100%) |
OR=188.18 [62.03, 570.89], phi=0.86 (p<0.001) | |||
2.9 Agreement: Attenuation Mean ~ CAP Steatosis stage
Variable | Details | yes | no | Total | Statistics |
Agreement | 140 (69.7%) | 61 (30.3%) | 201 | ||
Sex | F | 73 (52.5%) | 23 (38.3%) | 96 (48.2%) | OR=1.78 [0.96, 3.30] (p=0.089) |
M | 66 (47.5%) | 37 (61.7%) | 103 (51.8%) | ||
Age (years) | M (min:max) | 58 (19:87) | 63 (18:81) | 59 (18:87) | MW: p=0.028 |
μ ±SD | 56.37 ±12.2 | 59.97 ±13.6 | 57.46 ±12.7 | ||
Cirrhosis | 55 (39.3%) | 27 (44.3%) | 82 (40.8%) | OR=0.81 [0.44, 1.50] (p=0.535) | |
Etiology | alcohol | 29 (23.0%) | 17 (29.8%) | 46 (25.1%) | V=0.13 (p=0.379) |
viral | 68 (54.0%) | 32 (56.1%) | 100 (54.6%) | ||
metabolic | 23 (18.3%) | 5 (8.8%) | 28 (15.3%) | ||
cholestatic liver disease | 6 (4.8%) | 3 (5.3%) | 9 (4.9%) | ||
APP_DZ | 32 (22.9%) | 12 (20.3%) | 44 (22.1%) | OR=1.16 [0.55, 2.45] (p=0.852) | |
APP_HTAE | 46 (32.9%) | 23 (39.0%) | 69 (34.7%) | OR=0.77 [0.41, 1.44] (p=0.419) | |
APP_CVD | 27 (19.3%) | 21 (35.6%) | 48 (24.1%) | OR=0.43 [0.22, 0.85] (p=0.018) | |
APP_COPD | 5 (3.6%) | 4 (6.8%) | 9 (4.5%) | OR=0.51 [0.13, 1.97] (p=0.455) | |
APP_Renal | 4 (3.0%) | 4 (7.4%) | 8 (4.2%) | OR=0.38 [0.09, 1.58] (p=0.228) | |
Alcohol | 31 (30.4%) | 17 (38.6%) | 48 (32.9%) | OR=0.69 [0.33, 1.45] (p=0.343) | |
Dislipidemia | 9 (17.6%) | 3 (14.3%) | 12 (16.7%) | OR=1.29 [0.31, 5.31] (p>0.999) | |
Weight | M (min:max) | 80 (45:123) | 80.5 (53:112) | 80 (45:123) | T-test: p=0.418 |
μ ±SD | 79.50 ±16.5 | 81.70 ±14.7 | 80.17 ±16.0 | ||
Height | M (min:max) | 168 (150:190) | 169 (150:192) | 168 (150:192) | MW: p=0.773 |
μ ±SD | 168.80 ±8.37 | 169.21 ±9.11 | 168.92 ±8.57 | ||
BMI | M (min:max) | 27.27 (15.57:42.24) | 28.97 (19.36:36.58) | 27.85 (15.57:42.24) | T-test: p=0.502 |
μ ±SD | 27.92 ±5.29 | 28.50 ±4.38 | 28.10 ±5.02 | ||
Fibroscan_Probe | M | 131 (93.6%) | 56 (91.8%) | 187 (93.0%) | OR=1.30 [0.42, 4.05] (p=0.764) |
XL | 9 (6.4%) | 5 (8.2%) | 14 (7.0%) | ||
Fibroscan_Value | M (min:max) | 8.8 (2.5:75) | 10 (3.4:75) | 9.05 (2.5:75) | MW: p=0.983 |
μ ±SD | 18.12 ±19.2 | 17.67 ±19.9 | 17.98 ±19.4 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 55 (39.3%) | 23 (37.7%) | 78 (38.8%) | V=0.07 (p=0.649) |
F2 (7-10) | 22 (15.7%) | 7 (11.5%) | 29 (14.4%) | ||
F3-F4 (>10) | 63 (45.0%) | 31 (50.8%) | 94 (46.8%) | ||
Valid Elastography | 125 (89.3%) | 54 (88.5%) | 179 (89.1%) | OR=1.08 [0.42, 2.80] (p>0.999) | |
Stability index | M (min:max) | 90.5 (12:98) | 92 (28:99) | 91 (12:99) | MW: p=0.483 |
μ ±SD | 87.45 ±11.9 | 87.58 ±12.6 | 87.49 ±12.1 | ||
CAP_Value | M (min:max) | 253 (100:400) | 279 (100:354) | 268 (100:400) | MW: p=0.027 |
μ ±SD | 262.18 ±64.7 | 274.89 ±47.8 | 266.03 ±60.2 | ||
CAP Steatosis stage | No steatosis | 78 (55.7%) | 15 (24.6%) | 93 (46.3%) | OR=3.86 [1.97, 7.55] (p<0.001) |
S1-S3 (CAP ≥260) | 62 (44.3%) | 46 (75.4%) | 108 (53.7%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.710 |
μ ±SD | 2.27 ±0.989 | 2.33 ±0.953 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.18 (0.68:2.79) | 1.21 (0.6:2.29) | 1.19 (0.6:2.79) | MW: p=0.592 |
μ ±SD | 1.22 ±0.363 | 1.22 ±0.328 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.212 |
μ ±SD | 4.87 ±0.988 | 4.79 ±1.0 | 4.85 ±0.991 | ||
Attenuation Mean | M (min:max) | 0.43 (0.16:0.77) | 0.4 (0.17:0.6) | 0.41 (0.16:0.77) | MW: p=0.038 |
μ ±SD | 0.45 ±0.128 | 0.403 ±0.0805 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.860 |
μ ±SD | 4.96 ±0.877 | 4.98 ±0.785 | 4.97 ±0.848 | ||
Attenuation SOS Mean | M (min:max) | 1526.2 (1477:1598.4) | 1527 (1480:1584.8) | 1526.8 (1477:1598.4) | MW: p=0.616 |
μ ±SD | 1530.83 ±27.7 | 1530.38 ±19.0 | 1530.69 ±25.3 | ||
Elastography liver median 1 | M (min:max) | 9.25 (3.3:76.7) | 11.4 (3.9:74.6) | 9.6 (3.3:76.7) | MW: p=0.373 |
μ ±SD | 15.89 ±14.0 | 16.62 ±14.0 | 16.11 ±14.0 | ||
Elastography liver IQR 1 | M (min:max) | 1.6 (0.1:24.9) | 1.7 (0.2:14.6) | 1.7 (0.1:24.9) | MW: p=0.639 |
μ ±SD | 2.81 ±3.95 | 2.97 ±3.3 | 2.86 ±3.76 | ||
Elastography IQR/MED | M (min:max) | 14.16 (0:78.95) | 15.15 (0:41.18) | 14.53 (0:78.95) | MW: p=0.907 |
μ ±SD | 16.91 ±12.7 | 16.03 ±10.5 | 16.64 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.2 (1.1:4.9) | 2.4 (1.3:5) | 2.3 (1.1:5) | MW: p=0.269 |
μ ±SD | 2.38 ±0.876 | 2.44 ±0.748 | 2.40 ±0.838 | ||
Spleen diameter | M (min:max) | 11.54 (6.37:21.8) | 12.17 (7.26:18.37) | 11.92 (6.37:21.8) | MW: p=0.338 |
μ ±SD | 12.28 ±3.11 | 12.63 ±2.9 | 12.40 ±3.04 | ||
Spleen area | M (min:max) | 65.06 (15.73:193.16) | 56.07 (29.89:131.6) | 59.45 (15.73:193.16) | MW: p=0.862 |
μ ±SD | 70.12 ±37.2 | 68.78 ±32.2 | 69.56 ±34.9 | ||
VP Diam cm | M (min:max) | 1.14 (0.76:1.56) | 1.12 (0.52:1.76) | 1.13 (0.52:1.76) | T-test: p=0.741 |
μ ±SD | 1.14 ±0.213 | 1.16 ±0.272 | 1.15 ±0.232 | ||
VP Speed | M (min:max) | 27.79 (14.62:74.5) | 23.29 (14.38:49.44) | 26.54 (14.38:74.5) | MW: p=0.640 |
μ ±SD | 29.29 ±12.3 | 27.56 ±10.9 | 28.70 ±11.8 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.704 |
μ ±SD | 0.0152 ±0.0212 | 0.0217 ±0.033 | 0.0173 ±0.0253 | ||
Hb | M (min:max) | 13.8 (7.5:19.6) | 14.1 (8.5:17) | 13.9 (7.5:19.6) | MW: p=0.648 |
μ ±SD | 13.77 ±1.89 | 13.79 ±1.99 | 13.78 ±1.91 | ||
PTL | M (min:max) | 199 (2.39:440) | 174 (26:536) | 193 (2.39:536) | MW: p=0.233 |
μ ±SD | 195.04 ±91.5 | 179.51 ±106.5 | 190.27 ±96.3 | ||
GOT | M (min:max) | 29 (14:570) | 32.5 (13:183) | 30.5 (13:570) | MW: p=0.249 |
μ ±SD | 41.20 ±52.2 | 42.69 ±31.1 | 41.64 ±46.9 | ||
GPT | M (min:max) | 24 (8:387) | 25 (7:289) | 24 (7:387) | MW: p=0.538 |
μ ±SD | 33.45 ±42.8 | 38.38 ±46.1 | 34.93 ±43.8 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 1.1 (0.4:8.6) | 0.9 (0.3:11.1) | MW: p=0.252 |
μ ±SD | 1.38 ±1.51 | 1.65 ±1.62 | 1.47 ±1.54 | ||
BD | M (min:max) | 0.27 (0.09:8.96) | 0.35 (0.12:6.38) | 0.31 (0.09:8.96) | MW: p=0.054 |
μ ±SD | 0.546 ±1.03 | 0.735 ±1.11 | 0.602 ±1.05 | ||
GGT | M (min:max) | 51 (13:1128) | 41 (17:1914) | 44 (13:1914) | MW: p=0.657 |
μ ±SD | 104.51 ±176.1 | 124.58 ±291.1 | 110.85 ±218.2 | ||
FA | M (min:max) | 216 (108:899) | 225 (104:1042) | 221 (104:1042) | MW: p=0.997 |
μ ±SD | 262.38 ±133.1 | 265.53 ±167.2 | 263.36 ±143.9 | ||
ALB | M (min:max) | 4.2 (2.6:5.3) | 4.2 (2.9:5.2) | 4.2 (2.6:5.3) | MW: p=0.985 |
μ ±SD | 4.18 ±0.64 | 4.16 ±0.727 | 4.18 ±0.66 | ||
INR | M (min:max) | 1.08 (0.9:2.52) | 1.23 (0.9:2.7) | 1.13 (0.9:2.7) | MW: p=0.027 |
μ ±SD | 1.19 ±0.274 | 1.32 ±0.346 | 1.23 ±0.304 | ||
COL | M (min:max) | 187 (18:326) | 184 (120:288) | 186 (18:326) | MW: p=0.797 |
μ ±SD | 188.27 ±55.8 | 193.43 ±56.1 | 189.62 ±55.6 | ||
TG | M (min:max) | 98 (31:380) | 116 (62:239) | 105.5 (31:380) | MW: p=0.255 |
μ ±SD | 116.67 ±65.3 | 125.89 ±49.7 | 119.04 ±61.5 | ||
Fe | M (min:max) | 98 (26:218) | 90 (22:246) | 97 (22:246) | MW: p=0.996 |
μ ±SD | 100.25 ±39.3 | 105.38 ±59.5 | 101.71 ±45.6 | ||
Crea | M (min:max) | 0.78 (0.53:1.52) | 0.75 (0.54:1.2) | 0.77 (0.53:1.52) | MW: p=0.241 |
μ ±SD | 0.82 ±0.194 | 0.781 ±0.154 | 0.808 ±0.183 | ||
Uree | M (min:max) | 31 (10:92) | 32 (20:78) | 31 (10:92) | MW: p=0.518 |
μ ±SD | 34.62 ±15.0 | 36.56 ±14.5 | 35.19 ±14.8 | ||
Na | M (min:max) | 136 (125:142) | 137 (89:142) | 136 (89:142) | MW: p=0.639 |
μ ±SD | 136.14 ±2.9 | 135.12 ±8.81 | 135.81 ±5.54 | ||
Glicemie | M (min:max) | 103 (75.8:361.7) | 107.8 (75.7:245) | 104 (75.7:361.7) | MW: p=0.208 |
μ ±SD | 118.59 ±47.2 | 117.43 ±30.7 | 118.23 ±42.7 | ||
CRP | M (min:max) | 0.4 (0.2:22.2) | 0.38 (0.22:4.17) | 0.38 (0.2:22.2) | MW: p=0.362 |
μ ±SD | 1.68 ±4.04 | 0.508 ±0.716 | 1.25 ±3.28 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.25) | 0.06 (0:0.33) | 0.06 (0:0.33) | MW: p=0.741 |
μ ±SD | 0.068 ±0.0514 | 0.0736 ±0.0602 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 9.62 (0:84) | 13 (0:38) | 10.75 (0:84) | MW: p=0.010 |
μ ±SD | 12.35 ±12.1 | 14.34 ±8.44 | 12.95 ±11.1 | ||
Attenuation cuts | <0.45 | 78 (55.7%) | 46 (75.4%) | 124 (61.7%) | OR=0.41 [0.21, 0.80] (p=0.011) |
≥0.45 | 62 (44.3%) | 15 (24.6%) | 77 (38.3%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.45 | ≥0.45 | (total) |
No steatosis | 78 (83.9% / 62.9%) | 15 (16.1% / 19.5%) | 93 (46.3%) |
S1-S3 (CAP ≥260) | 46 (42.6% / 37.1%) | 62 (57.4% / 80.5%) | 108 (53.7%) |
(total) | 124 (61.7%) | 77 (38.3%) | 201 (100%) |
OR=7.01 [3.58, 13.72], phi=0.42 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 153 (76.1%) | 48 (23.9%) | 201 | ||
Sex | F | 75 (49.7%) | 21 (43.8%) | 96 (48.2%) | OR=1.27 [0.66, 2.44] (p=0.510) |
M | 76 (50.3%) | 27 (56.2%) | 103 (51.8%) | ||
Age (years) | M (min:max) | 57 (18:87) | 64 (27:78) | 59 (18:87) | MW: p=0.011 |
μ ±SD | 56.31 ±13.0 | 61.06 ±11.1 | 57.46 ±12.7 | ||
Cirrhosis | 62 (40.5%) | 20 (41.7%) | 82 (40.8%) | OR=0.95 [0.49, 1.84] (p>0.999) | |
Etiology | alcohol | 34 (24.5%) | 12 (27.3%) | 46 (25.1%) | V=0.06 (p=0.882) |
viral | 78 (56.1%) | 22 (50.0%) | 100 (54.6%) | ||
metabolic | 20 (14.4%) | 8 (18.2%) | 28 (15.3%) | ||
cholestatic liver disease | 7 (5.0%) | 2 (4.5%) | 9 (4.9%) | ||
APP_DZ | 37 (24.3%) | 7 (14.9%) | 44 (22.1%) | OR=1.84 [0.76, 4.45] (p=0.228) | |
APP_HTAE | 54 (35.5%) | 15 (31.9%) | 69 (34.7%) | OR=1.18 [0.59, 2.36] (p=0.727) | |
APP_CVD | 36 (23.7%) | 12 (25.5%) | 48 (24.1%) | OR=0.91 [0.43, 1.93] (p=0.846) | |
APP_COPD | 6 (3.9%) | 3 (6.4%) | 9 (4.5%) | OR=0.60 [0.14, 2.51] (p=0.443) | |
APP_Renal | 4 (2.7%) | 4 (9.3%) | 8 (4.2%) | OR=0.27 [0.07, 1.15] (p=0.081) | |
Alcohol | 35 (31.2%) | 13 (38.2%) | 48 (32.9%) | OR=0.73 [0.33, 1.63] (p=0.532) | |
Dislipidemia | 11 (18.6%) | 1 (7.7%) | 12 (16.7%) | OR=2.75 [0.32, 23.43] (p=0.681) | |
Weight | M (min:max) | 79 (45:123) | 84 (54:115) | 80 (45:123) | T-test: p=0.012 |
μ ±SD | 78.40 ±16.1 | 85.67 ±14.5 | 80.17 ±16.0 | ||
Height | M (min:max) | 168 (150:192) | 169.5 (157:190) | 168 (150:192) | MW: p=0.319 |
μ ±SD | 168.50 ±8.73 | 170.26 ±8.04 | 168.92 ±8.57 | ||
BMI | M (min:max) | 26.87 (15.57:40.86) | 28.81 (19.36:42.24) | 27.85 (15.57:42.24) | T-test: p=0.031 |
μ ±SD | 27.61 ±5.08 | 29.62 ±4.58 | 28.10 ±5.02 | ||
Fibroscan_Probe | M | 144 (94.1%) | 43 (89.6%) | 187 (93.0%) | OR=1.86 [0.59, 5.85] (p=0.329) |
XL | 9 (5.9%) | 5 (10.4%) | 14 (7.0%) | ||
Fibroscan_Value | M (min:max) | 8.8 (2.5:75) | 9.7 (3.7:75) | 9.05 (2.5:75) | MW: p=0.845 |
μ ±SD | 18.08 ±19.6 | 17.66 ±18.9 | 17.98 ±19.4 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 62 (40.5%) | 16 (33.3%) | 78 (38.8%) | V=0.08 (p=0.517) |
F2 (7-10) | 20 (13.1%) | 9 (18.8%) | 29 (14.4%) | ||
F3-F4 (>10) | 71 (46.4%) | 23 (47.9%) | 94 (46.8%) | ||
Valid Elastography | 135 (88.2%) | 44 (91.7%) | 179 (89.1%) | OR=0.68 [0.22, 2.12] (p=0.605) | |
Stability index | M (min:max) | 90.5 (12:99) | 92 (28:98) | 91 (12:99) | MW: p=0.369 |
μ ±SD | 87.22 ±12.1 | 88.34 ±12.2 | 87.49 ±12.1 | ||
CAP_Value | M (min:max) | 253 (100:400) | 297 (130:400) | 268 (100:400) | MW: p<0.001 |
μ ±SD | 256.31 ±60.7 | 297.04 ±47.1 | 266.03 ±60.2 | ||
CAP Steatosis stage | S0-S1 (CAP <285) | 113 (73.9%) | 14 (29.2%) | 127 (63.2%) | OR=6.86 [3.34, 14.09] (p<0.001) |
S2-S3 (CAP ≥285) | 40 (26.1%) | 34 (70.8%) | 74 (36.8%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.650 |
μ ±SD | 2.27 ±0.987 | 2.35 ±0.949 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.17 (0.68:2.29) | 1.21 (0.6:2.79) | 1.19 (0.6:2.79) | MW: p=0.327 |
μ ±SD | 1.19 ±0.296 | 1.30 ±0.475 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.973 |
μ ±SD | 4.82 ±1.0 | 4.92 ±0.964 | 4.85 ±0.991 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.44 (0.25:0.72) | 0.41 (0.16:0.77) | MW: p=0.270 |
μ ±SD | 0.433 ±0.122 | 0.447 ±0.101 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.352 |
μ ±SD | 4.93 ±0.889 | 5.10 ±0.692 | 4.97 ±0.848 | ||
Attenuation SOS Mean | M (min:max) | 1527 (1477:1598.4) | 1525.8 (1478:1583) | 1526.8 (1477:1598.4) | MW: p=0.334 |
μ ±SD | 1532.11 ±26.0 | 1526.17 ±22.9 | 1530.69 ±25.3 | ||
Elastography liver median 1 | M (min:max) | 9.3 (3.3:76.7) | 11 (4.4:74.6) | 9.6 (3.3:76.7) | MW: p=0.383 |
μ ±SD | 15.81 ±13.9 | 17.07 ±14.3 | 16.11 ±14.0 | ||
Elastography liver IQR 1 | M (min:max) | 1.6 (0.1:24.9) | 1.8 (0.1:14.6) | 1.7 (0.1:24.9) | MW: p=0.464 |
μ ±SD | 2.81 ±3.9 | 3.03 ±3.31 | 2.86 ±3.76 | ||
Elastography IQR/MED | M (min:max) | 14.24 (0:78.95) | 14.81 (0:41.18) | 14.53 (0:78.95) | MW: p=0.882 |
μ ±SD | 16.75 ±12.4 | 16.30 ±10.7 | 16.64 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.2 (1.1:5) | 2.4 (1.5:4.3) | 2.3 (1.1:5) | MW: p=0.059 |
μ ±SD | 2.36 ±0.88 | 2.51 ±0.69 | 2.40 ±0.838 | ||
Spleen diameter | M (min:max) | 11.6 (6.37:21.8) | 12.17 (7.68:17.65) | 11.92 (6.37:21.8) | MW: p=0.205 |
μ ±SD | 12.30 ±3.18 | 12.72 ±2.54 | 12.40 ±3.04 | ||
Spleen area | M (min:max) | 68.28 (15.73:193.16) | 56.04 (31.78:131.6) | 59.45 (15.73:193.16) | MW: p=0.363 |
μ ±SD | 72.64 ±37.9 | 63.22 ±27.6 | 69.56 ±34.9 | ||
VP Diam cm | M (min:max) | 1.09 (0.76:1.62) | 1.16 (0.52:1.76) | 1.13 (0.52:1.76) | T-test: p=0.325 |
μ ±SD | 1.14 ±0.224 | 1.20 ±0.259 | 1.15 ±0.232 | ||
VP Speed | M (min:max) | 27.79 (14.38:74.5) | 22.72 (15.72:49.44) | 26.54 (14.38:74.5) | MW: p=0.808 |
μ ±SD | 29.03 ±12.2 | 27.71 ±11.0 | 28.70 ±11.8 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.02 (0:0.1) | 0.01 (0:0.1) | MW: p=0.471 |
μ ±SD | 0.014 ±0.0196 | 0.0314 ±0.0414 | 0.0173 ±0.0253 | ||
Hb | M (min:max) | 13.9 (7.5:19.6) | 13.85 (8.5:17) | 13.9 (7.5:19.6) | MW: p=0.966 |
μ ±SD | 13.80 ±1.86 | 13.69 ±2.1 | 13.78 ±1.91 | ||
PTL | M (min:max) | 196.5 (2.39:536) | 184 (45:427) | 193 (2.39:536) | MW: p=0.437 |
μ ±SD | 192.95 ±97.7 | 181.24 ±92.1 | 190.27 ±96.3 | ||
GOT | M (min:max) | 29 (13:124) | 39 (15:570) | 30.5 (13:570) | MW: p=0.024 |
μ ±SD | 36.34 ±20.8 | 59.10 ±88.0 | 41.64 ±46.9 | ||
GPT | M (min:max) | 23.5 (8:387) | 27 (7:291) | 24 (7:387) | MW: p=0.079 |
μ ±SD | 31.90 ±40.7 | 44.98 ±52.0 | 34.93 ±43.8 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 1 (0.3:6) | 0.9 (0.3:11.1) | MW: p=0.575 |
μ ±SD | 1.46 ±1.63 | 1.50 ±1.29 | 1.47 ±1.54 | ||
BD | M (min:max) | 0.3 (0.1:8.96) | 0.32 (0.09:3.5) | 0.31 (0.09:8.96) | MW: p=0.362 |
μ ±SD | 0.608 ±1.16 | 0.584 ±0.65 | 0.602 ±1.05 | ||
GGT | M (min:max) | 43 (13:846) | 47 (18:1914) | 44 (13:1914) | MW: p=0.444 |
μ ±SD | 86.21 ±125.3 | 184.76 ±372.8 | 110.85 ±218.2 | ||
FA | M (min:max) | 224 (104:899) | 219 (112:1042) | 221 (104:1042) | MW: p=0.861 |
μ ±SD | 261.19 ±133.9 | 269.62 ±171.7 | 263.36 ±143.9 | ||
ALB | M (min:max) | 4.2 (2.9:5.3) | 4.2 (2.6:5.1) | 4.2 (2.6:5.3) | MW: p=0.827 |
μ ±SD | 4.20 ±0.642 | 4.08 ±0.741 | 4.18 ±0.66 | ||
INR | M (min:max) | 1.13 (0.9:2.7) | 1.13 (0.96:1.82) | 1.13 (0.9:2.7) | MW: p=0.959 |
μ ±SD | 1.23 ±0.317 | 1.23 ±0.263 | 1.23 ±0.304 | ||
COL | M (min:max) | 186 (18:326) | 187.5 (120:294) | 186 (18:326) | MW: p=0.450 |
μ ±SD | 186.95 ±55.2 | 198.83 ±57.5 | 189.62 ±55.6 | ||
TG | M (min:max) | 100 (31:380) | 112.5 (61:239) | 105.5 (31:380) | MW: p=0.332 |
μ ±SD | 117.25 ±65.4 | 124.61 ±48.5 | 119.04 ±61.5 | ||
Fe | M (min:max) | 97 (24:218) | 111 (22:246) | 97 (22:246) | MW: p=0.687 |
μ ±SD | 100.13 ±42.1 | 106.48 ±55.8 | 101.71 ±45.6 | ||
Crea | M (min:max) | 0.78 (0.53:1.52) | 0.74 (0.53:1.34) | 0.77 (0.53:1.52) | MW: p=0.360 |
μ ±SD | 0.814 ±0.184 | 0.791 ±0.182 | 0.808 ±0.183 | ||
Uree | M (min:max) | 31 (10:92) | 31 (18:78) | 31 (10:92) | MW: p=0.721 |
μ ±SD | 35.64 ±15.4 | 34.04 ±13.4 | 35.19 ±14.8 | ||
Na | M (min:max) | 136 (125:141) | 136 (89:142) | 136 (89:142) | MW: p=0.653 |
μ ±SD | 136.26 ±2.78 | 134.42 ±10.1 | 135.81 ±5.54 | ||
Glicemie | M (min:max) | 104 (75.7:361.7) | 104.5 (85:241.7) | 104 (75.7:361.7) | MW: p=0.493 |
μ ±SD | 118.14 ±45.5 | 118.53 ±32.9 | 118.23 ±42.7 | ||
CRP | M (min:max) | 0.39 (0.2:22.2) | 0.38 (0.22:9.74) | 0.38 (0.2:22.2) | MW: p=0.250 |
μ ±SD | 1.41 ±3.61 | 0.79 ±2.05 | 1.25 ±3.28 | ||
Attenuation IQR | M (min:max) | 0.05 (0:0.25) | 0.06 (0:0.33) | 0.06 (0:0.33) | MW: p=0.169 |
μ ±SD | 0.0657 ±0.0492 | 0.0826 ±0.0665 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 10.5 (0:84) | 13.75 (0.75:38) | 10.75 (0:84) | MW: p=0.222 |
μ ±SD | 12.74 ±11.8 | 13.62 ±8.77 | 12.95 ±11.1 | ||
Attenuation cuts | <0.5 | 113 (73.9%) | 34 (70.8%) | 147 (73.1%) | OR=1.16 [0.57, 2.39] (p=0.711) |
≥0.5 | 40 (26.1%) | 14 (29.2%) | 54 (26.9%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.5 | ≥0.5 | (total) |
S0-S1 (CAP <285) | 113 (89.0% / 76.9%) | 14 (11.0% / 25.9%) | 127 (63.2%) |
S2-S3 (CAP ≥285) | 34 (45.9% / 23.1%) | 40 (54.1% / 74.1%) | 74 (36.8%) |
(total) | 147 (73.1%) | 54 (26.9%) | 201 (100%) |
OR=9.50 [4.63, 19.50], phi=0.47 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 153 (76.1%) | 48 (23.9%) | 201 | ||
Sex | F | 73 (48.3%) | 23 (47.9%) | 96 (48.2%) | OR=1.02 [0.53, 1.95] (p>0.999) |
M | 78 (51.7%) | 25 (52.1%) | 103 (51.8%) | ||
Age (years) | M (min:max) | 57 (18:87) | 64 (35:78) | 59 (18:87) | MW: p=0.008 |
μ ±SD | 56.15 ±13.2 | 61.58 ±9.77 | 57.46 ±12.7 | ||
Cirrhosis | 60 (39.2%) | 22 (45.8%) | 82 (40.8%) | OR=0.76 [0.40, 1.47] (p=0.501) | |
Etiology | alcohol | 33 (23.7%) | 13 (29.5%) | 46 (25.1%) | V=0.06 (p=0.872) |
viral | 78 (56.1%) | 22 (50.0%) | 100 (54.6%) | ||
metabolic | 21 (15.1%) | 7 (15.9%) | 28 (15.3%) | ||
cholestatic liver disease | 7 (5.0%) | 2 (4.5%) | 9 (4.9%) | ||
APP_DZ | 34 (22.4%) | 10 (21.3%) | 44 (22.1%) | OR=1.07 [0.48, 2.36] (p>0.999) | |
APP_HTAE | 52 (34.2%) | 17 (36.2%) | 69 (34.7%) | OR=0.92 [0.46, 1.82] (p=0.861) | |
APP_CVD | 33 (21.7%) | 15 (31.9%) | 48 (24.1%) | OR=0.59 [0.29, 1.22] (p=0.174) | |
APP_COPD | 6 (3.9%) | 3 (6.4%) | 9 (4.5%) | OR=0.60 [0.14, 2.51] (p=0.443) | |
APP_Renal | 3 (2.0%) | 5 (11.9%) | 8 (4.2%) | OR=0.15 [0.04, 0.67] (p=0.014) | |
Alcohol | 34 (30.4%) | 14 (41.2%) | 48 (32.9%) | OR=0.62 [0.28, 1.38] (p=0.298) | |
Dislipidemia | 12 (19.7%) | 0 | 12 (16.7%) | OR=5.81 [0.32, 105.41] (p=0.192) | |
Weight | M (min:max) | 78 (45:123) | 85.5 (54:115) | 80 (45:123) | T-test: p=0.002 |
μ ±SD | 78.00 ±15.4 | 86.95 ±16.2 | 80.17 ±16.0 | ||
Height | M (min:max) | 168 (150:192) | 170 (157:190) | 168 (150:192) | MW: p=0.441 |
μ ±SD | 168.54 ±8.51 | 170.08 ±8.79 | 168.92 ±8.57 | ||
BMI | M (min:max) | 26.85 (15.57:40.86) | 30.42 (19.36:42.24) | 27.85 (15.57:42.24) | T-test: p=0.004 |
μ ±SD | 27.44 ±4.9 | 30.07 ±4.92 | 28.10 ±5.02 | ||
Fibroscan_Probe | M | 146 (95.4%) | 41 (85.4%) | 187 (93.0%) | OR=3.56 [1.18, 10.73] (p=0.044) |
XL | 7 (4.6%) | 7 (14.6%) | 14 (7.0%) | ||
Fibroscan_Value | M (min:max) | 8.45 (2.5:75) | 10.2 (3.7:75) | 9.05 (2.5:75) | MW: p=0.235 |
μ ±SD | 17.52 ±19.4 | 19.43 ±19.4 | 17.98 ±19.4 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 64 (41.8%) | 14 (29.2%) | 78 (38.8%) | V=0.12 (p=0.258) |
F2 (7-10) | 20 (13.1%) | 9 (18.8%) | 29 (14.4%) | ||
F3-F4 (>10) | 69 (45.1%) | 25 (52.1%) | 94 (46.8%) | ||
Valid Elastography | 135 (88.2%) | 44 (91.7%) | 179 (89.1%) | OR=0.68 [0.22, 2.12] (p=0.605) | |
Stability index | M (min:max) | 91 (12:99) | 92 (51:97) | 91 (12:99) | MW: p=0.921 |
μ ±SD | 87.30 ±12.7 | 88.11 ±9.7 | 87.49 ±12.1 | ||
CAP_Value | M (min:max) | 252 (100:400) | 306 (130:400) | 268 (100:400) | MW: p<0.001 |
μ ±SD | 252.75 ±58.3 | 308.38 ±45.3 | 266.03 ±60.2 | ||
CAP Steatosis stage | S0-S2 (CAP <295) | 126 (82.4%) | 10 (20.8%) | 136 (67.7%) | OR=17.73 [7.88, 39.91] (p<0.001) |
S3 (CAP ≥295) | 27 (17.6%) | 38 (79.2%) | 65 (32.3%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.558 |
μ ±SD | 2.26 ±0.989 | 2.37 ±0.942 | 2.29 ±0.975 | ||
HRI Mean | M (min:max) | 1.17 (0.68:2.79) | 1.21 (0.6:2.29) | 1.19 (0.6:2.79) | MW: p=0.447 |
μ ±SD | 1.21 ±0.352 | 1.24 ±0.354 | 1.22 ±0.351 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (2:7) | 5 (1:7) | MW: p=0.211 |
μ ±SD | 4.78 ±0.993 | 5.04 ±0.967 | 4.85 ±0.991 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.47 (0.25:0.72) | 0.41 (0.16:0.77) | MW: p=0.007 |
μ ±SD | 0.426 ±0.12 | 0.468 ±0.101 | 0.436 ±0.117 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.193 |
μ ±SD | 4.92 ±0.873 | 5.15 ±0.743 | 4.97 ±0.848 | ||
Attenuation SOS Mean | M (min:max) | 1529.2 (1477:1598.4) | 1521.6 (1478:1583) | 1526.8 (1477:1598.4) | MW: p=0.026 |
μ ±SD | 1532.97 ±25.5 | 1523.42 ±23.5 | 1530.69 ±25.3 | ||
Elastography liver median 1 | M (min:max) | 9.2 (3.3:76.7) | 11.7 (3.7:74.6) | 9.6 (3.3:76.7) | MW: p=0.243 |
μ ±SD | 15.70 ±14.0 | 17.43 ±14.2 | 16.11 ±14.0 | ||
Elastography liver IQR 1 | M (min:max) | 1.6 (0.1:24.9) | 1.8 (0.1:14.6) | 1.7 (0.1:24.9) | MW: p=0.663 |
μ ±SD | 2.87 ±3.95 | 2.84 ±3.12 | 2.86 ±3.76 | ||
Elastography IQR/MED | M (min:max) | 14.53 (0:78.95) | 14.12 (0:41.18) | 14.53 (0:78.95) | MW: p=0.744 |
μ ±SD | 16.88 ±12.4 | 15.88 ±10.8 | 16.64 ±12.0 | ||
Viscosity liver Median 1 | M (min:max) | 2.2 (1.2:5) | 2.5 (1.1:4.3) | 2.3 (1.1:5) | MW: p=0.068 |
μ ±SD | 2.36 ±0.865 | 2.52 ±0.746 | 2.40 ±0.838 | ||
Spleen diameter | M (min:max) | 11.54 (7.26:21.8) | 12.32 (6.37:17.65) | 11.92 (6.37:21.8) | MW: p=0.158 |
μ ±SD | 12.29 ±3.12 | 12.76 ±2.76 | 12.40 ±3.04 | ||
Spleen area | M (min:max) | 67.79 (15.98:193.16) | 49.27 (15.73:131.6) | 59.45 (15.73:193.16) | MW: p=0.278 |
μ ±SD | 72.97 ±36.9 | 62.53 ±30.2 | 69.56 ±34.9 | ||
VP Diam cm | M (min:max) | 1.1 (0.52:1.62) | 1.15 (0.95:1.76) | 1.13 (0.52:1.76) | T-test: p=0.210 |
μ ±SD | 1.13 ±0.237 | 1.21 ±0.207 | 1.15 ±0.232 | ||
VP Speed | M (min:max) | 26.45 (14.38:74.5) | 31.68 (19.82:49.44) | 26.54 (14.38:74.5) | MW: p=0.302 |
μ ±SD | 28.01 ±12.2 | 30.84 ±10.4 | 28.70 ±11.8 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.357 |
μ ±SD | 0.0124 ±0.0168 | 0.035 ±0.0414 | 0.0173 ±0.0253 | ||
Hb | M (min:max) | 13.9 (7.5:19.6) | 13.85 (8.7:17) | 13.9 (7.5:19.6) | MW: p=0.997 |
μ ±SD | 13.78 ±1.92 | 13.77 ±1.91 | 13.78 ±1.91 | ||
PTL | M (min:max) | 193 (2.39:536) | 196 (45:427) | 193 (2.39:536) | MW: p=0.567 |
μ ±SD | 192.57 ±98.9 | 183.03 ±88.2 | 190.27 ±96.3 | ||
GOT | M (min:max) | 29 (13:134) | 36 (17:570) | 30.5 (13:570) | MW: p=0.055 |
μ ±SD | 37.51 ±23.3 | 54.42 ±85.0 | 41.64 ±46.9 | ||
GPT | M (min:max) | 23.5 (8:387) | 30 (7:291) | 24 (7:387) | MW: p=0.065 |
μ ±SD | 33.62 ±43.9 | 39.00 ±43.5 | 34.93 ±43.8 | ||
BT | M (min:max) | 0.9 (0.3:8.6) | 1.1 (0.3:11.1) | 0.9 (0.3:11.1) | MW: p=0.507 |
μ ±SD | 1.38 ±1.33 | 1.73 ±2.06 | 1.47 ±1.54 | ||
BD | M (min:max) | 0.3 (0.09:6.38) | 0.33 (0.12:8.96) | 0.31 (0.09:8.96) | MW: p=0.360 |
μ ±SD | 0.535 ±0.798 | 0.801 ±1.59 | 0.602 ±1.05 | ||
GGT | M (min:max) | 41.5 (13:1128) | 53 (18:1914) | 44 (13:1914) | MW: p=0.144 |
μ ±SD | 94.98 ±159.8 | 158.45 ±336.5 | 110.85 ±218.2 | ||
FA | M (min:max) | 216 (104:899) | 222 (112:1042) | 221 (104:1042) | MW: p=0.585 |
μ ±SD | 257.65 ±132.1 | 279.87 ±174.7 | 263.36 ±143.9 | ||
ALB | M (min:max) | 4.2 (2.6:5.3) | 4.2 (3.4:5.1) | 4.2 (2.6:5.3) | MW: p=0.983 |
μ ±SD | 4.17 ±0.693 | 4.19 ±0.555 | 4.18 ±0.66 | ||
INR | M (min:max) | 1.13 (0.9:2.7) | 1.13 (0.9:2.52) | 1.13 (0.9:2.7) | MW: p=0.841 |
μ ±SD | 1.22 ±0.282 | 1.28 ±0.371 | 1.23 ±0.304 | ||
COL | M (min:max) | 187 (18:326) | 184 (120:288) | 186 (18:326) | MW: p=0.809 |
μ ±SD | 188.59 ±55.9 | 193.47 ±55.7 | 189.62 ±55.6 | ||
TG | M (min:max) | 103 (33:380) | 106 (31:239) | 105.5 (31:380) | MW: p=0.955 |
μ ±SD | 120.95 ±65.4 | 113.11 ±48.7 | 119.04 ±61.5 | ||
Fe | M (min:max) | 99 (22:218) | 84 (26:246) | 97 (22:246) | MW: p=0.518 |
μ ±SD | 102.06 ±41.7 | 100.67 ±57.1 | 101.71 ±45.6 | ||
Crea | M (min:max) | 0.78 (0.53:1.52) | 0.74 (0.53:1.34) | 0.77 (0.53:1.52) | MW: p=0.348 |
μ ±SD | 0.815 ±0.183 | 0.789 ±0.183 | 0.808 ±0.183 | ||
Uree | M (min:max) | 34 (10:92) | 30 (20:49) | 31 (10:92) | MW: p=0.378 |
μ ±SD | 36.60 ±16.5 | 31.39 ±7.75 | 35.19 ±14.8 | ||
Na | M (min:max) | 136 (125:140) | 137 (89:142) | 136 (89:142) | MW: p=0.368 |
μ ±SD | 136.03 ±2.73 | 135.16 ±10.0 | 135.81 ±5.54 | ||
Glicemie | M (min:max) | 105 (75.7:361.7) | 102.5 (77:241.7) | 104 (75.7:361.7) | MW: p=0.828 |
μ ±SD | 118.37 ±44.6 | 117.79 ±36.5 | 118.23 ±42.7 | ||
CRP | M (min:max) | 0.38 (0.22:22.2) | 0.39 (0.2:4.87) | 0.38 (0.2:22.2) | MW: p=0.509 |
μ ±SD | 1.44 ±3.69 | 0.639 ±1.06 | 1.25 ±3.28 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.25) | 0.05 (0:0.33) | 0.06 (0:0.33) | MW: p=0.680 |
μ ±SD | 0.067 ±0.0483 | 0.0785 ±0.0693 | 0.0697 ±0.0541 | ||
Attenuation SOS IQR | M (min:max) | 10.5 (0:84) | 11 (2:32.25) | 10.75 (0:84) | MW: p=0.381 |
μ ±SD | 12.93 ±12.0 | 13.02 ±7.94 | 12.95 ±11.1 | ||
Attenuation cuts | <0.55 | 126 (82.4%) | 38 (79.2%) | 164 (81.6%) | OR=1.23 [0.55, 2.76] (p=0.670) |
≥0.55 | 27 (17.6%) | 10 (20.8%) | 37 (18.4%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.55 | ≥0.55 | (total) |
S0-S2 (CAP <295) | 126 (92.6% / 76.8%) | 10 (7.4% / 27.0%) | 136 (67.7%) |
S3 (CAP ≥295) | 38 (58.5% / 23.2%) | 27 (41.5% / 73.0%) | 65 (32.3%) |
(total) | 164 (81.6%) | 37 (18.4%) | 201 (100%) |
OR=8.95 [3.98, 20.15], phi=0.41 (p<0.001) | |||
2.10 Agreement: Attenuation Mean ~ CAP Steatosis stage: F0-F2
Variable | Details | yes | no | Total | Statistics |
Agreement | 77 (72.0%) | 30 (28.0%) | 107 | ||
Sex | F | 49 (63.6%) | 13 (43.3%) | 62 (57.9%) | OR=2.29 [0.97, 5.40] (p=0.081) |
M | 28 (36.4%) | 17 (56.7%) | 45 (42.1%) | ||
Age (years) | M (min:max) | 54 (19:77) | 63.5 (18:79) | 58 (18:79) | MW: p=0.015 |
μ ±SD | 53.56 ±12.7 | 59.63 ±16.5 | 55.26 ±14.1 | ||
Cirrhosis | 0 | 0 | 0 | OR=0.39 [0.01, 20.28] (p>0.999) | |
Etiology | alcohol | 4 (6.0%) | 3 (11.1%) | 7 (7.4%) | V=0.12 (p=0.711) |
viral | 46 (68.7%) | 18 (66.7%) | 64 (68.1%) | ||
metabolic | 14 (20.9%) | 4 (14.8%) | 18 (19.1%) | ||
cholestatic liver disease | 3 (4.5%) | 2 (7.4%) | 5 (5.3%) | ||
APP_DZ | 13 (16.9%) | 4 (13.3%) | 17 (15.9%) | OR=1.32 [0.39, 4.43] (p=0.774) | |
APP_HTAE | 24 (31.2%) | 14 (46.7%) | 38 (35.5%) | OR=0.52 [0.22, 1.23] (p=0.177) | |
APP_CVD | 14 (18.2%) | 12 (40.0%) | 26 (24.3%) | OR=0.33 [0.13, 0.85] (p=0.025) | |
APP_COPD | 2 (2.6%) | 0 | 2 (1.9%) | OR=2.02 [0.09, 43.31] (p>0.999) | |
APP_Renal | 0 | 1 (3.6%) | 1 (1.0%) | OR=0.12 [0.00, 3.15] (p=0.277) | |
Alcohol | 4 (7.5%) | 3 (15.8%) | 7 (9.7%) | OR=0.44 [0.09, 2.16] (p=0.371) | |
Dislipidemia | 7 (21.9%) | 1 (11.1%) | 8 (19.5%) | OR=2.24 [0.24, 21.07] (p=0.659) | |
Weight | M (min:max) | 75.5 (45:123) | 77.5 (54:107) | 76 (45:123) | T-test: p=0.081 |
μ ±SD | 73.54 ±14.3 | 79.35 ±13.4 | 75.26 ±14.2 | ||
Height | M (min:max) | 166 (150:185) | 169 (152:192) | 168 (150:192) | MW: p=0.288 |
μ ±SD | 167.07 ±8.48 | 169.17 ±8.7 | 167.67 ±8.54 | ||
BMI | M (min:max) | 25.95 (15.57:40.86) | 27.41 (19.36:35.99) | 26.28 (15.57:40.86) | T-test: p=0.345 |
μ ±SD | 26.55 ±5.26 | 27.70 ±4.25 | 26.88 ±4.99 | ||
Fibroscan_Probe | M | 76 (98.7%) | 28 (93.3%) | 104 (97.2%) | OR=5.43 [0.47, 62.24] (p=0.189) |
XL | 1 (1.3%) | 2 (6.7%) | 3 (2.8%) | ||
Fibroscan_Value | M (min:max) | 5.1 (2.5:9.9) | 4.9 (3.4:9.6) | 5.1 (2.5:9.9) | MW: p=0.421 |
μ ±SD | 5.77 ±1.87 | 5.51 ±1.82 | 5.69 ±1.85 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 55 (71.4%) | 23 (76.7%) | 78 (72.9%) | V=0.05 (p=0.584) |
F2 (7-10) | 22 (28.6%) | 7 (23.3%) | 29 (27.1%) | ||
F3-F4 (>10) | 0 | 0 | 0 | ||
Valid Elastography | 67 (87.0%) | 26 (86.7%) | 93 (86.9%) | OR=1.03 [0.30, 3.58] (p>0.999) | |
Stability index | M (min:max) | 91 (57:98) | 92 (28:99) | 92 (28:99) | MW: p=0.796 |
μ ±SD | 89.16 ±8.15 | 88.29 ±13.0 | 88.92 ±9.62 | ||
CAP_Value | M (min:max) | 252 (100:400) | 277 (130:344) | 263 (100:400) | T-test: p=0.272 |
μ ±SD | 256.53 ±60.3 | 269.90 ±44.0 | 260.28 ±56.4 | ||
CAP Steatosis stage | No steatosis | 45 (58.4%) | 8 (26.7%) | 53 (49.5%) | OR=3.87 [1.53, 9.78] (p=0.005) |
S1-S3 (CAP ≥260) | 32 (41.6%) | 22 (73.3%) | 54 (50.5%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.814 |
μ ±SD | 2.17 ±1.01 | 2.23 ±0.992 | 2.19 ±0.999 | ||
HRI Mean | M (min:max) | 1.18 (0.69:2.79) | 1.2 (0.6:2) | 1.19 (0.6:2.79) | MW: p=0.899 |
μ ±SD | 1.23 ±0.38 | 1.18 ±0.335 | 1.21 ±0.366 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.683 |
μ ±SD | 4.75 ±1.1 | 4.80 ±0.961 | 4.77 ±1.06 | ||
Attenuation Mean | M (min:max) | 0.42 (0.21:0.73) | 0.41 (0.26:0.6) | 0.42 (0.21:0.73) | MW: p=0.388 |
μ ±SD | 0.445 ±0.124 | 0.414 ±0.081 | 0.436 ±0.114 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.776 |
μ ±SD | 4.90 ±0.981 | 5.00 ±0.83 | 4.93 ±0.939 | ||
Attenuation SOS Mean | M (min:max) | 1531.8 (1477:1598.4) | 1527 (1507:1584.8) | 1531.5 (1477:1598.4) | MW: p=0.439 |
μ ±SD | 1537.11 ±30.6 | 1531.84 ±18.2 | 1535.63 ±27.7 | ||
Elastography liver median 1 | M (min:max) | 6.3 (3.3:28.8) | 6.2 (3.9:37.7) | 6.3 (3.3:37.7) | MW: p=0.330 |
μ ±SD | 6.96 ±3.39 | 8.06 ±6.14 | 7.27 ±4.34 | ||
Elastography liver IQR 1 | M (min:max) | 0.9 (0.1:6) | 0.9 (0.2:14.6) | 0.9 (0.1:14.6) | MW: p=0.872 |
μ ±SD | 1.23 ±1.14 | 1.49 ±2.65 | 1.30 ±1.67 | ||
Elastography IQR/MED | M (min:max) | 14.53 (0:78.95) | 13.1 (0:41.18) | 14.08 (0:78.95) | MW: p=0.386 |
μ ±SD | 17.41 ±13.6 | 14.82 ±11.0 | 16.69 ±13.0 | ||
Viscosity liver Median 1 | M (min:max) | 1.7 (1.1:3) | 1.9 (1.3:3) | 1.8 (1.1:3) | MW: p=0.086 |
μ ±SD | 1.87 ±0.424 | 2.00 ±0.382 | 1.90 ±0.416 | ||
Spleen diameter | M (min:max) | 12.34 (6.37:20.03) | 12.21 (9.03:18.37) | 12.25 (6.37:20.03) | MW: p=0.454 |
μ ±SD | 12.67 ±3.14 | 13.24 ±3.01 | 12.85 ±3.09 | ||
Spleen area | M (min:max) | 62.32 (15.73:136.44) | 77.72 (36.96:130.44) | 62.32 (15.73:136.44) | T-test: p=0.436 |
μ ±SD | 68.55 ±31.9 | 78.51 ±34.9 | 71.76 ±32.6 | ||
VP Diam cm | M (min:max) | 1.17 (0.89:1.56) | 1.1 (0.52:1.76) | 1.15 (0.52:1.76) | Welch: p=0.983 |
μ ±SD | 1.18 ±0.21 | 1.18 ±0.352 | 1.18 ±0.243 | ||
VP Speed | M (min:max) | 27.79 (18:46.47) | 31.68 (18.99:49.44) | 27.91 (18:49.44) | MW: p=0.514 |
μ ±SD | 28.08 ±8.0 | 32.39 ±12.0 | 29.11 ±9.02 | ||
VP RI | M (min:max) | 0.01 (0:0.07) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.834 |
μ ±SD | 0.0135 ±0.018 | 0.026 ±0.0422 | 0.0164 ±0.0248 | ||
Hb | M (min:max) | 13.8 (8.7:19.6) | 14.06 (8.5:16.6) | 13.9 (8.5:19.6) | T-test: p=0.709 |
μ ±SD | 13.72 ±1.96 | 13.89 ±1.79 | 13.77 ±1.9 | ||
PTL | M (min:max) | 210 (38:440) | 200 (45:536) | 202 (38:536) | MW: p=0.354 |
μ ±SD | 201.07 ±99.6 | 186.12 ±116.9 | 196.72 ±104.5 | ||
GOT | M (min:max) | 30 (14:570) | 39 (13:183) | 32.5 (13:570) | MW: p=0.533 |
μ ±SD | 44.93 ±68.1 | 46.80 ±37.4 | 45.43 ±61.1 | ||
GPT | M (min:max) | 24 (8:387) | 21.5 (14:289) | 24 (8:387) | MW: p=0.827 |
μ ±SD | 38.19 ±56.3 | 44.62 ±57.5 | 39.99 ±56.4 | ||
BT | M (min:max) | 0.85 (0.3:6.6) | 1 (0.4:6) | 0.9 (0.3:6.6) | MW: p=0.381 |
μ ±SD | 1.38 ±1.38 | 1.50 ±1.31 | 1.41 ±1.35 | ||
BD | M (min:max) | 0.27 (0.09:3.97) | 0.38 (0.12:3.5) | 0.3 (0.09:3.97) | MW: p=0.131 |
μ ±SD | 0.473 ±0.626 | 0.712 ±0.817 | 0.541 ±0.688 | ||
GGT | M (min:max) | 53 (17:846) | 45 (17:1914) | 50 (17:1914) | MW: p=0.893 |
μ ±SD | 103.12 ±165.8 | 166.73 ±376.8 | 123.29 ±251.8 | ||
FA | M (min:max) | 206.5 (119:899) | 272 (118:1042) | 216.5 (118:1042) | MW: p=0.256 |
μ ±SD | 253.46 ±131.4 | 302.27 ±208.4 | 268.94 ±160.1 | ||
ALB | M (min:max) | 4.2 (3.4:5.3) | 4.2 (2.9:5.2) | 4.2 (2.9:5.3) | T-test: p=0.770 |
μ ±SD | 4.26 ±0.614 | 4.19 ±0.762 | 4.24 ±0.645 | ||
INR | M (min:max) | 1.13 (0.92:1.73) | 1.2 (0.9:1.82) | 1.14 (0.9:1.82) | MW: p=0.286 |
μ ±SD | 1.18 ±0.214 | 1.26 ±0.262 | 1.21 ±0.232 | ||
COL | M (min:max) | 184 (18:306) | 206.5 (120:288) | 187 (18:306) | T-test: p=0.262 |
μ ±SD | 180.94 ±54.9 | 203.50 ±54.9 | 186.19 ±55.1 | ||
TG | M (min:max) | 110 (33:380) | 105.5 (66:239) | 110 (33:380) | MW: p=0.702 |
μ ±SD | 134.00 ±73.8 | 120.62 ±56.0 | 131.26 ±70.1 | ||
Fe | M (min:max) | 102 (26:218) | 93 (32:165) | 102 (26:218) | MW: p=0.463 |
μ ±SD | 104.70 ±42.4 | 90.88 ±46.6 | 101.79 ±43.0 | ||
Crea | M (min:max) | 0.81 (0.54:1.52) | 0.74 (0.58:1.2) | 0.79 (0.54:1.52) | MW: p=0.095 |
μ ±SD | 0.858 ±0.209 | 0.784 ±0.165 | 0.835 ±0.198 | ||
Uree | M (min:max) | 35.5 (19:74) | 32 (20:78) | 35 (19:78) | MW: p=0.865 |
μ ±SD | 35.87 ±13.4 | 36.67 ±15.8 | 36.17 ±14.2 | ||
Na | M (min:max) | 137.5 (125:142) | 137 (131:141) | 137 (125:142) | MW: p=0.347 |
μ ±SD | 136.79 ±3.18 | 136.28 ±2.61 | 136.62 ±2.98 | ||
Glicemie | M (min:max) | 103.5 (85:361.7) | 107.8 (86:245) | 104 (85:361.7) | MW: p=0.317 |
μ ±SD | 114.53 ±41.0 | 119.09 ±34.8 | 115.97 ±38.9 | ||
CRP | M (min:max) | 0.39 (0.2:2.35) | 0.37 (0.22:0.45) | 0.38 (0.2:2.35) | MW: p=0.380 |
μ ±SD | 0.579 ±0.582 | 0.345 ±0.066 | 0.48 ±0.454 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.25) | 0.05 (0.01:0.33) | 0.06 (0:0.33) | MW: p=0.779 |
μ ±SD | 0.0654 ±0.049 | 0.0727 ±0.0636 | 0.0675 ±0.0533 | ||
Attenuation SOS IQR | M (min:max) | 9 (0:80) | 14.75 (0:35) | 10.5 (0:80) | MW: p=0.053 |
μ ±SD | 12.64 ±12.8 | 14.33 ±8.13 | 13.11 ±11.7 | ||
Attenuation cuts | <0.45 | 45 (58.4%) | 22 (73.3%) | 67 (62.6%) | OR=0.51 [0.20, 1.29] (p=0.186) |
≥0.45 | 32 (41.6%) | 8 (26.7%) | 40 (37.4%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.45 | ≥0.45 | (total) |
No steatosis | 45 (84.9% / 67.2%) | 8 (15.1% / 20.0%) | 53 (49.5%) |
S1-S3 (CAP ≥260) | 22 (40.7% / 32.8%) | 32 (59.3% / 80.0%) | 54 (50.5%) |
(total) | 67 (62.6%) | 40 (37.4%) | 107 (100%) |
OR=8.18 [3.24, 20.68], phi=0.46 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 82 (76.6%) | 25 (23.4%) | 107 | ||
Sex | F | 48 (58.5%) | 14 (56.0%) | 62 (57.9%) | OR=1.11 [0.45, 2.74] (p=0.822) |
M | 34 (41.5%) | 11 (44.0%) | 45 (42.1%) | ||
Age (years) | M (min:max) | 54.5 (18:79) | 64 (27:78) | 58 (18:79) | MW: p=0.016 |
μ ±SD | 53.60 ±13.9 | 60.72 ±13.4 | 55.26 ±14.1 | ||
Cirrhosis | 0 | 0 | 0 | OR=0.31 [0.01, 15.97] (p>0.999) | |
Etiology | alcohol | 6 (8.2%) | 1 (4.8%) | 7 (7.4%) | V=0.13 (p=0.641) |
viral | 51 (69.9%) | 13 (61.9%) | 64 (68.1%) | ||
metabolic | 12 (16.4%) | 6 (28.6%) | 18 (19.1%) | ||
cholestatic liver disease | 4 (5.5%) | 1 (4.8%) | 5 (5.3%) | ||
APP_DZ | 16 (19.5%) | 1 (4.0%) | 17 (15.9%) | OR=5.82 [0.73, 46.27] (p=0.114) | |
APP_HTAE | 29 (35.4%) | 9 (36.0%) | 38 (35.5%) | OR=0.97 [0.38, 2.47] (p>0.999) | |
APP_CVD | 19 (23.2%) | 7 (28.0%) | 26 (24.3%) | OR=0.78 [0.28, 2.13] (p=0.605) | |
APP_COPD | 2 (2.4%) | 0 | 2 (1.9%) | OR=1.58 [0.07, 34.08] (p>0.999) | |
APP_Renal | 0 | 1 (4.2%) | 1 (1.0%) | OR=0.10 [0.00, 2.56] (p=0.238) | |
Alcohol | 6 (10.3%) | 1 (7.1%) | 7 (9.7%) | OR=1.50 [0.17, 13.57] (p>0.999) | |
Dislipidemia | 7 (20.0%) | 1 (16.7%) | 8 (19.5%) | OR=1.25 [0.13, 12.48] (p>0.999) | |
Weight | M (min:max) | 75 (45:123) | 78 (54:104) | 76 (45:123) | T-test: p=0.163 |
μ ±SD | 74.07 ±14.8 | 79.05 ±11.5 | 75.26 ±14.2 | ||
Height | M (min:max) | 168 (150:192) | 168 (157:178) | 168 (150:192) | MW: p=0.831 |
μ ±SD | 167.71 ±9.31 | 167.55 ±5.67 | 167.67 ±8.54 | ||
BMI | M (min:max) | 25.42 (15.57:40.86) | 27.66 (19.36:35.99) | 26.28 (15.57:40.86) | T-test: p=0.220 |
μ ±SD | 26.50 ±5.29 | 28.08 ±3.78 | 26.88 ±4.99 | ||
Fibroscan_Probe | M | 80 (97.6%) | 24 (96.0%) | 104 (97.2%) | OR=1.67 [0.14, 19.19] (p=0.554) |
XL | 2 (2.4%) | 1 (4.0%) | 3 (2.8%) | ||
Fibroscan_Value | M (min:max) | 5.1 (2.5:9.9) | 4.9 (3.7:9.8) | 5.1 (2.5:9.9) | MW: p=0.702 |
μ ±SD | 5.61 ±1.78 | 5.98 ±2.09 | 5.69 ±1.85 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 62 (75.6%) | 16 (64.0%) | 78 (72.9%) | V=0.11 (p=0.253) |
F2 (7-10) | 20 (24.4%) | 9 (36.0%) | 29 (27.1%) | ||
F3-F4 (>10) | 0 | 0 | 0 | ||
Valid Elastography | 70 (85.4%) | 23 (92.0%) | 93 (86.9%) | OR=0.51 [0.11, 2.44] (p=0.513) | |
Stability index | M (min:max) | 91 (57:99) | 92 (28:97) | 92 (28:99) | MW: p=0.624 |
μ ±SD | 89.02 ±8.17 | 88.58 ±13.6 | 88.92 ±9.62 | ||
CAP_Value | M (min:max) | 251 (100:400) | 295 (130:400) | 263 (100:400) | T-test: p=0.003 |
μ ±SD | 251.54 ±56.1 | 288.96 ±48.0 | 260.28 ±56.4 | ||
CAP Steatosis stage | S0-S1 (CAP <285) | 63 (76.8%) | 9 (36.0%) | 72 (67.3%) | OR=5.89 [2.25, 15.46] (p<0.001) |
S2-S3 (CAP ≥285) | 19 (23.2%) | 16 (64.0%) | 35 (32.7%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.533 |
μ ±SD | 2.15 ±1.01 | 2.30 ±0.974 | 2.19 ±0.999 | ||
HRI Mean | M (min:max) | 1.15 (0.69:2) | 1.21 (0.6:2.79) | 1.19 (0.6:2.79) | MW: p=0.437 |
μ ±SD | 1.18 ±0.289 | 1.31 ±0.525 | 1.21 ±0.366 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.554 |
μ ±SD | 4.77 ±1.11 | 4.76 ±0.879 | 4.77 ±1.06 | ||
Attenuation Mean | M (min:max) | 0.41 (0.21:0.73) | 0.45 (0.26:0.6) | 0.42 (0.21:0.73) | MW: p=0.263 |
μ ±SD | 0.433 ±0.12 | 0.447 ±0.0918 | 0.436 ±0.114 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.689 |
μ ±SD | 4.89 ±0.981 | 5.04 ±0.79 | 4.93 ±0.939 | ||
Attenuation SOS Mean | M (min:max) | 1531.7 (1477:1598.4) | 1526.6 (1478:1571.4) | 1531.5 (1477:1598.4) | MW: p=0.116 |
μ ±SD | 1538.37 ±28.8 | 1526.65 ±21.7 | 1535.63 ±27.7 | ||
Elastography liver median 1 | M (min:max) | 6.25 (3.3:28.8) | 6.8 (4.4:37.7) | 6.3 (3.3:37.7) | MW: p=0.296 |
μ ±SD | 6.91 ±3.29 | 8.45 ±6.69 | 7.27 ±4.34 | ||
Elastography liver IQR 1 | M (min:max) | 0.9 (0.1:6) | 1 (0.1:14.6) | 0.9 (0.1:14.6) | MW: p=0.649 |
μ ±SD | 1.20 ±1.12 | 1.63 ±2.9 | 1.30 ±1.67 | ||
Elastography IQR/MED | M (min:max) | 14.31 (0:78.95) | 13.24 (0:41.18) | 14.08 (0:78.95) | MW: p=0.713 |
μ ±SD | 17.09 ±13.5 | 15.35 ±11.2 | 16.69 ±13.0 | ||
Viscosity liver Median 1 | M (min:max) | 1.7 (1.1:3) | 2 (1.5:3) | 1.8 (1.1:3) | MW: p=0.050 |
μ ±SD | 1.86 ±0.42 | 2.03 ±0.382 | 1.90 ±0.416 | ||
Spleen diameter | M (min:max) | 12.35 (6.37:20.03) | 12.01 (9.77:17.45) | 12.25 (6.37:20.03) | MW: p=0.896 |
μ ±SD | 12.91 ±3.27 | 12.68 ±2.53 | 12.85 ±3.09 | ||
Spleen area | M (min:max) | 74.06 (15.73:136.44) | 49.27 (36.96:104.08) | 62.32 (15.73:136.44) | T-test: p=0.222 |
μ ±SD | 76.40 ±34.7 | 60.43 ±25.2 | 71.76 ±32.6 | ||
VP Diam cm | M (min:max) | 1.15 (0.89:1.62) | 1.23 (0.52:1.76) | 1.15 (0.52:1.76) | T-test: p=0.897 |
μ ±SD | 1.18 ±0.22 | 1.17 ±0.327 | 1.18 ±0.243 | ||
VP Speed | M (min:max) | 27.79 (18:46.47) | 31.68 (20.28:49.44) | 27.91 (18:49.44) | MW: p=0.366 |
μ ±SD | 27.99 ±8.1 | 32.68 ±11.6 | 29.11 ±9.02 | ||
VP RI | M (min:max) | 0.01 (0:0.07) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.891 |
μ ±SD | 0.0133 ±0.0175 | 0.03 ±0.0476 | 0.0164 ±0.0248 | ||
Hb | M (min:max) | 13.9 (8.5:19.6) | 13.95 (8.7:16.4) | 13.9 (8.5:19.6) | T-test: p=0.650 |
μ ±SD | 13.82 ±1.87 | 13.60 ±2.07 | 13.77 ±1.9 | ||
PTL | M (min:max) | 169 (38:536) | 215.5 (45:427) | 202 (38:536) | MW: p=0.500 |
μ ±SD | 192.32 ±106.9 | 211.25 ±97.1 | 196.72 ±104.5 | ||
GOT | M (min:max) | 30 (13:118) | 41 (15:570) | 32.5 (13:570) | MW: p=0.122 |
μ ±SD | 37.03 ±21.1 | 73.86 ±119.7 | 45.43 ±61.1 | ||
GPT | M (min:max) | 22.5 (8:387) | 25 (12:291) | 24 (8:387) | MW: p=0.171 |
μ ±SD | 36.65 ±54.4 | 51.43 ±62.9 | 39.99 ±56.4 | ||
BT | M (min:max) | 0.9 (0.3:6.6) | 0.9 (0.3:6) | 0.9 (0.3:6.6) | MW: p=0.635 |
μ ±SD | 1.43 ±1.36 | 1.35 ±1.36 | 1.41 ±1.35 | ||
BD | M (min:max) | 0.3 (0.1:3.97) | 0.25 (0.09:3.5) | 0.3 (0.09:3.97) | MW: p=0.644 |
μ ±SD | 0.533 ±0.652 | 0.564 ±0.795 | 0.541 ±0.688 | ||
GGT | M (min:max) | 51.5 (17:846) | 45 (18:1914) | 50 (17:1914) | MW: p=0.757 |
μ ±SD | 94.50 ±137.9 | 201.82 ±426.9 | 123.29 ±251.8 | ||
FA | M (min:max) | 223 (119:899) | 215 (118:1042) | 216.5 (118:1042) | MW: p=0.900 |
μ ±SD | 263.62 ±142.9 | 283.45 ±203.2 | 268.94 ±160.1 | ||
ALB | M (min:max) | 4.2 (2.9:5.3) | 4.5 (3.6:5.1) | 4.2 (2.9:5.3) | T-test: p=0.471 |
μ ±SD | 4.21 ±0.645 | 4.44 ±0.684 | 4.24 ±0.645 | ||
INR | M (min:max) | 1.15 (0.9:1.73) | 1.13 (0.96:1.82) | 1.14 (0.9:1.82) | MW: p=0.724 |
μ ±SD | 1.21 ±0.228 | 1.20 ±0.255 | 1.21 ±0.232 | ||
COL | M (min:max) | 185.5 (18:306) | 192 (120:294) | 187 (18:306) | T-test: p=0.299 |
μ ±SD | 181.65 ±53.2 | 203.33 ±62.1 | 186.19 ±55.1 | ||
TG | M (min:max) | 110.5 (33:380) | 107 (66:239) | 110 (33:380) | MW: p=0.934 |
μ ±SD | 131.63 ±74.0 | 130.00 ±59.0 | 131.26 ±70.1 | ||
Fe | M (min:max) | 97 (26:218) | 112 (34:165) | 102 (26:218) | MW: p=0.823 |
μ ±SD | 102.28 ±43.9 | 100.22 ±42.5 | 101.79 ±43.0 | ||
Crea | M (min:max) | 0.79 (0.54:1.52) | 0.76 (0.59:1.34) | 0.79 (0.54:1.52) | MW: p=0.818 |
μ ±SD | 0.835 ±0.198 | 0.834 ±0.203 | 0.835 ±0.198 | ||
Uree | M (min:max) | 35 (19:74) | 33 (20:78) | 35 (19:78) | MW: p=0.973 |
μ ±SD | 36.30 ±14.3 | 35.87 ±14.4 | 36.17 ±14.2 | ||
Na | M (min:max) | 137 (125:141) | 137 (131:142) | 137 (125:142) | MW: p=0.617 |
μ ±SD | 136.67 ±2.92 | 136.46 ±3.26 | 136.62 ±2.98 | ||
Glicemie | M (min:max) | 104 (87:361.7) | 103.75 (85:169.3) | 104 (85:361.7) | MW: p=0.875 |
μ ±SD | 117.49 ±43.1 | 111.49 ±23.2 | 115.97 ±38.9 | ||
CRP | M (min:max) | 0.38 (0.2:2.35) | 0.34 (0.22:0.42) | 0.38 (0.2:2.35) | MW: p=0.477 |
μ ±SD | 0.54 ±0.533 | 0.34 ±0.0644 | 0.48 ±0.454 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.25) | 0.05 (0.01:0.33) | 0.06 (0:0.33) | MW: p=0.802 |
μ ±SD | 0.0655 ±0.0461 | 0.074 ±0.073 | 0.0675 ±0.0533 | ||
Attenuation SOS IQR | M (min:max) | 10.5 (0:80) | 14.5 (0.75:29) | 10.5 (0:80) | MW: p=0.500 |
μ ±SD | 13.21 ±12.7 | 12.80 ±7.84 | 13.11 ±11.7 | ||
Attenuation cuts | <0.5 | 63 (76.8%) | 16 (64.0%) | 79 (73.8%) | OR=1.87 [0.71, 4.89] (p=0.206) |
≥0.5 | 19 (23.2%) | 9 (36.0%) | 28 (26.2%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.5 | ≥0.5 | (total) |
S0-S1 (CAP <285) | 63 (87.5% / 79.7%) | 9 (12.5% / 32.1%) | 72 (67.3%) |
S2-S3 (CAP ≥285) | 16 (45.7% / 20.3%) | 19 (54.3% / 67.9%) | 35 (32.7%) |
(total) | 79 (73.8%) | 28 (26.2%) | 107 (100%) |
OR=8.31 [3.17, 21.81], phi=0.45 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 84 (78.5%) | 23 (21.5%) | 107 | ||
Sex | F | 47 (56.0%) | 15 (65.2%) | 62 (57.9%) | OR=0.68 [0.26, 1.77] (p=0.482) |
M | 37 (44.0%) | 8 (34.8%) | 45 (42.1%) | ||
Age (years) | M (min:max) | 54 (18:79) | 64 (35:78) | 58 (18:79) | MW: p=0.008 |
μ ±SD | 53.44 ±14.4 | 61.91 ±10.5 | 55.26 ±14.1 | ||
Cirrhosis | 0 | 0 | 0 | OR=0.28 [0.01, 14.39] (p>0.999) | |
Etiology | alcohol | 7 (9.5%) | 0 | 7 (7.4%) | V=0.19 (p=0.321) |
viral | 51 (68.9%) | 13 (65.0%) | 64 (68.1%) | ||
metabolic | 12 (16.2%) | 6 (30.0%) | 18 (19.1%) | ||
cholestatic liver disease | 4 (5.4%) | 1 (5.0%) | 5 (5.3%) | ||
APP_DZ | 15 (17.9%) | 2 (8.7%) | 17 (15.9%) | OR=2.28 [0.48, 10.80] (p=0.355) | |
APP_HTAE | 30 (35.7%) | 8 (34.8%) | 38 (35.5%) | OR=1.04 [0.40, 2.74] (p>0.999) | |
APP_CVD | 16 (19.0%) | 10 (43.5%) | 26 (24.3%) | OR=0.31 [0.11, 0.82] (p=0.026) | |
APP_COPD | 2 (2.4%) | 0 | 2 (1.9%) | OR=1.42 [0.07, 30.70] (p>0.999) | |
APP_Renal | 0 | 1 (4.8%) | 1 (1.0%) | OR=0.08 [0.00, 2.16] (p=0.208) | |
Alcohol | 7 (11.9%) | 0 | 7 (9.7%) | OR=3.86 [0.21, 71.84] (p=0.337) | |
Dislipidemia | 8 (22.2%) | 0 | 8 (19.5%) | OR=3.28 [0.16, 65.54] (p=0.563) | |
Weight | M (min:max) | 76 (45:123) | 76.5 (54:104) | 76 (45:123) | T-test: p=0.423 |
μ ±SD | 74.64 ±14.6 | 77.67 ±12.8 | 75.26 ±14.2 | ||
Height | M (min:max) | 168 (150:192) | 166.5 (157:178) | 168 (150:192) | MW: p=0.352 |
μ ±SD | 168.18 ±9.02 | 165.83 ±6.41 | 167.67 ±8.54 | ||
BMI | M (min:max) | 25.85 (15.57:40.86) | 28.49 (19.36:35.99) | 26.28 (15.57:40.86) | T-test: p=0.201 |
μ ±SD | 26.51 ±5.16 | 28.22 ±4.16 | 26.88 ±4.99 | ||
Fibroscan_Probe | M | 82 (97.6%) | 22 (95.7%) | 104 (97.2%) | OR=1.86 [0.16, 21.51] (p=0.520) |
XL | 2 (2.4%) | 1 (4.3%) | 3 (2.8%) | ||
Fibroscan_Value | M (min:max) | 5 (2.5:9.9) | 5.6 (3.7:9.6) | 5.1 (2.5:9.9) | MW: p=0.266 |
μ ±SD | 5.57 ±1.8 | 6.16 ±2.0 | 5.69 ±1.85 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 64 (76.2%) | 14 (60.9%) | 78 (72.9%) | V=0.14 (p=0.143) |
F2 (7-10) | 20 (23.8%) | 9 (39.1%) | 29 (27.1%) | ||
F3-F4 (>10) | 0 | 0 | 0 | ||
Valid Elastography | 72 (85.7%) | 21 (91.3%) | 93 (86.9%) | OR=0.57 [0.12, 2.76] (p=0.730) | |
Stability index | M (min:max) | 91 (28:99) | 92 (72:97) | 92 (28:99) | MW: p=0.822 |
μ ±SD | 88.63 ±10.3 | 90.05 ±6.29 | 88.92 ±9.62 | ||
CAP_Value | M (min:max) | 252 (100:400) | 298 (130:400) | 263 (100:400) | T-test: p<0.001 |
μ ±SD | 250.88 ±54.7 | 294.61 ±49.5 | 260.28 ±56.4 | ||
CAP Steatosis stage | S0-S2 (CAP <295) | 70 (83.3%) | 6 (26.1%) | 76 (71.0%) | OR=14.17 [4.75, 42.28] (p<0.001) |
S3 (CAP ≥295) | 14 (16.7%) | 17 (73.9%) | 31 (29.0%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.460 |
μ ±SD | 2.15 ±1.01 | 2.33 ±0.966 | 2.19 ±0.999 | ||
HRI Mean | M (min:max) | 1.16 (0.69:2.79) | 1.21 (0.6:2) | 1.19 (0.6:2.79) | MW: p=0.660 |
μ ±SD | 1.21 ±0.372 | 1.22 ±0.354 | 1.21 ±0.366 | ||
Number Attenuation measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.549 |
μ ±SD | 4.76 ±1.12 | 4.78 ±0.85 | 4.77 ±1.06 | ||
Attenuation Mean | M (min:max) | 0.41 (0.21:0.73) | 0.46 (0.26:0.66) | 0.42 (0.21:0.73) | MW: p=0.036 |
μ ±SD | 0.427 ±0.117 | 0.47 ±0.0972 | 0.436 ±0.114 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (1:7) | 5 (3:7) | 5 (1:7) | MW: p=0.712 |
μ ±SD | 4.92 ±0.972 | 4.96 ±0.825 | 4.93 ±0.939 | ||
Attenuation SOS Mean | M (min:max) | 1533.27 (1477:1598.4) | 1523.6 (1478:1571.4) | 1531.5 (1477:1598.4) | MW: p=0.056 |
μ ±SD | 1538.21 ±28.6 | 1526.23 ±22.3 | 1535.63 ±27.7 | ||
Elastography liver median 1 | M (min:max) | 6.2 (3.3:28.8) | 6.8 (3.7:37.7) | 6.3 (3.3:37.7) | MW: p=0.462 |
μ ±SD | 7.02 ±3.42 | 8.19 ±6.73 | 7.27 ±4.34 | ||
Elastography liver IQR 1 | M (min:max) | 0.9 (0.1:6) | 1.05 (0.1:14.6) | 0.9 (0.1:14.6) | MW: p=0.858 |
μ ±SD | 1.20 ±1.11 | 1.66 ±2.98 | 1.30 ±1.67 | ||
Elastography IQR/MED | M (min:max) | 13.99 (0:78.95) | 14.91 (0:41.18) | 14.08 (0:78.95) | MW: p=0.903 |
μ ±SD | 16.83 ±13.3 | 16.15 ±11.7 | 16.69 ±13.0 | ||
Viscosity liver Median 1 | M (min:max) | 1.8 (1.2:3) | 1.9 (1.1:3) | 1.8 (1.1:3) | MW: p=0.578 |
μ ±SD | 1.89 ±0.407 | 1.94 ±0.457 | 1.90 ±0.416 | ||
Spleen diameter | M (min:max) | 12.26 (7.37:20.03) | 12.02 (6.37:17.45) | 12.25 (6.37:20.03) | MW: p=0.984 |
μ ±SD | 12.90 ±3.14 | 12.68 ±2.99 | 12.85 ±3.09 | ||
Spleen area | M (min:max) | 76.8 (15.98:136.44) | 48.62 (15.73:104.08) | 62.32 (15.73:136.44) | T-test: p=0.048 |
μ ±SD | 80.28 ±32.8 | 56.27 ±27.2 | 71.76 ±32.6 | ||
VP Diam cm | M (min:max) | 1.15 (0.52:1.62) | 1.2 (0.95:1.76) | 1.15 (0.52:1.76) | T-test: p=0.549 |
μ ±SD | 1.17 ±0.24 | 1.23 ±0.266 | 1.18 ±0.243 | ||
VP Speed | M (min:max) | 26.54 (18:46.47) | 32.39 (20.28:49.44) | 27.91 (18:49.44) | MW: p=0.097 |
μ ±SD | 27.10 ±8.04 | 33.40 ±10.0 | 29.11 ±9.02 | ||
VP RI | M (min:max) | 0.01 (0:0.04) | 0.01 (0:0.1) | 0.01 (0:0.1) | MW: p=0.344 |
μ ±SD | 0.01 ±0.011 | 0.0333 ±0.0418 | 0.0164 ±0.0248 | ||
Hb | M (min:max) | 13.95 (8.5:19.6) | 13.75 (8.7:16.3) | 13.9 (8.5:19.6) | T-test: p=0.279 |
μ ±SD | 13.89 ±1.85 | 13.36 ±2.06 | 13.77 ±1.9 | ||
PTL | M (min:max) | 179 (38:536) | 215 (45:427) | 202 (38:536) | MW: p=0.894 |
μ ±SD | 195.77 ±106.8 | 199.85 ±98.9 | 196.72 ±104.5 | ||
GOT | M (min:max) | 30 (13:118) | 41 (18:570) | 32.5 (13:570) | MW: p=0.071 |
μ ±SD | 37.32 ±22.3 | 72.86 ±119.3 | 45.43 ±61.1 | ||
GPT | M (min:max) | 23 (8:387) | 30 (12:291) | 24 (8:387) | MW: p=0.126 |
μ ±SD | 37.64 ±55.5 | 48.05 ±60.0 | 39.99 ±56.4 | ||
BT | M (min:max) | 0.9 (0.3:6.6) | 0.95 (0.3:6) | 0.9 (0.3:6.6) | MW: p=0.842 |
μ ±SD | 1.39 ±1.31 | 1.48 ±1.51 | 1.41 ±1.35 | ||
BD | M (min:max) | 0.3 (0.09:3.97) | 0.24 (0.12:3.5) | 0.3 (0.09:3.97) | MW: p=0.875 |
μ ±SD | 0.512 ±0.636 | 0.634 ±0.845 | 0.541 ±0.688 | ||
GGT | M (min:max) | 51.5 (17:846) | 45 (18:1914) | 50 (17:1914) | MW: p=0.953 |
μ ±SD | 95.87 ±138.2 | 208.30 ±446.0 | 123.29 ±251.8 | ||
FA | M (min:max) | 216.5 (118:899) | 215 (120:1042) | 216.5 (118:1042) | MW: p=0.623 |
μ ±SD | 259.52 ±141.9 | 298.15 ±208.5 | 268.94 ±160.1 | ||
ALB | M (min:max) | 4.2 (2.9:5.3) | 4.05 (3.4:5.1) | 4.2 (2.9:5.3) | T-test: p=0.911 |
μ ±SD | 4.25 ±0.639 | 4.22 ±0.736 | 4.24 ±0.645 | ||
INR | M (min:max) | 1.15 (0.9:1.73) | 1.13 (0.96:1.82) | 1.14 (0.9:1.82) | MW: p=0.911 |
μ ±SD | 1.20 ±0.223 | 1.22 ±0.276 | 1.21 ±0.232 | ||
COL | M (min:max) | 189 (18:306) | 184 (120:288) | 187 (18:306) | T-test: p=0.827 |
μ ±SD | 185.36 ±54.7 | 190.43 ±61.3 | 186.19 ±55.1 | ||
TG | M (min:max) | 111 (33:380) | 100 (66:239) | 110 (33:380) | MW: p=0.444 |
μ ±SD | 135.48 ±73.4 | 114.88 ±56.4 | 131.26 ±70.1 | ||
Fe | M (min:max) | 102 (32:218) | 93.5 (26:212) | 102 (26:218) | MW: p=0.543 |
μ ±SD | 103.00 ±35.9 | 97.25 ±66.4 | 101.79 ±43.0 | ||
Crea | M (min:max) | 0.78 (0.54:1.52) | 0.8 (0.59:1.34) | 0.79 (0.54:1.52) | MW: p=0.987 |
μ ±SD | 0.836 ±0.204 | 0.83 ±0.184 | 0.835 ±0.198 | ||
Uree | M (min:max) | 35 (19:78) | 32 (20:49) | 35 (19:78) | MW: p=0.794 |
μ ±SD | 37.38 ±15.8 | 33.21 ±8.95 | 36.17 ±14.2 | ||
Na | M (min:max) | 137 (125:140) | 138 (132:142) | 137 (125:142) | MW: p=0.254 |
μ ±SD | 136.31 ±2.91 | 137.54 ±3.1 | 136.62 ±2.98 | ||
Glicemie | M (min:max) | 105 (87:361.7) | 97.95 (85:169.3) | 104 (85:361.7) | MW: p=0.240 |
μ ±SD | 118.14 ±42.2 | 108.63 ±24.2 | 115.97 ±38.9 | ||
CRP | M (min:max) | 0.38 (0.22:2.35) | 0.37 (0.2:0.42) | 0.38 (0.2:2.35) | MW: p=0.338 |
μ ±SD | 0.536 ±0.523 | 0.333 ±0.0793 | 0.48 ±0.454 | ||
Attenuation IQR | M (min:max) | 0.06 (0:0.25) | 0.04 (0.01:0.33) | 0.06 (0:0.33) | MW: p=0.170 |
μ ±SD | 0.0676 ±0.0461 | 0.0668 ±0.0754 | 0.0675 ±0.0533 | ||
Attenuation SOS IQR | M (min:max) | 10.5 (0:80) | 14 (2:29) | 10.5 (0:80) | MW: p=0.516 |
μ ±SD | 13.18 ±12.6 | 12.86 ±7.63 | 13.11 ±11.7 | ||
Attenuation cuts | <0.55 | 70 (83.3%) | 17 (73.9%) | 87 (81.3%) | OR=1.76 [0.59, 5.27] (p=0.366) |
≥0.55 | 14 (16.7%) | 6 (26.1%) | 20 (18.7%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.55 | ≥0.55 | (total) |
S0-S2 (CAP <295) | 70 (92.1% / 80.5%) | 6 (7.9% / 30.0%) | 76 (71.0%) |
S3 (CAP ≥295) | 17 (54.8% / 19.5%) | 14 (45.2% / 70.0%) | 31 (29.0%) |
(total) | 87 (81.3%) | 20 (18.7%) | 107 (100%) |
OR=9.61 [3.22, 28.67], phi=0.43 (p<0.001) | |||
2.11 Agreement: Attenuation Mean ~ CAP Steatosis stage: F3-F4
Variable | Details | yes | no | Total | Statistics |
Agreement | 63 (67.0%) | 31 (33.0%) | 94 | ||
Sex | F | 24 (38.7%) | 10 (33.3%) | 34 (37.0%) | OR=1.26 [0.51, 3.15] (p=0.653) |
M | 38 (61.3%) | 20 (66.7%) | 58 (63.0%) | ||
Age (years) | M (min:max) | 61 (32:87) | 60.5 (39:81) | 61 (32:87) | T-test: p=0.853 |
μ ±SD | 59.87 ±10.5 | 60.30 ±10.1 | 60.01 ±10.3 | ||
Cirrhosis | 55 (87.3%) | 27 (87.1%) | 82 (87.2%) | OR=1.02 [0.28, 3.68] (p>0.999) | |
Etiology | alcohol | 25 (42.4%) | 14 (46.7%) | 39 (43.8%) | V=0.19 (p=0.367) |
viral | 22 (37.3%) | 14 (46.7%) | 36 (40.4%) | ||
metabolic | 9 (15.3%) | 1 (3.3%) | 10 (11.2%) | ||
cholestatic liver disease | 3 (5.1%) | 1 (3.3%) | 4 (4.5%) | ||
APP_DZ | 19 (30.2%) | 8 (27.6%) | 27 (29.3%) | OR=1.13 [0.43, 3.01] (p>0.999) | |
APP_HTAE | 22 (34.9%) | 9 (31.0%) | 31 (33.7%) | OR=1.19 [0.46, 3.06] (p=0.814) | |
APP_CVD | 13 (20.6%) | 9 (31.0%) | 22 (23.9%) | OR=0.58 [0.21, 1.56] (p=0.301) | |
APP_COPD | 3 (4.8%) | 4 (13.8%) | 7 (7.6%) | OR=0.31 [0.07, 1.50] (p=0.201) | |
APP_Renal | 4 (6.5%) | 3 (11.5%) | 7 (8.0%) | OR=0.53 [0.11, 2.55] (p=0.417) | |
Alcohol | 27 (55.1%) | 14 (56.0%) | 41 (55.4%) | OR=0.96 [0.37, 2.54] (p>0.999) | |
Dislipidemia | 2 (10.5%) | 2 (16.7%) | 4 (12.9%) | OR=0.59 [0.07, 4.85] (p=0.630) | |
Weight | M (min:max) | 86 (52:120) | 83.5 (53:112) | 85 (52:120) | T-test: p=0.578 |
μ ±SD | 86.47 ±16.3 | 84.25 ±15.9 | 85.78 ±16.1 | ||
Height | M (min:max) | 170 (153:190) | 168.5 (150:190) | 170 (150:190) | MW: p=0.361 |
μ ±SD | 170.84 ±7.83 | 169.25 ±9.7 | 170.32 ±8.45 | ||
BMI | M (min:max) | 29.53 (19.1:42.24) | 29.93 (20.2:36.58) | 29.54 (19.1:42.24) | T-test: p=0.869 |
μ ±SD | 29.51 ±4.91 | 29.31 ±4.45 | 29.44 ±4.74 | ||
Fibroscan_Probe | M | 55 (87.3%) | 28 (90.3%) | 83 (88.3%) | OR=0.74 [0.18, 3.00] (p>0.999) |
XL | 8 (12.7%) | 3 (9.7%) | 11 (11.7%) | ||
Fibroscan_Value | M (min:max) | 29.7 (10.1:75) | 18.4 (10:75) | 24.2 (10:75) | MW: p=0.206 |
μ ±SD | 33.46 ±20.0 | 29.43 ±22.3 | 32.12 ±20.8 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 0 | 0 | 0 | V=NA (p>0.999) |
F2 (7-10) | 0 | 0 | 0 | ||
F3-F4 (>10) | 63 (100%) | 31 (100%) | 94 (100%) | ||
Valid Elastography | 58 (92.1%) | 28 (90.3%) | 86 (91.5%) | OR=1.24 [0.28, 5.57] (p>0.999) | |
Stability index | M (min:max) | 90 (12:96) | 92 (51:98) | 91 (12:98) | MW: p=0.395 |
μ ±SD | 85.37 ±15.1 | 86.94 ±12.4 | 85.88 ±14.2 | ||
CAP_Value | M (min:max) | 255 (100:400) | 282 (100:354) | 272 (100:400) | T-test: p=0.452 |
μ ±SD | 269.08 ±69.4 | 279.71 ±51.4 | 272.59 ±64.0 | ||
CAP Steatosis stage | No steatosis | 33 (52.4%) | 7 (22.6%) | 40 (42.6%) | OR=3.77 [1.42, 10.01] (p=0.008) |
S1-S3 (CAP ≥260) | 30 (47.6%) | 24 (77.4%) | 54 (57.4%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.851 |
μ ±SD | 2.42 ±0.948 | 2.47 ±0.905 | 2.44 ±0.926 | ||
HRI Mean | M (min:max) | 1.17 (0.68:2.29) | 1.21 (0.86:2.29) | 1.19 (0.68:2.29) | MW: p=0.374 |
μ ±SD | 1.20 ±0.337 | 1.28 ±0.319 | 1.23 ±0.331 | ||
Number Attenuation measurements | M (min:max) | 5 (3:7) | 5 (2:7) | 5 (2:7) | MW: p=0.158 |
μ ±SD | 5.02 ±0.813 | 4.77 ±1.06 | 4.94 ±0.902 | ||
Attenuation Mean | M (min:max) | 0.43 (0.16:0.77) | 0.4 (0.17:0.56) | 0.41 (0.16:0.77) | Welch: p=0.004 |
μ ±SD | 0.457 ±0.133 | 0.393 ±0.0801 | 0.436 ±0.121 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (3:7) | 5 (3:7) | 5 (3:7) | MW: p=0.588 |
μ ±SD | 5.05 ±0.728 | 4.97 ±0.752 | 5.02 ±0.733 | ||
Attenuation SOS Mean | M (min:max) | 1516.8 (1485:1583) | 1527 (1480:1565.2) | 1524.75 (1480:1583) | T-test: p=0.212 |
μ ±SD | 1523.15 ±21.7 | 1528.97 ±19.9 | 1525.07 ±21.2 | ||
Elastography liver median 1 | M (min:max) | 23.6 (6.5:76.7) | 18.1 (8.9:74.6) | 22.6 (6.5:76.7) | MW: p=0.469 |
μ ±SD | 26.81 ±14.4 | 24.90 ±14.6 | 26.18 ±14.4 | ||
Elastography liver IQR 1 | M (min:max) | 3.05 (0.4:24.9) | 3.2 (0.6:11.2) | 3.1 (0.4:24.9) | MW: p=0.791 |
μ ±SD | 4.76 ±5.15 | 4.31 ±3.29 | 4.61 ±4.6 | ||
Elastography IQR/MED | M (min:max) | 13.71 (0:53.32) | 15.83 (3.37:39.47) | 14.79 (0:53.32) | MW: p=0.474 |
μ ±SD | 16.30 ±11.4 | 17.19 ±10.0 | 16.59 ±10.9 | ||
Viscosity liver Median 1 | M (min:max) | 3 (1.2:4.9) | 2.65 (1.3:5) | 2.8 (1.2:5) | MW: p=0.192 |
μ ±SD | 3.05 ±0.864 | 2.82 ±0.782 | 2.97 ±0.839 | ||
Spleen diameter | M (min:max) | 10.84 (8.39:21.8) | 11.66 (7.26:17.65) | 11.12 (7.26:21.8) | MW: p=0.577 |
μ ±SD | 11.84 ±3.04 | 11.99 ±2.68 | 11.89 ±2.91 | ||
Spleen area | M (min:max) | 71.76 (21.3:193.16) | 53.2 (29.89:131.6) | 56.1 (21.3:193.16) | MW: p=0.602 |
μ ±SD | 73.80 ±49.6 | 60.68 ±28.8 | 66.30 ±38.6 | ||
VP Diam cm | M (min:max) | 1.06 (0.76:1.49) | 1.12 (0.76:1.62) | 1.11 (0.76:1.62) | T-test: p=0.350 |
μ ±SD | 1.08 ±0.208 | 1.15 ±0.228 | 1.11 ±0.216 | ||
VP Speed | M (min:max) | 26.68 (14.62:74.5) | 21.98 (14.38:42.15) | 23.27 (14.38:74.5) | MW: p=0.462 |
μ ±SD | 32.18 ±19.7 | 23.94 ±9.05 | 28.06 ±15.4 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.01 (0:0.08) | 0.01 (0:0.08) | MW: p=0.855 |
μ ±SD | 0.0187 ±0.028 | 0.0186 ±0.0279 | 0.0187 ±0.027 | ||
Hb | M (min:max) | 13.75 (7.5:17.3) | 14.1 (8.5:17) | 13.85 (7.5:17.3) | MW: p=0.906 |
μ ±SD | 13.84 ±1.81 | 13.69 ±2.2 | 13.79 ±1.94 | ||
PTL | M (min:max) | 196.5 (2.39:343) | 158 (26:353) | 186.5 (2.39:353) | T-test: p=0.470 |
μ ±SD | 188.23 ±81.8 | 173.15 ±97.3 | 183.33 ±86.8 | ||
GOT | M (min:max) | 27 (17:124) | 31 (16:134) | 30 (16:134) | MW: p=0.242 |
μ ±SD | 36.82 ±22.0 | 38.89 ±23.8 | 37.49 ±22.5 | ||
GPT | M (min:max) | 24 (9:75) | 26 (7:183) | 24.5 (7:183) | MW: p=0.562 |
μ ±SD | 27.88 ±15.4 | 32.37 ±31.6 | 29.32 ±21.9 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 1.2 (0.4:8.6) | 1 (0.3:11.1) | MW: p=0.452 |
μ ±SD | 1.39 ±1.65 | 1.81 ±1.91 | 1.53 ±1.73 | ||
BD | M (min:max) | 0.27 (0.13:8.96) | 0.35 (0.15:6.38) | 0.32 (0.13:8.96) | MW: p=0.199 |
μ ±SD | 0.63 ±1.35 | 0.759 ±1.39 | 0.67 ±1.35 | ||
GGT | M (min:max) | 40.5 (13:1128) | 35 (19:611) | 36.5 (13:1128) | MW: p=0.709 |
μ ±SD | 106.12 ±189.1 | 74.77 ±125.8 | 96.27 ±171.5 | ||
FA | M (min:max) | 230 (108:737) | 199 (104:403) | 223 (104:737) | MW: p=0.183 |
μ ±SD | 272.57 ±135.7 | 220.05 ±77.7 | 256.81 ±123.1 | ||
ALB | M (min:max) | 4.2 (2.6:5.1) | 4.2 (3.3:5) | 4.2 (2.6:5.1) | T-test: p=0.752 |
μ ±SD | 4.02 ±0.682 | 4.13 ±0.739 | 4.06 ±0.685 | ||
INR | M (min:max) | 1.06 (0.9:2.52) | 1.3 (1.01:2.7) | 1.08 (0.9:2.7) | MW: p=0.046 |
μ ±SD | 1.20 ±0.332 | 1.38 ±0.42 | 1.26 ±0.369 | ||
COL | M (min:max) | 205.5 (124:326) | 155 (132:280) | 185 (124:326) | MW: p=0.829 |
μ ±SD | 197.58 ±56.5 | 184.27 ±58.2 | 193.62 ±56.6 | ||
TG | M (min:max) | 85 (31:189) | 118 (62:224) | 98 (31:224) | T-test: p=0.039 |
μ ±SD | 94.29 ±44.6 | 129.73 ±46.9 | 105.43 ±47.7 | ||
Fe | M (min:max) | 92.5 (36:191) | 90 (22:246) | 92 (22:246) | MW: p=0.496 |
μ ±SD | 95.80 ±36.0 | 112.62 ±65.2 | 101.65 ±48.2 | ||
Crea | M (min:max) | 0.76 (0.53:1.27) | 0.76 (0.54:1.11) | 0.76 (0.53:1.27) | MW: p=0.865 |
μ ±SD | 0.776 ±0.167 | 0.778 ±0.143 | 0.777 ±0.159 | ||
Uree | M (min:max) | 30 (10:92) | 32 (26:58) | 30 (10:92) | MW: p=0.332 |
μ ±SD | 33.37 ±16.6 | 36.29 ±11.7 | 33.92 ±15.7 | ||
Na | M (min:max) | 135 (128:140) | 136.5 (89:142) | 135 (89:142) | MW: p=0.096 |
μ ±SD | 135.44 ±2.42 | 133.64 ±13.1 | 134.89 ±7.38 | ||
Glicemie | M (min:max) | 103 (75.8:336) | 108.5 (75.7:177.5) | 103.4 (75.7:336) | MW: p=0.463 |
μ ±SD | 123.25 ±53.6 | 115.35 ±25.4 | 120.89 ±46.9 | ||
CRP | M (min:max) | 0.4 (0.26:22.2) | 0.39 (0.23:4.17) | 0.39 (0.23:22.2) | MW: p=0.713 |
μ ±SD | 2.56 ±5.26 | 0.72 ±1.07 | 1.99 ±4.47 | ||
Attenuation IQR | M (min:max) | 0.05 (0.01:0.25) | 0.06 (0:0.23) | 0.05 (0:0.25) | MW: p=0.936 |
μ ±SD | 0.0712 ±0.0543 | 0.0745 ±0.0578 | 0.0723 ±0.0552 | ||
Attenuation SOS IQR | M (min:max) | 10 (1:84) | 12 (2:38) | 10.88 (1:84) | MW: p=0.118 |
μ ±SD | 11.99 ±11.3 | 14.35 ±8.87 | 12.77 ±10.6 | ||
Attenuation cuts | <0.45 | 33 (52.4%) | 24 (77.4%) | 57 (60.6%) | OR=0.32 [0.12, 0.85] (p=0.025) |
≥0.45 | 30 (47.6%) | 7 (22.6%) | 37 (39.4%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.45 | ≥0.45 | (total) |
No steatosis | 33 (82.5% / 57.9%) | 7 (17.5% / 18.9%) | 40 (42.6%) |
S1-S3 (CAP ≥260) | 24 (44.4% / 42.1%) | 30 (55.6% / 81.1%) | 54 (57.4%) |
(total) | 57 (60.6%) | 37 (39.4%) | 94 (100%) |
OR=5.89 [2.22, 15.64], phi=0.39 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 71 (75.5%) | 23 (24.5%) | 94 | ||
Sex | F | 27 (39.1%) | 7 (30.4%) | 34 (37.0%) | OR=1.47 [0.53, 4.04] (p=0.619) |
M | 42 (60.9%) | 16 (69.6%) | 58 (63.0%) | ||
Age (years) | M (min:max) | 59 (32:87) | 64 (40:76) | 61 (32:87) | T-test: p=0.449 |
μ ±SD | 59.54 ±11.0 | 61.43 ±8.13 | 60.01 ±10.3 | ||
Cirrhosis | 62 (87.3%) | 20 (87.0%) | 82 (87.2%) | OR=1.03 [0.25, 4.19] (p>0.999) | |
Etiology | alcohol | 28 (42.4%) | 11 (47.8%) | 39 (43.8%) | V=0.06 (p=0.959) |
viral | 27 (40.9%) | 9 (39.1%) | 36 (40.4%) | ||
metabolic | 8 (12.1%) | 2 (8.7%) | 10 (11.2%) | ||
cholestatic liver disease | 3 (4.5%) | 1 (4.3%) | 4 (4.5%) | ||
APP_DZ | 21 (30.0%) | 6 (27.3%) | 27 (29.3%) | OR=1.14 [0.39, 3.33] (p>0.999) | |
APP_HTAE | 25 (35.7%) | 6 (27.3%) | 31 (33.7%) | OR=1.48 [0.51, 4.27] (p=0.607) | |
APP_CVD | 17 (24.3%) | 5 (22.7%) | 22 (23.9%) | OR=1.09 [0.35, 3.40] (p>0.999) | |
APP_COPD | 4 (5.7%) | 3 (13.6%) | 7 (7.6%) | OR=0.38 [0.08, 1.87] (p=0.352) | |
APP_Renal | 4 (5.8%) | 3 (15.8%) | 7 (8.0%) | OR=0.33 [0.07, 1.62] (p=0.169) | |
Alcohol | 29 (53.7%) | 12 (60.0%) | 41 (55.4%) | OR=0.77 [0.27, 2.19] (p=0.793) | |
Dislipidemia | 4 (16.7%) | 0 | 4 (12.9%) | OR=3.29 [0.16, 68.77] (p=0.550) | |
Weight | M (min:max) | 83.5 (52:120) | 95 (70:115) | 85 (52:120) | T-test: p=0.023 |
μ ±SD | 83.41 ±16.1 | 93.00 ±14.1 | 85.78 ±16.1 | ||
Height | M (min:max) | 168 (150:183) | 170.5 (160:190) | 170 (150:190) | MW: p=0.135 |
μ ±SD | 169.38 ±8.01 | 173.28 ±9.3 | 170.32 ±8.45 | ||
BMI | M (min:max) | 29.39 (19.1:38.06) | 31.65 (23.1:42.24) | 29.54 (19.1:42.24) | T-test: p=0.051 |
μ ±SD | 28.83 ±4.57 | 31.33 ±4.89 | 29.44 ±4.74 | ||
Fibroscan_Probe | M | 64 (90.1%) | 19 (82.6%) | 83 (88.3%) | OR=1.92 [0.51, 7.28] (p=0.454) |
XL | 7 (9.9%) | 4 (17.4%) | 11 (11.7%) | ||
Fibroscan_Value | M (min:max) | 25.15 (10.1:75) | 22.8 (10:75) | 24.2 (10:75) | MW: p=0.650 |
μ ±SD | 32.69 ±20.9 | 30.36 ±20.8 | 32.12 ±20.8 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 0 | 0 | 0 | V=NA (p>0.999) |
F2 (7-10) | 0 | 0 | 0 | ||
F3-F4 (>10) | 71 (100%) | 23 (100%) | 94 (100%) | ||
Valid Elastography | 65 (91.5%) | 21 (91.3%) | 86 (91.5%) | OR=1.03 [0.19, 5.50] (p>0.999) | |
Stability index | M (min:max) | 90 (12:98) | 92 (51:98) | 91 (12:98) | MW: p=0.350 |
μ ±SD | 85.17 ±15.2 | 88.09 ±10.8 | 85.88 ±14.2 | ||
CAP_Value | M (min:max) | 255 (100:400) | 319 (162:386) | 272 (100:400) | T-test: p=0.004 |
μ ±SD | 261.82 ±65.6 | 305.83 ±45.5 | 272.59 ±64.0 | ||
CAP Steatosis stage | S0-S1 (CAP <285) | 50 (70.4%) | 5 (21.7%) | 55 (58.5%) | OR=8.57 [2.81, 26.12] (p<0.001) |
S2-S3 (CAP ≥285) | 21 (29.6%) | 18 (78.3%) | 39 (41.5%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.973 |
μ ±SD | 2.44 ±0.934 | 2.43 ±0.938 | 2.44 ±0.926 | ||
HRI Mean | M (min:max) | 1.18 (0.68:2.29) | 1.25 (0.72:2.29) | 1.19 (0.68:2.29) | MW: p=0.565 |
μ ±SD | 1.21 ±0.309 | 1.28 ±0.398 | 1.23 ±0.331 | ||
Number Attenuation measurements | M (min:max) | 5 (2:7) | 5 (2:7) | 5 (2:7) | MW: p=0.501 |
μ ±SD | 4.89 ±0.854 | 5.09 ±1.04 | 4.94 ±0.902 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.41 (0.25:0.72) | 0.41 (0.16:0.77) | T-test: p=0.663 |
μ ±SD | 0.433 ±0.125 | 0.446 ±0.112 | 0.436 ±0.121 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (3:7) | 5 (4:7) | 5 (3:7) | MW: p=0.348 |
μ ±SD | 4.97 ±0.774 | 5.17 ±0.576 | 5.02 ±0.733 | ||
Attenuation SOS Mean | M (min:max) | 1524.5 (1485:1581.67) | 1525 (1480:1583) | 1524.75 (1480:1583) | T-test: p=0.880 |
μ ±SD | 1524.88 ±20.1 | 1525.65 ±24.6 | 1525.07 ±21.2 | ||
Elastography liver median 1 | M (min:max) | 22.4 (6.5:76.7) | 22.8 (10.5:74.6) | 22.6 (6.5:76.7) | MW: p=0.833 |
μ ±SD | 26.09 ±14.5 | 26.45 ±14.6 | 26.18 ±14.4 | ||
Elastography liver IQR 1 | M (min:max) | 3.1 (0.4:24.9) | 4 (0.4:10.3) | 3.1 (0.4:24.9) | MW: p=0.634 |
μ ±SD | 4.67 ±5.0 | 4.42 ±3.14 | 4.61 ±4.6 | ||
Elastography IQR/MED | M (min:max) | 14.24 (0:53.32) | 15.83 (3.37:39.47) | 14.79 (0:53.32) | MW: p=0.544 |
μ ±SD | 16.35 ±11.2 | 17.33 ±10.4 | 16.59 ±10.9 | ||
Viscosity liver Median 1 | M (min:max) | 2.75 (1.2:5) | 2.9 (2.3:4.3) | 2.8 (1.2:5) | MW: p=0.547 |
μ ±SD | 2.96 ±0.916 | 2.99 ±0.592 | 2.97 ±0.839 | ||
Spleen diameter | M (min:max) | 10.82 (7.26:21.8) | 12.66 (7.68:17.65) | 11.12 (7.26:21.8) | MW: p=0.075 |
μ ±SD | 11.63 ±2.96 | 12.76 ±2.63 | 11.89 ±2.91 | ||
Spleen area | M (min:max) | 53.76 (21.3:193.16) | 60.11 (31.78:131.6) | 56.1 (21.3:193.16) | MW: p=0.750 |
μ ±SD | 66.27 ±43.5 | 66.35 ±31.6 | 66.30 ±38.6 | ||
VP Diam cm | M (min:max) | 1.07 (0.76:1.49) | 1.16 (1.05:1.62) | 1.11 (0.76:1.62) | T-test: p=0.086 |
μ ±SD | 1.08 ±0.22 | 1.22 ±0.17 | 1.11 ±0.216 | ||
VP Speed | M (min:max) | 26.68 (14.38:74.5) | 20.62 (15.72:24.03) | 23.27 (14.38:74.5) | MW: p=0.332 |
μ ±SD | 30.67 ±17.1 | 20.25 ±3.48 | 28.06 ±15.4 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.02 (0:0.08) | 0.01 (0:0.08) | MW: p=0.447 |
μ ±SD | 0.015 ±0.0232 | 0.0333 ±0.0416 | 0.0187 ±0.027 | ||
Hb | M (min:max) | 13.95 (7.5:17.3) | 13.75 (8.5:17) | 13.85 (7.5:17.3) | MW: p=0.831 |
μ ±SD | 13.79 ±1.87 | 13.81 ±2.19 | 13.79 ±1.94 | ||
PTL | M (min:max) | 209.5 (2.39:353) | 129 (56:292) | 186.5 (2.39:353) | T-test: p=0.048 |
μ ±SD | 193.62 ±87.7 | 147.89 ±75.4 | 183.33 ±86.8 | ||
GOT | M (min:max) | 27.5 (16:124) | 36.5 (17:134) | 30 (16:134) | MW: p=0.075 |
μ ±SD | 35.58 ±20.6 | 43.60 ±27.3 | 37.49 ±22.5 | ||
GPT | M (min:max) | 24 (9:75) | 30 (7:183) | 24.5 (7:183) | MW: p=0.268 |
μ ±SD | 26.55 ±12.9 | 38.20 ±37.8 | 29.32 ±21.9 | ||
BT | M (min:max) | 0.9 (0.3:11.1) | 1.5 (0.5:5.2) | 1 (0.3:11.1) | MW: p=0.149 |
μ ±SD | 1.48 ±1.88 | 1.66 ±1.21 | 1.53 ±1.73 | ||
BD | M (min:max) | 0.28 (0.13:8.96) | 0.5 (0.18:1.8) | 0.32 (0.13:8.96) | MW: p=0.036 |
μ ±SD | 0.69 ±1.54 | 0.609 ±0.428 | 0.67 ±1.35 | ||
GGT | M (min:max) | 33 (13:650) | 62 (21:1128) | 36.5 (13:1128) | MW: p=0.164 |
μ ±SD | 77.00 ±110.0 | 161.31 ±294.3 | 96.27 ±171.5 | ||
FA | M (min:max) | 224 (104:737) | 219 (112:661) | 223 (104:737) | MW: p=0.984 |
μ ±SD | 258.45 ±124.2 | 251.71 ±123.3 | 256.81 ±123.1 | ||
ALB | M (min:max) | 4.4 (3.2:5.1) | 4.2 (2.6:4.5) | 4.2 (2.6:5.1) | T-test: p=0.279 |
μ ±SD | 4.18 ±0.662 | 3.83 ±0.716 | 4.06 ±0.685 | ||
INR | M (min:max) | 1.08 (0.9:2.7) | 1.04 (1:1.71) | 1.08 (0.9:2.7) | MW: p=0.897 |
μ ±SD | 1.26 ±0.399 | 1.25 ±0.278 | 1.26 ±0.369 | ||
COL | M (min:max) | 189.5 (124:326) | 177 (138:280) | 185 (124:326) | MW: p=0.571 |
μ ±SD | 193.39 ±57.8 | 194.33 ±55.9 | 193.62 ±56.6 | ||
TG | M (min:max) | 89.5 (31:224) | 118 (61:181) | 98 (31:224) | T-test: p=0.321 |
μ ±SD | 100.65 ±50.4 | 119.22 ±38.1 | 105.43 ±47.7 | ||
Fe | M (min:max) | 92.5 (24:191) | 86 (22:246) | 92 (22:246) | MW: p=0.754 |
μ ±SD | 98.29 ±41.1 | 111.17 ±65.6 | 101.65 ±48.2 | ||
Crea | M (min:max) | 0.77 (0.53:1.27) | 0.74 (0.53:0.98) | 0.76 (0.53:1.27) | MW: p=0.232 |
μ ±SD | 0.791 ±0.164 | 0.731 ±0.133 | 0.777 ±0.159 | ||
Uree | M (min:max) | 30 (10:92) | 30 (18:58) | 30 (10:92) | MW: p=0.658 |
μ ±SD | 34.86 ±16.8 | 31.00 ±11.6 | 33.92 ±15.7 | ||
Na | M (min:max) | 135 (128:140) | 135 (89:142) | 135 (89:142) | MW: p=0.896 |
μ ±SD | 135.80 ±2.59 | 132.00 ±14.5 | 134.89 ±7.38 | ||
Glicemie | M (min:max) | 103.25 (75.7:336) | 115 (85:241.7) | 103.4 (75.7:336) | MW: p=0.244 |
μ ±SD | 118.87 ±48.5 | 127.91 ±41.7 | 120.89 ±46.9 | ||
CRP | M (min:max) | 0.4 (0.26:22.2) | 0.39 (0.23:9.74) | 0.39 (0.23:22.2) | MW: p=0.416 |
μ ±SD | 2.15 ±4.79 | 1.39 ±3.13 | 1.99 ±4.47 | ||
Attenuation IQR | M (min:max) | 0.05 (0:0.25) | 0.09 (0:0.24) | 0.05 (0:0.25) | MW: p=0.027 |
μ ±SD | 0.066 ±0.0528 | 0.092 ±0.0588 | 0.0723 ±0.0552 | ||
Attenuation SOS IQR | M (min:max) | 10.5 (1:84) | 13.5 (2:38) | 10.88 (1:84) | MW: p=0.307 |
μ ±SD | 12.20 ±10.8 | 14.51 ±9.79 | 12.77 ±10.6 | ||
Attenuation cuts | <0.5 | 50 (70.4%) | 18 (78.3%) | 68 (72.3%) | OR=0.66 [0.22, 2.02] (p=0.595) |
≥0.5 | 21 (29.6%) | 5 (21.7%) | 26 (27.7%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.5 | ≥0.5 | (total) |
S0-S1 (CAP <285) | 50 (90.9% / 73.5%) | 5 (9.1% / 19.2%) | 55 (58.5%) |
S2-S3 (CAP ≥285) | 18 (46.2% / 26.5%) | 21 (53.8% / 80.8%) | 39 (41.5%) |
(total) | 68 (72.3%) | 26 (27.7%) | 94 (100%) |
OR=11.67 [3.83, 35.55], phi=0.49 (p<0.001) | |||
Variable | Details | yes | no | Total | Statistics |
Agreement | 69 (73.4%) | 25 (26.6%) | 94 | ||
Sex | F | 26 (38.8%) | 8 (32.0%) | 34 (37.0%) | OR=1.35 [0.51, 3.57] (p=0.632) |
M | 41 (61.2%) | 17 (68.0%) | 58 (63.0%) | ||
Age (years) | M (min:max) | 59 (32:87) | 64 (40:76) | 61 (32:87) | T-test: p=0.475 |
μ ±SD | 59.54 ±10.8 | 61.28 ±9.24 | 60.01 ±10.3 | ||
Cirrhosis | 60 (87.0%) | 22 (88.0%) | 82 (87.2%) | OR=0.91 [0.23, 3.67] (p>0.999) | |
Etiology | alcohol | 26 (40.0%) | 13 (54.2%) | 39 (43.8%) | V=0.16 (p=0.504) |
viral | 27 (41.5%) | 9 (37.5%) | 36 (40.4%) | ||
metabolic | 9 (13.8%) | 1 (4.2%) | 10 (11.2%) | ||
cholestatic liver disease | 3 (4.6%) | 1 (4.2%) | 4 (4.5%) | ||
APP_DZ | 19 (27.9%) | 8 (33.3%) | 27 (29.3%) | OR=0.78 [0.29, 2.11] (p=0.612) | |
APP_HTAE | 22 (32.4%) | 9 (37.5%) | 31 (33.7%) | OR=0.80 [0.30, 2.10] (p=0.802) | |
APP_CVD | 17 (25.0%) | 5 (20.8%) | 22 (23.9%) | OR=1.27 [0.41, 3.91] (p=0.786) | |
APP_COPD | 4 (5.9%) | 3 (12.5%) | 7 (7.6%) | OR=0.44 [0.09, 2.12] (p=0.372) | |
APP_Renal | 3 (4.5%) | 4 (19.0%) | 7 (8.0%) | OR=0.20 [0.04, 0.98] (p=0.053) | |
Alcohol | 27 (50.9%) | 14 (66.7%) | 41 (55.4%) | OR=0.52 [0.18, 1.49] (p=0.301) | |
Dislipidemia | 4 (16.0%) | 0 | 4 (12.9%) | OR=2.72 [0.13, 57.49] (p=0.561) | |
Weight | M (min:max) | 82 (52:120) | 95.5 (61:115) | 85 (52:120) | T-test: p=0.002 |
μ ±SD | 82.27 ±15.4 | 94.55 ±14.8 | 85.78 ±16.1 | ||
Height | M (min:max) | 168 (150:183) | 173 (160:190) | 170 (150:190) | MW: p=0.047 |
μ ±SD | 168.98 ±7.89 | 173.71 ±9.05 | 170.32 ±8.45 | ||
BMI | M (min:max) | 29.05 (19.1:37.04) | 32.81 (23.1:42.24) | 29.54 (19.1:42.24) | T-test: p=0.011 |
μ ±SD | 28.57 ±4.36 | 31.65 ±5.05 | 29.44 ±4.74 | ||
Fibroscan_Probe | M | 64 (92.8%) | 19 (76.0%) | 83 (88.3%) | OR=4.04 [1.11, 14.72] (p=0.062) |
XL | 5 (7.2%) | 6 (24.0%) | 11 (11.7%) | ||
Fibroscan_Value | M (min:max) | 24.65 (10.1:75) | 22.8 (10:75) | 24.2 (10:75) | MW: p>0.999 |
μ ±SD | 32.30 ±21.1 | 31.63 ±20.2 | 32.12 ±20.8 | ||
Fibroscan fibrosis stage | F0-F1 (<7) | 0 | 0 | 0 | V=NA (p>0.999) |
F2 (7-10) | 0 | 0 | 0 | ||
F3-F4 (>10) | 69 (100%) | 25 (100%) | 94 (100%) | ||
Valid Elastography | 63 (91.3%) | 23 (92.0%) | 86 (91.5%) | OR=0.91 [0.17, 4.85] (p>0.999) | |
Stability index | M (min:max) | 91 (12:98) | 91 (51:96) | 91 (12:98) | MW: p=0.898 |
μ ±SD | 85.70 ±15.1 | 86.40 ±11.8 | 85.88 ±14.2 | ||
CAP_Value | M (min:max) | 253 (100:398) | 322 (233:400) | 272 (100:400) | Welch: p<0.001 |
μ ±SD | 255.03 ±62.6 | 321.04 ±37.6 | 272.59 ±64.0 | ||
CAP Steatosis stage | S0-S2 (CAP <295) | 56 (81.2%) | 4 (16.0%) | 60 (63.8%) | OR=22.62 [6.63, 77.20] (p<0.001) |
S3 (CAP ≥295) | 13 (18.8%) | 21 (84.0%) | 34 (36.2%) | ||
HRI number measurements | M (min:max) | 3 (1:4) | 3 (1:3) | 3 (1:4) | MW: p=0.897 |
μ ±SD | 2.45 ±0.932 | 2.41 ±0.939 | 2.44 ±0.926 | ||
HRI Mean | M (min:max) | 1.17 (0.68:2.29) | 1.23 (0.72:2.29) | 1.19 (0.68:2.29) | MW: p=0.601 |
μ ±SD | 1.21 ±0.32 | 1.27 ±0.362 | 1.23 ±0.331 | ||
Number Attenuation measurements | M (min:max) | 5 (2:7) | 5 (2:7) | 5 (2:7) | MW: p=0.020 |
μ ±SD | 4.81 ±0.827 | 5.28 ±1.02 | 4.94 ±0.902 | ||
Attenuation Mean | M (min:max) | 0.41 (0.16:0.77) | 0.48 (0.25:0.72) | 0.41 (0.16:0.77) | T-test: p=0.132 |
μ ±SD | 0.425 ±0.125 | 0.467 ±0.107 | 0.436 ±0.121 | ||
Number Attenuation SOS measurements | M (min:max) | 5 (3:7) | 5 (5:7) | 5 (3:7) | MW: p=0.026 |
μ ±SD | 4.91 ±0.742 | 5.32 ±0.627 | 5.02 ±0.733 | ||
Attenuation SOS Mean | M (min:max) | 1525.33 (1488.6:1581.67) | 1518.67 (1480:1583) | 1524.75 (1480:1583) | T-test: p=0.246 |
μ ±SD | 1526.60 ±19.7 | 1520.84 ±24.8 | 1525.07 ±21.2 | ||
Elastography liver median 1 | M (min:max) | 22 (6.5:76.7) | 22.8 (10.5:74.6) | 22.6 (6.5:76.7) | MW: p=0.932 |
μ ±SD | 26.27 ±14.7 | 25.94 ±14.0 | 26.18 ±14.4 | ||
Elastography liver IQR 1 | M (min:max) | 3.15 (0.4:24.9) | 3 (0.4:10.3) | 3.1 (0.4:24.9) | MW: p=0.646 |
μ ±SD | 4.88 ±5.07 | 3.88 ±2.92 | 4.61 ±4.6 | ||
Elastography IQR/MED | M (min:max) | 15.15 (0:53.32) | 13.54 (3.3:39.47) | 14.79 (0:53.32) | MW: p=0.681 |
μ ±SD | 16.94 ±11.2 | 15.63 ±10.2 | 16.59 ±10.9 | ||
Viscosity liver Median 1 | M (min:max) | 2.75 (1.2:5) | 2.9 (2.3:4.3) | 2.8 (1.2:5) | MW: p=0.438 |
μ ±SD | 2.96 ±0.927 | 3.00 ±0.582 | 2.97 ±0.839 | ||
Spleen diameter | M (min:max) | 10.69 (7.26:21.8) | 12.99 (7.68:17.65) | 11.12 (7.26:21.8) | MW: p=0.041 |
μ ±SD | 11.57 ±2.96 | 12.84 ±2.59 | 11.89 ±2.91 | ||
Spleen area | M (min:max) | 53.76 (21.3:193.16) | 73.48 (31.78:131.6) | 56.1 (21.3:193.16) | MW: p=0.267 |
μ ±SD | 63.22 ±40.7 | 74.02 ±34.7 | 66.30 ±38.6 | ||
VP Diam cm | M (min:max) | 1.07 (0.76:1.49) | 1.15 (1.02:1.62) | 1.11 (0.76:1.62) | T-test: p=0.149 |
μ ±SD | 1.08 ±0.227 | 1.19 ±0.166 | 1.11 ±0.216 | ||
VP Speed | M (min:max) | 24.02 (14.38:74.5) | 20.62 (19.82:21.41) | 23.27 (14.38:74.5) | MW: p=0.427 |
μ ±SD | 29.13 ±16.3 | 20.62 ±1.12 | 28.06 ±15.4 | ||
VP RI | M (min:max) | 0.01 (0:0.08) | 0.04 (0:0.08) | 0.01 (0:0.08) | MW: p=0.858 |
μ ±SD | 0.0154 ±0.0222 | 0.04 ±0.0566 | 0.0187 ±0.027 | ||
Hb | M (min:max) | 13.8 (7.5:17.3) | 14 (10.8:17) | 13.85 (7.5:17.3) | MW: p=0.368 |
μ ±SD | 13.66 ±2.0 | 14.18 ±1.71 | 13.79 ±1.94 | ||
PTL | M (min:max) | 200.5 (2.39:353) | 162.5 (60:292) | 186.5 (2.39:353) | T-test: p=0.311 |
μ ±SD | 189.04 ±90.3 | 166.20 ±74.7 | 183.33 ±86.8 | ||
GOT | M (min:max) | 29 (16:134) | 31.5 (17:78) | 30 (16:134) | MW: p=0.311 |
μ ±SD | 37.73 ±24.6 | 36.82 ±15.5 | 37.49 ±22.5 | ||
GPT | M (min:max) | 24 (9:183) | 30 (7:60) | 24.5 (7:183) | MW: p=0.265 |
μ ±SD | 28.95 ±24.0 | 30.36 ±14.4 | 29.32 ±21.9 | ||
BT | M (min:max) | 0.95 (0.3:8.6) | 1.4 (0.5:11.1) | 1 (0.3:11.1) | MW: p=0.215 |
μ ±SD | 1.37 ±1.36 | 1.98 ±2.52 | 1.53 ±1.73 | ||
BD | M (min:max) | 0.28 (0.13:6.38) | 0.42 (0.18:8.96) | 0.32 (0.13:8.96) | MW: p=0.116 |
μ ±SD | 0.563 ±0.957 | 0.979 ±2.14 | 0.67 ±1.35 | ||
GGT | M (min:max) | 30 (13:1128) | 78 (21:611) | 36.5 (13:1128) | MW: p=0.047 |
μ ±SD | 93.92 ±183.7 | 103.06 ±134.1 | 96.27 ±171.5 | ||
FA | M (min:max) | 216 (104:661) | 234 (112:737) | 223 (104:737) | MW: p=0.712 |
μ ±SD | 255.39 ±120.4 | 260.63 ±133.4 | 256.81 ±123.1 | ||
ALB | M (min:max) | 4.25 (2.6:5.1) | 4.2 (3.5:4.5) | 4.2 (2.6:5.1) | T-test: p=0.661 |
μ ±SD | 4.01 ±0.791 | 4.17 ±0.367 | 4.06 ±0.685 | ||
INR | M (min:max) | 1.08 (0.95:2.7) | 1.18 (0.9:2.52) | 1.08 (0.9:2.7) | MW: p=0.784 |
μ ±SD | 1.24 ±0.344 | 1.33 ±0.437 | 1.26 ±0.369 | ||
COL | M (min:max) | 185 (124:326) | 184 (132:280) | 185 (124:326) | MW: p=0.669 |
μ ±SD | 192.89 ±58.2 | 195.60 ±54.7 | 193.62 ±56.6 | ||
TG | M (min:max) | 87 (39:224) | 111.5 (31:181) | 98 (31:224) | T-test: p=0.630 |
μ ±SD | 102.92 ±49.5 | 111.70 ±44.7 | 105.43 ±47.7 | ||
Fe | M (min:max) | 93 (22:206) | 84 (52:246) | 92 (22:246) | MW: p=0.817 |
μ ±SD | 101.21 ±46.9 | 102.77 ±53.3 | 101.65 ±48.2 | ||
Crea | M (min:max) | 0.77 (0.53:1.24) | 0.69 (0.53:1.27) | 0.76 (0.53:1.27) | MW: p=0.189 |
μ ±SD | 0.788 ±0.152 | 0.744 ±0.177 | 0.777 ±0.159 | ||
Uree | M (min:max) | 30.5 (10:92) | 28 (20:36) | 30 (10:92) | MW: p=0.385 |
μ ±SD | 35.64 ±17.6 | 28.56 ±4.48 | 33.92 ±15.7 | ||
Na | M (min:max) | 135.5 (128:140) | 135 (89:142) | 135 (89:142) | MW: p=0.909 |
μ ±SD | 135.71 ±2.52 | 132.58 ±14.0 | 134.89 ±7.38 | ||
Glicemie | M (min:max) | 104.7 (75.7:336) | 103 (77:241.7) | 103.4 (75.7:336) | MW: p=0.379 |
μ ±SD | 118.65 ±47.8 | 127.48 ±44.9 | 120.89 ±46.9 | ||
CRP | M (min:max) | 0.38 (0.26:22.2) | 0.4 (0.23:4.87) | 0.39 (0.23:22.2) | MW: p=0.911 |
μ ±SD | 2.21 ±4.9 | 1.06 ±1.59 | 1.99 ±4.47 | ||
Attenuation IQR | M (min:max) | 0.05 (0:0.25) | 0.09 (0:0.24) | 0.05 (0:0.25) | MW: p=0.069 |
μ ±SD | 0.0662 ±0.0512 | 0.0892 ±0.0629 | 0.0723 ±0.0552 | ||
Attenuation SOS IQR | M (min:max) | 10.75 (1:84) | 11 (2:32.25) | 10.88 (1:84) | MW: p=0.653 |
μ ±SD | 12.62 ±11.3 | 13.17 ±8.38 | 12.77 ±10.6 | ||
Attenuation cuts | <0.55 | 56 (81.2%) | 21 (84.0%) | 77 (81.9%) | OR=0.82 [0.24, 2.80] (p>0.999) |
≥0.55 | 13 (18.8%) | 4 (16.0%) | 17 (18.1%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
vs. Attenuation cuts | |||
CAP Steatosis stage | <0.55 | ≥0.55 | (total) |
S0-S2 (CAP <295) | 56 (93.3% / 72.7%) | 4 (6.7% / 23.5%) | 60 (63.8%) |
S3 (CAP ≥295) | 21 (61.8% / 27.3%) | 13 (38.2% / 76.5%) | 34 (36.2%) |
(total) | 77 (81.9%) | 17 (18.1%) | 94 (100%) |
OR=8.67 [2.54, 29.58], phi=0.39 (p<0.001) | |||
.
.